PROTOCOL: SHP634 -101
TITLE: An Open -Label, Randomized, Crossover Study  to Assess the
Pharmacokinetic and Pharmacod ynamic Profiles of Once -Dailyand 
Twice -Daily  Dose Regimens of recombinant human Parathy roid
Hormone (rhPTH[1- 84]) Administered Subcutaneously  to Subjects with 
Hypoparathy roidism
DRUG: rhPTH(1 -84)
IND: 076514
BLA: [ADDRESS_717468] NO.: 2015-004757-40
SPONSOR: 
Shire
[ADDRESS_717469] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PRINCIPAL/
COORDINATING
INVESTIGATOR:
[INVESTIGATOR_59649]:Protocol Amendment 5 : 18Jun 2018
Protocol Amendment 4: 12 Jun2017
Protocol Amendment 3: 29 Jul 2016
Protocol Amendment 2: 03 Jun 2016
Protocol Amendment 1: 26 Feb 2016
Original Protocol: [ADDRESS_717470] party without the express written 
consent of Shire.

Shire CONFIDENTIAL Page 3
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
SUMMAR Y OF CHANGES FROM PREVIOUS VERSION
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
5Amendment Date
18 Jun 2018Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
[ADDRESS_717471] of World has been revised 
from to 
Reason for change: ClarificationProduct Quality  Complaints
2 Language has been added to the protocol to:
Indicate that cohorts must have at least [ADDRESS_717472] 8 
subjects and the number of subjects expected to 
complete the study  has been revised from 32 
subjects to approximately  32 subjects.
Indicate that the planned safet yreview will take 
place after [ADDRESS_717473] can be entered into the next 
cohort rather than after completion of the respective 
cohorts.
Allow previous cohorts to be expanded to include 
additional subjects to ensure that sufficient data for 
analysis are collected to complete study  objectives.
Reason for change: The protocol is being amended to allow 
additional enrollment, if needed, to ensure that 8 evaluable 
subjects per cohort complete the trial.Study  Synopsis , Section 
3.1(including Table 5),
Section 4.5, Section 9.6
3 Study  period (planned):
The concluding date of the planned study  period has been 
revised from Nov 2017 to May  2019.
The planned stud y period was revised from approximately  
18 months to approximately  36 months.
Reason for change: Study recruitment has gone more 
slowly  than originall y anticipated. The anticipated end of 
the study  has been revised to May  [ADDRESS_717474] re cruitment.Study  Synopsis and 
Section 3.2

Shire CONFIDENTIAL Page 4
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
5Amendment Date
18 Jun 2018Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
[ADDRESS_717475] been 
revised:
The all -enrolled population was revised from consisting of 
all subjects who meet the inclusion/exclusion criteria and 
sign the informed consent form to consisting of all subjects 
who sign the informed consent form and are randomized in 
the study .
The pharmacokinetic population was revised from 
consisting of subjects who receive at least 1 dose of 
rhPTH(1 -84) and have at least [ADDRESS_717476] 1 dose of rhPTH(1-84) and have at least [ADDRESS_717477] 1 dose of 
rhPTH(1 -84) and have at least [ADDRESS_717478] 1 
dose of rhPTH(1- 84) and have at least [ADDRESS_717479] -
dose pharmacod ynamic value available for 1 dose regimen.
Reason for the change: Clarification.Study  Synopsis and 
Section 9.7
5 Sites and regions:
The word “approximately” has been added to indicate that 
more than 1 -2 subjects might be enrolled at any  
investigational site.
Reason for change: Clarification needed.Section 3.3
6 Rescreening of subjects:
Wording has been clarified regarding when a subject may  
be rescreened.
Previously , rescreening was allowed one additional time 
only for subjects whose failure to meet inclusion/ exclusion 
criteria was transient and temporary .  The language has 
been revised to remo ve the restriction on the number of 
times that these subjects can be rescreened.  Section [IP_ADDRESS]
Shire CONFIDENTIAL Page 5
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
5Amendment Date
18 Jun 2018Global
Item #Description of Change Section(s) Affected by
[CONTACT_548158].
Previously  rescreening, based on investigator discretion 
and sponsor approval, was also allowed for subjects who 
continued to meet all inclusion/exclusion criteria, but were 
unable participate in the study  due to scheduling 
conflicts/timing.  This language has been revised to specify  
that subjects who continued to meet all inclusion/exc lusion 
criteria can also be rescreened if they  were unable to 
participate in the stud y due to appropriate slot availability  
at an investigational site. 
Reason for change: Clarification was needed for 
investigational sites that subjects could be rescreened if 
needed based on investigator judgment because of (1) 
screen failure due to conditions that were transient and 
temporary ; or (2) scheduling issues.
See Appendices for protocol history , including all amendments
Shire CONFIDENTIAL Page 6
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717480] fax or e- mail the Shire Clinical Study Serious 
Adverse Event and Non -serious AEs Required b y the Protocol Form within 24 hours to the Shire 
Global Pharmacovigilance and Risk Management Department. Applicable fax numbers and
e-mail address can be found on the form (sent under separate cover). A copy  of this form must 
also be sent to the Contract Research Organization (CRO) by  [CONTACT_3719] e -mail using the details 
below. [COMPANY_003] is t he CRO for this study .
[COMPANY_003] e -mail: (for US sites only ):
[COMPANY_003] e -mail (for EU sites only ):  [COMPANY_003] Fax (for US 
sites only ):
[COMPANY_003] Fax (for EU sites only ): 
Forprotocol -orsafety- related issues, theinvestigator must contact [CONTACT_548159]:
By [CONTACT_1381]:
[COMPANY_003] 24 -hour safet y Hotline (for US sites only): 
[COMPANY_003] 24-hour safet yHotline (forEUsites only):
The [COMPANY_003] Medical Monitors for this study are:
, MD: Medical Monitor- North America 
, MD: Medical Monitor -Europe 

Shire CONFIDENTIAL Page 7
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717481] theCRO ([COMPANY_003]):
or

Shire CONFIDENTIAL Page 8
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717482] quality  complaints to Shire (and local 
or regional Regulatory  authoritie s if required) within [ADDRESS_717483] (marketed or investigational; including 
Shire provided devices used in the process of drug delivery ) does not meet expectations (eg, 
inadequat e or fault y closure, product contamination) or that the product did not meet the 
specifications defined in the application for the product (eg, wrong product such that the label 
and contents are different products). For instructions on reporting AEs related to product 
complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference if needed): 
Shire, Lexington, MA ([LOCATION_003])

Shire CONFIDENTIAL Page 9
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717484] AINTS .......................................................................................... 8
ABBREVIAT IONS ....................................................................................................................... 15
STUDY SYNOPSI S....................................................................................................................... 17
STUDY SCHEDULE(S) ................................................................................................................ [ADDRESS_717485] Background ................................................................................................ .35 1.2
1.2.1 Preclinical Information .......................................................................................... 35
1.2.2 Clinical Information ............................................................................................... 36
Risk/Benefit and Ethical Assessment....................................................................... 37 1.3
2.STUDY OBJECTIVES AND PURPOSE .............................................................................. 39
Rationale for the Study ............................................................................................. 39 2.1
Study  Objectives ...................................................................................................... 39 2.2
2.2.1 Primary Objectives ................................................................................................ .39
Secondary Objectives ............................................................................................... 39 2.3
3.STUDY DESIGN ................................................................................................................... 40
Study  Design and Flow Chart .................................................................................. 40 3.1
Duration and Study  Completion Definition ............................................................. 46 3.2
Sites and Regions ..................................................................................................... 46 3.3
4.STUDY POPUL ATION ......................................................................................................... 47
Inclusion Criteria ...................................................................................................... 47 4.1
Exclusion Criteria ..................................................................................................... 48 4.2
Restrictions ............................................................................................................... 50 4.3
Reproductive Potential ............................................................................................. 51 4.4
4.4.1 Female Contraception ............................................................................................ 51
4.4.2 Male Contraception ................................................................................................ 51
Discontinuation of Subjects ...................................................................................... 52 4.5
4.5.1 Reasons for Discontinuation .................................................................................. 52
4.5.2 Subjects “Lost to Follow -up” Prior to Last Scheduled Visit ................................ .52
5.PRIOR AND CONCOMITANT TREATMENT ................................................................... 53
Prior Treatment ......................................................................................................... 53 5.1
Shire CONFIDENTIAL Page 10
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717486](s) ........................................................... [ADDRESS_717487] ing Samples ......................... 58 6.6
7.STUDY PROCEDURES ........................................................................................................ 59
Dosing and Procedure Observations ........................................................................ 59 7.1
Study  Schedule ......................................................................................................... 59 7.2
7.2.1 Screening Period .................................................................................................... 59
Administrative Screening and Remote Consent Process ........................ 59 [IP_ADDRESS]
Clinical Screening .................................................................................. 60 [IP_ADDRESS]
Screening Failure .................................................................................... 61 [IP_ADDRESS]
Rescreening of Subjects ......................................................................... 61 [IP_ADDRESS]
7.2.2 Treatment Period .................................................................................................... 61
[IP_ADDRESS] Day 1 to Day  2 (Treatment Periods 1 and 2) .......................................... 61
7.2.3 Final Visit............................................................................................................... 61
7.2.4 Follow -upPeriod ................................................................................................... 61
7.2.5 Additional Care of Subjects after the Stud y.......................................................... 62
Study  Evaluations and Procedures ........................................................................... 62 7.3
7.3.1 Demographic and Other Baseline Characteristics ................................................. 62
Demographics ......................................................................................... 62 [IP_ADDRESS]
7.3.2 Safety ..................................................................................................................... 62
Medical and Medication History ............................................................ 62 [IP_ADDRESS]
Physical Examination (Including Height and Weight) ........................... 63 [IP_ADDRESS]
Adverse Event Collection ....................................................................... 63 [IP_ADDRESS]
Vital Signs, Blood Pressure and Pulse Rate ........................................... 63 [IP_ADDRESS]
Clinical L aboratory  Evaluations ............................................................. 64 [IP_ADDRESS]
Pregnancy Test ....................................................................................... 66 [IP_ADDRESS]
Shire CONFIDENTIAL Page 11
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 2018
Drug and Alcohol Screen ....................................................................... 66 [IP_ADDRESS]
Serology Screen ...................................................................................... 66 [IP_ADDRESS]
Electrocardiogram .................................................................................. 67 [IP_ADDRESS]
7.3.3 Pharmacokinetic Procedures .................................................................................. 68
Pharmacokinetic Blood Sample Collection and Handling Procedures .. 68 [IP_ADDRESS]
Shipment of Plasma Pharmacokinetic Samples ..................................... 69 [IP_ADDRESS]
Pharmacokinetic Plasma Assay  Methodology ....................................... 69 [IP_ADDRESS]
7.3.4 Pharmacod ynamic Procedures ............................................................................... 69
Pharmacod ynamic Blood Sample Collection and Handling [IP_ADDRESS]
Procedures .............................................................................................. 70
Shipment of Serum Pharmacod ynamic Samples ................................... 70 [IP_ADDRESS]
Pharmacod ynamic Serum A ssay Methodology ..................................... 71 [IP_ADDRESS]
Pharmacod ynamic Urine Sample Collection and Handling [IP_ADDRESS]
Procedures .............................................................................................. 71
Shipment of Urine Pharmacod ynamic Samples ..................................... 71 [IP_ADDRESS]
Pharmacod ynamic Urine Assay Methodology ....................................... 72 [IP_ADDRESS]
7.3.[ADDRESS_717488], Ethics Committee, and Site 
Reporting ................................................................................................................ 81
9.DATA MANAGEMENT AND STATISTICAL METHODS ............................................... 82
Data Collection ......................................................................................................... 82 9.1
Shire CONFIDENTIAL Page 12
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 2018
Clinical Data Management ....................................................................................... 82 9.2
Data Handling Considerations .................................................................................. 82 9.3
Statistical Analy sisProcess ...................................................................................... 82 9.4
Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ......83 9.5
Sample Size Calcula tion and Power Considerations ................................................ 83 9.6
Study  Population ...................................................................................................... 83 9.7
Pharmacokinetic and Pharmacod ynamic Anal yses.................................................. 83 9.8
9.8.1 Pharmacokinetic Analy sis...................................................................................... 83
Statistical Analy sis of Pharmacokinetic Parameters ............................... 84 [IP_ADDRESS]
9.8.2 Pharmacod ynamic Anal ysis................................................................................... 84
Statistical Analy sis of Pharmacod ynamic Parameters ........................... 85 [IP_ADDRESS]
9.8.3 Pharmacokinetic and Pharmacod ynamic Anal ysis................................................ 85
9.8.4 Population Pharmacokinetic and Quantitative S ystemPharmacology  
Modeling and Simulation ....................................................................................... 85
Safety Anal yses........................................................................................................ 86 9.9
10.SPONSOR’S AND I NVESTI GATOR’S RESPONSIBILIT IES........................................... 87
Sponsor’s Responsibilities ....................................................................................... 87 10.1
10.1.1 Good Clinical Practice Compliance ....................................................................... 87
10.1.2 Indemnity /Liability  and Insurance ......................................................................... 87
10.1.3 Public Posting of Study Information ...................................................................... 88
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Au thorities 
of Member States Concerned and Ethics Committees ........................................... 88
10.1.5 Study  Suspension, Termination, and Completion .................................................. 88
Investigator’s Responsibilities ................................................................................. 88 10.2
10.2.1 Good Clinical Practice Compliance ....................................................................... 88
10.2.2 Protocol Adherence and Investigator Agreement .................................................. 89
10.2.3 Documentation and Retention of Records ............................................................. 89
Case Report Forms ................................................................................. 89 [IP_ADDRESS]
Recording, Access, and Retention of Source Data and Study  [IP_ADDRESS]
Documents .............................................................................................. 89
Audit/I nspection ..................................................................................... 90 [IP_ADDRESS]
Financial Disclosure ............................................................................... 90 [IP_ADDRESS]
Ethical Considerations .............................................................................................. [ADDRESS_717489] or Ethics Committee .................................................. 91
Privacy  and Confidentiality ...................................................................................... 91 10.4
Study  Results / Publication Policy ........................................................................... 92 10.5
11.REFERENCES ....................................................................................................................... 94
Shire CONFIDENTIAL Page 13
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
12.APPENDI CES ........................................................................................................................95
Appendix 1 Protocol History ...................................................................................................96
Appendix 2 Remote I nformed Consent Process ....................................................................132
Shire CONFIDENTIAL Page 14
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717490] OF TABLES
Table 1 Schedule of Assessments .................................................................................26
Table 2: Detailed Schedule of Assessments: Day  -1 (Prior to Treatment Periods 1 
and2)................................................................................................................30
Table 3: Detailed Schedule of Assessments: Treatment Periods 1 and 2, Day  
1/Day  2 (QD Regimen) ....................................................................................31
Table 4: Detailed Schedule ofAssessments: Treatment Periods 1and2,Day
1/Day 2(BID Regimen) ...................................................................................32
Table 5: Treatment Scheme ............................................................................................40
Table 6: Volume of Blood to be Drawn from Each Subject ..........................................[ADDRESS_717491] OFFIGURES
Figure 1: Study  Design Flow Chart .........................................................................................44
Shire CONFIDENTIAL Page 15
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
ABBREVIA TIONS
1,25(OH) 2D3 1,25- dihydroxyvitamin D 3, 1,25- dihydroxycholecalciferol, calcitriol
25(OH)D 25-hydroxyvitamin D
1(OH)D 3 α-calcidol
AE adverse event
β-HCG beta-human chorionic gonadotropin
AUC area under the curve
AUC 0-24 area under the curve between two time points (0 -24 hours)
AUC 0-t area under the curve between two time points (0 -defined time)
AUC 0-inf area under the curve between two time points (0 -infinity)
BID twice- daily
cAMP cyclic adenosine monophosphate
CaSR calcium sensing receptor
CL/F clearance of drug from plasma
Cmax maximum concentration
CRA clinical research associate
CRC clinical research center
CRF case report form
CRO contract research organization
CV% coefficient variation percent
DMC data monitoring committee
EC ethics committee
ECG electrocardiogram
EMA European Medicines Agency
Emax maximum effect
EU European Union
FDA food and drug administration
FGF23 fibroblast growth factor [ADDRESS_717492]
IRT interactive response technology
Shire CONFIDENTIAL Page 16
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717493] (represents the time taken for the ventricles to 
depolarize & then repolarize)
QTc the QT interval on an ECG trace t hat has been corrected
QTcB the QT interval on an ECG trace that has been corrected using Bazett's formula
QTcF the QT interval on an ECG trace that has been corrected using Fridericia’s 
formula
RACE PAR C10 008 protocol
rhPTH(1-84) recombinant human p arathyroid hormone (1 -84 amino acids)
REPLACE CL1-11-[ADDRESS_717494]
[LOCATION_006] [LOCATION_008]
US [LOCATION_002]
VZ/F volume of distribution during terminal phase
Shire CONFIDENTIAL Page 17
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
STUDY SYNOPSIS
Protocol number:
SHP634 -101Drug:
rhPTH(1 -84)
Title of the study:
An Open -Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles
of Once -Daily and T wice -Daily Dose Regimens of recombinant human Parathyroid Hormone (rhPTH[1 -84])
Administered Subcutaneously to Subjects w ithHypoparathyroidism
Number of subjects (total and for each treatm entarm):
Approximately thirty -two (32) subjects are expected to complete the study. A sufficient number of subjects will 
bescreened and enrolled to ensure that at least 8 subjects complete each treatment in their assigned cohort and 
provide sufficient data to meet study objectives. Enrollment in thestudy will be staggered as 4 sequential cohorts 
(of at least 8 subjects/cohort) and, w ithin each cohort, subjects will berandomly assigned to [ADDRESS_717495] does not complete each treatment (which
wouldinclude thecrossover dose). Replacement subjects may beenrolled ona case- by-case basis (asasubject
is discontinued), and, if a subject is replaced, that subject w ill follow the same [ADDRESS_717496] w ho discontinued (regardless of when the subjectdiscontinued). Cohorts may be expanded to 
include additional subjects to ensure thatsufficient data for analysis are collected to complete the study 
objectives.
Investigator(s):
Coordinating Investigator:
[CONTACT_93529](s) and Region(s):
This is a global study, with sites planned in North America and countries within Europe. Approximately
20-30study sites are planned to participate in the study.
Study period (planned):
May 2016 -May 2019Clinical phase: 1
Objectives:
Prim ary:
To assess the pharmacokinetic profile and pharmacodynamic effects (control of serum calcium and
urinary calcium excretion) of rhPTH(1 -84) administered as SC doses of 25μg administered twice-daily,
50μg administered tw ice-daily, and 100μg administered once -daily, as well as the effect of
supplemental oral calcium intake, in subjects with hypoparathyroidism.
Secondary:
To assess the safety and tolerability of rhPTH(1 -84) administration in subjects with
hypoparathyroidism.

Shire CONFIDENTIAL Page 18
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Rationale:
This study is being conducted to characterize the effect of twice -daily administration of rhPTH(1 -84)on
pharmacokinetics, pharmacodynamics, safety and tolerability over the course of 24- [ADDRESS_717497], dose, and m ode of administration:
 The investigational product (rhPTH[1 -84]) is provided as a lyophilized pow der for reconstitution and is
administered as a subcutaneous (SC) injection in alternating thighs. The l yophilized pow der and sterile
water are provided in a dual chamber glass cartridge that requires mixing with a provided mixing
apparatus and delivered with a provided injector pen. Doses of rhPTH(1 -84) to be used in this study are
25µg, 50µg and 100µg as SC injections dependent upon cohort assignment and the order of treatment
according to the randomization schedule.
 Dosing of rhPTH(1 -84) w ill be administered in the presence or absence of supplemental oral calcium
(dependent upon randomized treatment allocation) which will be provided by [CONTACT_548160].
No rescue treatment will be provided by [CONTACT_456].
Methodology:
For each cohort, this study will consist of the Administrative Screening Period (up to [ADDRESS_717498]
dose , if needed), the Clinical Screening Period (within [ADDRESS_717499] dose), 2 treatment periods, the
respective doses of which are to be separated by a washout ( ≥5 days but ≤30 days) betw een the administration
of rhPTH(1 -84) or the first administration f or once daily or twice daily dosing, respectively, in each period, and
afollow -upvisit (30±2 days after thelastdose ofrhPTH[1 -84]) isadministered). Themaximal total duration of
study participation fora subject is90days (~3months), ifthemaximum clinical screening, washout and
follow -up visit durations are used. If the Administrative Screening Period is required, the maximum duration 
ofstudy participation is 182 days.
TheAdministrative Screening Period (within 120daysofthefirstdose) ispermitted (ifneeded) toallow forthe
time required to obtain medical records for subjects interested in participating at a site outside of their
immediate care network. In this case, the subject must sign an informed consent in order to have their medica l
records released to a participating site. Clinical screening will occur w ithin [ADDRESS_717500] dose. Subjects
who meet theinclusion/exclusion criteria asspecified intheprotocol willreport totheClinical Research Center
(CRC) for admission on Day -[ADDRESS_717501] 24 -hour serum calcium and urinary calcium profiles prior to treatment on Day 1. Subjects w illbe
randomly assigned to 1 of 2 treatment sequences prior to admi nistration of rhPTH(1 -84) on Day [ADDRESS_717502] been confirmed. The treatment sequence assignments within each
cohort are as follows:
Treatm entScheme
Cohort Treat ment Period 1
(Day 1)Treat ment Period 2
(Day 1)
1 
(n=8*)n=4A
(25 µg BID, no calcium)→B
(100 µg QD, no calcium)
n=4B
(100 µg QD, no calcium)→A
(25 µg BID, no calcium)
2 
(n=8*)n=4C
(50 µg BID, no calcium)→B
(100 µg QD, no calcium)
n=4B
(100 µg QD, no calcium)→C
(50 µg BID, no calcium)
3 
(n=8*)n=4D
(25 µg BID, with calcium)→E
(100 µg QD, with calcium)
n=4E
(100 µg QD, with calcium)→D
(25 µg BID, with calcium)
4
(n=8*)n=4 F
(50 µg BID with calcium)→ E
(100 µg QD with calcium)
n=4 E
(100 µg QD with calcium)→ F
(50 µg BID with calcium)
Shire CONFIDENTIAL Page 19
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
BID=twice -daily; QD=once -daily 
Where:
Treatment A= 25 µg BID, no supplemental oral calcium 
Treatment B= 100 µg QD, no supplemental oral calcium 
Treatment C= 50 µg BID, no supplemental oral calcium
Treatment D= 25 µg BID, with supplemental oral calcium 
Treatment E= 100 µg QD, with supplemental oral calcium 
Treatment F= 50 µg BID, with supplemental oral calcium
With/without calcium refers to adjunctive therapy with dose; no active vitamin D
* at least 8 subjects per cohort
On Day 1 of Treatment Period 1:
Subjects inCohort 1willreceive rhPTH(1 -84) aseither atwice -daily regim en(12hours apart)
oftwo25µg doses (without calcium; Treatment A) or a once -daily regimen of one 100µg dose
(without calcium) in the morning (Treatment B).
Subjects inCohort 2willreceive rhPTH(1 -84) aseither asatwice -daily regimen (12hours
apart) oftwo50µg doses (without calcium; Treatment C)oraonce -daily regimen ofone100µg
dose (without calcium; Treatment B).
Subjects inCohort 3willreceive rhPTH(1 -84) either asatwice -daily regim en(12hours apart)
oftwo25µg doses (with calcium; Treatment D) or a once -daily regimen of one 100µg dose 
(withcalcium; Treatm ent E).
Subjects inCohort 4willreceive rhPTH(1 -84) either asatwice -daily regim en(12hours apart)
oftwo50µg doses (with calcium; Treatment F) or a once- daily  regimen of one 100µg dose 
(withcalcium; Treatm entE).
OnDay 1ofTreatment Period 2,subjects willreceive thealternative treatment (according totherandomization
schedule). For example, if a subject w as randomized to cohort [ADDRESS_717503]
treatment period, they w ould receive Treatment B in the second treatment period. All rhPTH(1- 84) will be
administered via SC injection into alternating thighs at each administration.
Subjects enrolled in the study must require daily doses of calcium supplements of ≥1000mg prior to baseline
(Day  1). Subjects enrolled in the study must also require minimum daily doses of active vitamin D
(1,25[OH] 2D3 [1,25 -dihydroxycholecalciferol, (eg, calcitriol, α -calcidol [1(OH)D 3])]) of ≥0.25µg calcitriol or
equivalent. Subjects willbeexpected toadhere tostandard meals provided during their confinement intheCRC
during each period (from check -inonDay -2until discharge onDay 2).Allsubjects (inalltreatment arms)will
take their usual doses at the usual regimen of supplemental oral calcium and active vitamin D on Day -2and
Day-1. For all subjects in all cohorts, active vitamin D supplements must be withheld on Day 1 through the
completion of all study procedures on Day 2. Subjects may then resume active vitamin D follow ing final study
procedures on Day 2 at the discretion or direction of the investigator.
During Treatm ents A, B, and C (Cohorts 1 and 2), supplemental oral calcium and active vitamin D will be
withheld starting on Day 1 (predose), through the completion of all study procedures on Day 2 for both the
once -daily and twice -daily dosing regimens. Upon com pletion of all study procedures on Day 2, subjects will
then resume their usual supplemental oral calcium and active vitamin D at their next usual daily schedule.
During Treatments D, E, and F (Cohorts 3 and 4), subjects will withhold active vitamin D on Day  1 but take
their usual dose(s) of supplemental oral calcium according to their usual regimen, regardless of the
schedule/timing of IP administration(s). Critically, oral calcium supplementation should be identical on Day -1,
Day 1 and Day 2 in Treatmen t Period 1 and Treatment Period 2. On Day 2, subjects w ill continue with their
usual supplemental calcium regimen (ie, identical on Day -1 and Day 1) and, following the completion of all
study procedures, subjects w ill then re -start their active vitamin D at their next usual daily schedule.
Shire CONFIDENTIAL Page 20
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
During thecrossover washout period, subjects willbeinstructed totake their usual doses ofsupplemental oral
calcium and active vitamin D.
For all dosing regimens, rhPTH(1 -84) will be administered in the morning of Day [ADDRESS_717504] until approximately 
2hours after rhPTH(1- 84) administration, at which time a standardized meal will be served. For subjects 
assigned to thetwice-daily dose regimen, the evening dose of rhPTH(1 -84) w ill be administered 12 hours 
after the morning dose, and 2 hours prior to the evening meal. A snack or light meal may be provided to 
the subjects prior to theevening dose, provided it is consumed ≥2 hours prior to rhPTH(1 -84) dose
administration.
Serial blood samples for pharmacokinetic analyses will be collected on Day 1 of each treatment period for
thedetermination of PTH concentrations at predose and up to 24 hour postdose (for those randomized to the
twice-daily regimen, serial PK samples will be collected up to [ADDRESS_717505] the second dose). These blood
samples will be collected according to the schedule of assessment tables. Serial blood and urine samples for
pharmacodynamic analysis willbecollected onDay-1andonDay 1predose andfollowing the
administration ofrhPTH(1 -84) according to the schedule of assessment tables.
Additional blood samples for safety purposes will be collected as specified on the schedule of assessment
tables for assessment of anti -PTH antibodies.
Safety and tolerability will be closely monitored during the time the subject is confined to the CRC during
thestudy. Adverse events will be recorded from the time the informed consent is signed, through 
completion of thestudy at follow -up.
A safety revie w will be conducted at the completion of 8 subjects in each of Cohorts 1, 2, and 3 (w ith or 
without the inclusion of the follow -upvisit data), before any subject can be enrolled in the next cohort. The
review willinclude allavailable safety data and will include, at a minimum, the Coordinating Investigator 
[INVESTIGATOR_548136]. Minutes of the review will be disseminated to all participating
investigators.
One or more interim analyses may be performed in this study. If an analysis is deemed to be necessary, then a
prospective statistical analysis plan willbedeveloped prior totheanalysis. Theplan willinclude, ataminimum:
rationale to perform the interim analysis; (2) parameters to be an alyzed; and (3) the 
distribution list for theinterim analysis results. Interim data may be used for (but not 
limited to) PK/PD modeling and/or regulatory subm issions. The trial w ill not stop due to 
the results of any interim analysis.
Subjects who complete this study may have the opportunity to enroll into an open -label extension trial if an
open -label extension study is available and approved by [CONTACT_779]’s IRB/EC
Inclusion and exclusion criteria:
Inclusion Criteria:
The subject must meet all of the criteria below  in order to be eligible for the study:
oAn understanding, ability and willingness to fully comply with study procedures and
restrictions.
oAbility to voluntarily provide written, signed, and dated informed consent as 
applicable toparticipate in the study.
oAdult men or w omen aged ≥[ADDRESS_717506] signature 
[CONTACT_548214]. The Screening 
Period forthis study may encompass both the Administrative Screening Period (if needed) 
and the Clinical Screening Period. For purposes of this inclusion criterion, age will only be 
assessed at the time theinformed consent is first signed by [CONTACT_1177].
Shire CONFIDENTIAL Page 21
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
oHistory of hypoparathyroidism for ≥[ADDRESS_717507] PTH concentrations 
below  thelower limit of the laboratory normal range.
oRequirement for supplemental oral calcium treatment ≥1000 m g elemental calcium per day.
oRequirement for therapy with active forms of vitamin D at a minimum dose of ≥0.25µg 
perday (ie, ≥0.25µg calcitriol or equivalent per day).
oSerum calcium level within the laboratory normal reference range based on clinical 
chemistry labresults at the Clinical Screening Visit (based on central and/or local lab 
results) and Treatment Period 1, Day -2 (based on central and/or local lab results), or, if 
outside of normal range, considered not clinically significant by [CONTACT_093].
oUrinary calcium exc retion ≥200mg (5mmol)/24h, based on a 24 -hour collection,
collected anytime during the Clinical Screening Period, but prior to check -in to the 
CRC at Treatment Period 1, Day -2 (based on central and/or local lab results).
oSerum magnesium level within the laboratory normal range at the Clinical Screening 
Visit or, ifoutside of normal range, considered not clinically significant by [CONTACT_31035].
oSerum thyroid function tests within normal laboratory limits at the Clinical Screening 
Visit, or, ifoutside of normal range, considered as not clinically significant by [CONTACT_31035].
oSerum 25(OH)D level betw eenthelower limit ofnorm aland1.5-foldthelaboratory upper
limit ofnorm al, or if outside of this range, considered not clinically significant by [CONTACT_1275], at theClinical Screening Visit.
oSerum creatinine <1.5mg/dL (<133µm ol/L) AND estim ated creatinine clearance
>60mL/minute (>1.002mL/s) at the Clinical Screening Visit, and serum creatinine 
<1.5mg/dL (<133µmol/L) atTreatm ent Period 1, Day -2.
oMale or non -pregnant, non -lactating female who agrees to comply with any
applicable contraceptive requirements of the protocol or females of non -
childbearing potential.
Exclusion Criteria:
Subjects will be excluded from the study if any of the following exclusion criteria are met:
Participation in any other investigational drug study in which the last dose of 
investigational drug occurred within 3 months prior to Day 1 of Treatment Period 1 (or 
within 5 half -lives, if theelimination half -life is greater than 18 days).
Presence or history of a clinically significant disorder involving the cardiovascular, respi[INVESTIGATOR_696],
renal, gastrointestinal, immunologic, hematologic, endocrine (w ith exception of the condition
under study), or neurologic system(s) or psychiatric disease as determined by [CONTACT_093].
Known history of hypoparathyroidism resulting from an activation mutation in the calcium
sensing receptor (CaSR) gene or impaired responsiveness to PTH
(Pseudohypoparathyroidism).
Any disease that might affect calcium metabolism or calcium -phosphate homeostasis other
than hypoparathyroidism, including but not limited to, active hyperthyroidism; poorly
controlled insulin -dependent diabetes mellitus or type 2 diabetes mellitus; severe and chronic 
cardiac, liver orrenal disease; Cushing's syndrome; neuromuscular disease such as 
rheumatoid arthritis; myeloma; pancreatitis; malnutrition; rickets; recent prolonged 
immobility; active malignancy, bone metastases or a history of skeletal malignancies; 
primar y or secondary hyperparathyroidism; ahistory of parathyroid carcinoma; 
hypopi[INVESTIGATOR_297], acromegaly; or multiple endocrine neoplasia types 1 and 2, as determined 
by [CONTACT_093].
Shire CONFIDENTIAL Page 22
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
In male and female rats, parathyroid hormone caused an increase in the in cidence of
osteosarcoma (a malignant bone tumor). The occurrence of osteosarcoma was dependent on
parathyroid horm one dose and treatment duration. This effect w as observed at parathyroid 
horm oneexposure levels ranging from 3 to 71 times the exposure levels in humans receiving 
a 100µg dose ofrhPTH(1 -84). Therefore, subjects who are at increased baseline risk for 
osteosarcoma such assubjects with Paget’s disease of bone or unexplained elevations of 
alkaline phosphatase, pediatric and young adult subjects w ith open epi[INVESTIGATOR_269643], subjects with 
hereditary disorders predisposing toosteosarcoma or subjects with a prior history of external 
beam or implant radiation therapy involving the skeleton are excluded.
Subjects who have a known history of hypercalcemia during initiation of treatment with
PTH, PTH analogues or fragments of PTH.
Subjects who have a known history of hypocalcemia following abrupt withdrawal of
treatment with PTH, PTH analogues or fragments of PTH.
Subjects dependent on regular parenteral calcium infusions (eg, calcium gluconate) to
maintain calcium homeostasis w ithin 3 months prior to enrollment, as determined by [CONTACT_31035].
Use of the following medications prior to administration of investigational product within:
o14 days –thiazide diuretics
o30 days –loop diuretics, lithium, systemic corticosteroids (medical judgment is required
by [CONTACT_093]. Primarily high doses of systemic corticosteroids [eg, prednisone]
should be excluded. Stable doses of hydrocortisone [eg, as treatment forAddison’s
disease] may be acceptable).
o3 months –calcitonin, cinacalcet hydrochloride, treatment with rhPTH(1 -84) or
N-terminal PTH or PTH -related peptide fragments or analogs
oFor females: changes in hormone replacement therapy within 3 months are excluded.
Stable ( ≥ 3 months) hormone replacement therapy is acceptable.
o6 months –fluoride tablets, oral bisphosphonates, methotrexate, grow thhorm one,
digoxin, raloxifene or similar selective estrogen receptor modulators (SERMs)
o12 months –intravenous bisphosphonates, drug or alcohol abuse, as determined by [CONTACT_31035].
Presence of any clinically significant results from laboratory tests, vital signs 
assessments, orECGs, as judged by [CONTACT_093].
Twelve-lead ECG values (average of triplicate readings) demonstrating QTc >450msec 
(males) or>470msec (females) at the Clinical Screening Visit and/or any time points up to 
andincluding predose of Day 1 (Period 1).
Any medical condition or prior therapy that, in the opi[INVESTIGATOR_871], w ould 
make thesubject unsuitable for this study.
Positive test result for any of the following viral infections at the Clinical Screening Visit:
oHepatitis B surface antigen
oHepatitis C
Known significant bleeding diathesis that could preclude multiple venipunc tures as determined by
[CONTACT_36705].
Subjects who have donated a total of [ADDRESS_717508] donated a total of more than 499 mL of whole blood within 
56days prior to dosing.
A positive screen for drugs of abuse at the Clinical Screening Visit, and/or a positive screen for
drugs of abuse and alcohol at check -in to the CRC at Treatment Period 1. Subjects taking
prescription medications that might be detected during the urine screen for drugs of abuse (listed
inSection [IP_ADDRESS]) may be enrolled per the investigator’s medical judgment.
Shire CONFIDENTIAL Page 23
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
History of a clinically significant illness during the 4 w eeks prior to dosing (as determined by [CONTACT_31035]).
History of any clinically significant surgery or procedure w ithin [ADDRESS_717509] dose, as
determined by [CONTACT_093].
History of an allergic response(s) to PTH or PTH analogs, or other clinically significant
allergies, as determined by [CONTACT_093].
Maximum duration of subject involv ement in the study:
The maximal total duration of study participation for a subject is 90 days (~3 months), if the maximum clinical
screening, washout and follow -up visit durations are used. If the Administrative Screening Period is required,
the maximum d uration of study participation is 182 days.
The Administrative Screening Period (if needed) may be permitted (up to [ADDRESS_717510]
dose) to allow  for the time required to authorize release and obtain medical records for subjects
outside of their immediate care netw ork. The subject must sign an informed consent at the onset
of the Administrative Screening Period in order to authorize and have their medical records
released to a participating site.
The Clinical Screening Period is a maximum of [ADDRESS_717511] treatment period (Day -2 to Day -1 inclusive).
There are 2 treatment periods; investigational product is administered on Day 1 of each period.
The 2 treatment periods are separated by a minimum of a 120 hour (5 day) w ashout period and a
maximum of a 30 day washout period betw een the administration of the dose (QD), or first dose
(BID) in each perio d.
The total maximum duration of active study participation is approximately 90 days which would
include the full 28 day Clinical Screening Period, Treatment Period 1, a maximum washout of
30days between treatments, Treatment Period 2 and follow  up of 30±[ADDRESS_717512].
The total overnight stays for the study (independent of the amount of time used for screening or
washout periods) comprises 3 nights per treatment period. Therefore, a total of 6 overnight stays
are required during treatment.
The follow  up for the study is defined as 30±[ADDRESS_717513].
Endpoints and Statistical Analysis:
Analysis populations
Four analysis populations are defined for this study: the all-enrolled, safety, pharmacokinetic, and
pharmacodynamic populations:
The all -enrolled population consists of all subjects who sign the informed consent form and are 
randomized in the study.
The safety population includes enrolled subjects who have recei ved at least 1 dose of 
rhPTH(1 -84).Allanalyses of safety data will be based on this population.
The pharmacokinetic population consists of all -enrolled subjects who, receive at least 
1dose of rhPTH(1 -84)andhave at least 1 evaluable postdose pharmacoki netic 
concentration value available for 1 dose regimen.
The pharmacodynamic population consists of all -enrolled subjects who receive at least 
1dose of rhPTH(1 -84)andhave at least 1 evaluable postdose pharmacodynamic value 
available for 1 dose regimen.
Shire CONFIDENTIAL Page 24
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Pharm acokinetic Endpoints:
PTH concentrations will be used to calculate the following pharmacokinetic parameters using a
non- compartmental approach: maximum observed concentration maximum (C max), time of maximum
concentration (Tmax), area under the concen tration curve (from time zero to the last measurable 
concentration and from time zero to infinity (AUC 0-t and AUC 0-inf), area under the concentration curve 
from time zero to [ADDRESS_717514] dose ([AUC 0-24h] for those on the QD regimen, and up to [ADDRESS_717515] the second dose for those on theBID regimen), elimination rate constant (K el), apparent clearance 
(CL/F), apparent volume of distribution (Vz/F) and elimination half -life(t1/2).
All assessment dates will be related to the first day of rhPTH(1 -84) administration. This first day of
investigational product administration is referred to as Day 1. Day -1 is the day that is preceding Day 1, 
andaDay 0 will not be defined.
Pharm acokinetic analyses based on raw  and baseline- adjusted PTH concen trations will be performed. The
baseline is defined as the predose endogenous PTH level on Day 1, and baseline -adjusted PTH
concentrations are to be calculated by [CONTACT_548161].
Pharm acodynamic Endpoints:
Pharm acody namic parameters w ill be computed from the individual concentrations of serum calcium
(uncorrected and corrected for serum albumin levels), phosphate, albumin, creatinine, magnesium,
1,25(OH) 2D3, and FGF23 using a non -compartmental approach. The calcium -phosphate product w illbe
computed. Pharm acodynamic parameters willbeestimated based with andwithout baseline adjustments.
The follow ing parameters will be calculated using the serum concentration data:
AUC 0-24h: the area under the concentration versus time curve, from time 0 to 24 hours
TE max: time to maximum effect
Emax: maximum effect
The parameters representing urinary excretion of each analysis will be calculated, if data allow :
Total amount of sodium, calcium, magnesium, citrate, phosphate, cyclic AMP 
(cAMP), andcreatinine in each sample
Total amount of sodium, calcium, magnesium, citrate, cAMP, and phosphate excreted 
ineach sample relative to the total amount of creatinine excreted
Renal clearance of sodium, calcium, magnesium, citrate, creatinine, and phosphate 
(mL/min)
Fractional excretion of sodium, calcium, citrate, magnesium, and phosphate
Safety Endpoints:
Safety will be assessed by [CONTACT_364516]:
AEs including epi[INVESTIGATOR_548137], hypercalcemia, andhypercalciuria
Laboratory test results (hematology, serum chemistries, creatinine clearance,
urinary chemistries (24 -hr urinary calcium, sodium, citrate, phosphate, cAMP, 
magnesium, andcreatinine excretion), immunology (anti -PTH antibody), and
urina lysis
Shire CONFIDENTIAL Page 25
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
ECG
Physical examinations (including vital signs).
Sample Size Justification:
At least 8 subjects with sufficient data to meet the study objectives will be required to complete each 
treatment in each cohort. The sample size wasdetermined based on a similar, prior 
pharmacokinetic/pharmacodynamic study. The number of subjects in this study is not based on statistical 
power considerations because the statistical analyses are primarily descriptive, and no hypothesis testing is 
specified in the study.
Statistical Methodology for Safety Endpoint(s):
Safety data including clinical laboratory tests, anti -PTH antibodies, concomitant medications, AEs, ECG,
andvital signs will be summarized by [CONTACT_548162]. Descriptive statistics (arithmetic
mean, standard deviation, median, minimum and maximum) will be calculated for quantitative safety data 
as wellasfor the difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_548138].
Statistical Methodology for Pharm acokinetic Endpoint(s):
Individual concentrations and pharmacokinetic parameters of PTH w ill be listed and summarized with
descriptive statistics (number, arithmetic mean, standard deviation [SD], coefficient of variation [CV%],
median, minimum, maximum, geometric mean, and geometric CV%) by [CONTACT_3148]. Figures of individual
andmean (+/-SD)concentration -time profiles ofrawandbaseline -adjustment plasma PTH willbe
generated onboth linear and log scales.
Statistical Methodology for Pharm acodynamic Endpoint(s) :
Individual concentrations and pharmacodynamic parameters of serum total calcium and albumin -corrected
calcium, phosphate, albumin, creatinine, magnesium 1,25(OH) 2D3, and FGF23 will be summarized with
descriptive statistics (number, arithmetic mean, SD, CV%, median, minimum, maximum, geometric mean,
andgeometric CV%).
The urinary excretion of calcium, sodium, citrate, magnesium, cAMP, and phosphate will also be
expressed relative to that of creatinine and will be summarized w ith descriptive statistics.
Pharm acokinetic -pharmacodynamic correlation between PTH concentrations andtheabove indicators of
PTH bioactivity will be assessed using exploratory figures. If required, pharmacokinetic/
pharmacodynamic models may be developed to describe the effect of PTH concentrations and 
biochemical indicators of PTH activity.
Shire CONFIDENTIAL Page 26
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
STUDY SCHEDULE(S)
Table 1Schedule of Assessments
Screening Predose Assessment Treat ment Period 1 Washout Predose Assessment Treat ment Period 2 Follow -
up
Study Visit Admin. Clinical TP1, D-2 TP1, D-1 TP1, D1 TP1, D2 Wa,bTP2, D-2 TP2, D-1 TP2, D1 TP2, D2 FU
Study Relative Day/
Study Procedures-120 to -03 –[ADDRESS_717516] 
releaseXdXd
Inclusion/exclusion 
criteriaX XeXe
Demography and 
medical/medication 
historyX Xe
Physical examfX XeXg
Randomization Xh
Vital signs (blood 
pressure, pulse) f ,i, j X X X X X X X X
Height and weight fX XkX k,g
Electrocardiogram
(12-lead) f , j,l X X X X X X X X
Biochemistry,
hematology, and 
urinalysisfXmX XgX XgX
Serum 25(OH)D X
Anti-PTH antibody
sampling f X X
HIV, HBsAg, and 
HCV screenX
Pregnancy testf,nX X X XgX
FSH levelsoX
Urine drug screening X X X
Shire CONFIDENTIAL Page 27
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 1Schedule of Assessments
Screening Predose Assessment Treat ment Period 1 Washout Predose Assessment Treat ment Period 2 Follow -
up
Study Visit Admin. Clinical TP1, D-2 TP1, D-1 TP1, D1 TP1, D2 Wa,bTP2, D-2 TP2, D-1 TP2, D1 TP2, D2 FU
Study Relative Day/
Study Procedures-120 to -03 –[ADDRESS_717517] 
screeningX X
Urine collection 
container provided to 
subjectXp
IP administration X X
PK blood samplingjX X X X
PD blood samplingj X X X X X X
PD urine (continuous 
collection)jX X X X X X
Check -in to CRC X X
24-hour urine 
collection obtainedXq
In-house 
confinementX X X X X X
Discharge from CRC
(after last
assessment)X X
Adverse
events/serious 
adverse eventsfXrX X X X X X X X X X X
Concomitant 
medication f X X X X X X X X X X X
Administration of
usual supplemental 
oral calcium and 
active vitamin DX X X X X X X
Shire CONFIDENTIAL Page 28
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 1Schedule of Assessments
Screening Predose Assessment Treat ment Period 1 Washout Predose Assessment Treat ment Period 2 Follow -
up
Study Visit Admin. Clinical TP1, D-2 TP1, D-1 TP1, D1 TP1, D2 Wa,bTP2, D-2 TP2, D-1 TP2, D1 TP2, D2 FU
Study Relative Day/
Study Procedures-120 to -03 –28 to -03 -2 -1 1 2 -2 -1 1 2 Follow -
upc
Withhold 
supplemental oral 
calcium and active
vitamin D sX tX t
Administration of
supplemental oral 
calcium only (no 
active vitamin D)uXvXv
HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus
a Washout period should be ≥5 days (ie, 120 hours) and ≤[ADDRESS_717518] dose of each treatment period (whether dosing regimen is BID or QD).
b The investigator may elect to keep the subject in -clinic for the duration of the study, if the washout period is short (eg, 120-172 hours) and/or there are any safety concerns, and 
provided that there is a minimum washout of ≥[ADDRESS_717519] be completed 30 [ADDRESS_717520] is prematurely discontinued from the study, every attempt should be made to complete these assessments.
g The safety blood and urine assessments (Period 1 and Period 2), pregnancy test (for all females, Period 2), physical exam (Period 2), and weight (Period 2) should be collected 
after the scheduled serial PK and PD assessments have been completed on this study day, and prior to discharging the subject from the Clinical Research Center.
h Randomization will occur prior to administration of IP at Treatment Period 1, Day [ADDRESS_717521] been confirmed/re-confirmed.
i Vital sign measurements should be collected in the supi[INVESTIGATOR_548139].
j See Table 2 , Table 3,and Table 4 for detailed collection time points.
k Weight measurement only.
l ECGs will be performed in triplicate measurement at each time point.
mIncludes thyroid function tests, andestimated creatinine clearance (Cockcroft –Gault formula) atClinical screening visit only.
n Serum β -HCG test at Screening is required for all females. Urine pregnancy test is required for all females at subsequent sche duled time points.
o Females only, to confirm menopausal status.
p At the end of the Clinical Screening Visit, subjects will be provided with a urine collection container to take home. Subject s will be given instructions to provide a 24 -hour urine 
collection starting anytime during theClinical Screening Period, butprior totheir next admission totheCRC (eg,Day -3andending 24hours later onDay -2).Thesample must 
be kept in cold conditions (~4°C) and returned to the CRC upon collection, as per the instructions provided by [CONTACT_779].
q A 24 -hour urine sample should be collected and provided to the site anytime during the Clinical Screening Period, but provision of the sample should be no later than check-in to 
the CRC at Period 1, Day -2.
r Adverse events to be collected from time of informed consent. This includes the period of an administrative screen, if utilized.
s Applies to subjects assigned to Treatment A, Treatment B and Treatment C only.
Shire CONFIDENTIAL Page 29
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 1Schedule of Assessments
Screening Predose Assessment Treat ment Period 1 Washout Predose Assessment Treat ment Period 2 Follow -
up
Study Visit Admin. Clinical TP1, D-2 TP1, D-1 TP1, D1 TP1, D2 Wa,bTP2, D-2 TP2, D-1 TP2, D1 TP2, D2 FU
Study Relative Day/
Study Procedures-120 to -03 –[ADDRESS_717522]’s usual daily regimen (but active vitamin D must be withheld).
Shire CONFIDENTIAL Page 30
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 2:Detailed Schedule of Assessments: Day -1 (Prior to Treatment Periods 1 and 2)
Study Day -1 1
Time point (relative to 
scheduled dosing time on
Day 1 [QD, 1st dose 
BID])
(hour)Predose 1 1.5 2 3 4 6 8 10 12 13 13.5 14 15 16 18 20 22 24
Vital signs (blood pressure, 
pulse) a,bXcX X X X X X X X X X X X X Xd
ECG (12 -lead) a,eXcX X X X X X X X X X X X X Xd
IP administration Xd
PK blood sampling Xd
PD blood samplingfXcX X X X X X X X Xd
PD urine sampling g ,hXi
→ → → → → → → → → → → → → → → → →Xd
aAn attempt to perform these assessments and procedures should be made for any subject who withdraws or is removed from the study.
bVital signs should be collected in the supi[INVESTIGATOR_548139]. Subject should also be supi[INVESTIGATOR_199165] 5 minutes prior to vitals collection. Vital signs include blood 
pressure and pulse.
cThese assessments should be performed within 30 minutes prior to the relative time of scheduled administration of IP on Day 1.
dRefer toDetailed Schedule ofAssessments (Table 3andTable 4)forcollection time points (note: thistime point is thesame asthepredose collection time point onDay 1.
eECGs will be performed in triplicate measurement at each time point.
fPD blood sampling assessments will include: total serum calcium, magnesium, phosphate, albumin, creatinine, 1,25 -dihyroxyvitamin D, and FGF23.
g24-hour urine collection for PD analysis will be collected according to the following collection intervals (relative to the Day 1 morning dose): 0-3 hours, 3 -6 hours, 6 -9hours, 
9-12 hours, 12 -15 hours, 15 -18 hours, 18 -24 hours. ‘X’ denotes the start and stop of the entire urine collection period and ‘ →’ denotes continuous collection.
hPD urin e collection assessments will include: calcium, sodium, citrate, phosphate, magnesium, cAMP and creatinine.
iThe predose time point for PD urine sampling is used to signify the action that the subject needs to empty his/her bladder im mediately before the start of the 0 -3urine collection 
based on the predicted dosing time of Day 1. It is not a separate predose urine collection.
Shire CONFIDENTIAL Page 31
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 3: Detailed Schedule of Assessments: Treatment Periods 1 and 2, Day 1/Day 2 (QD Regimen)
Study Day 1 2
Timepoint
(relative to dosing time
on Day 1)
(h=hour/m=minute)Pre-
dose0 10m 20m 30m 1 1.5 2 4 6 8 10 12 13 13.5 14 16 18 20 22 24
Vital signs (blood 
pressure, pulse) a,b XcX X X X X X X X X X X X X Xj
ECG (12 -lead) a,dXcX X X X X X X X X X X X X Xj
Randomization Xe
IP administration X
PK blood sampling XcX X X X X X X X X X X
PD blood samplingfXcX X X X X X X X X X
Anti-PTH antibody
sampling g Xc
PD urine sampling h,iXk→ → → → → → → → → → → → → → → → → → → X
a An attempt to perform these assessments and procedures should be made for any subject who withdraws or is removed from the study.
b Vital signs should be collected in the supi[INVESTIGATOR_548139]. Subject should also be supi[INVESTIGATOR_199165] 5 minutes p rior to vitals collection. Vital signs include blood 
pressure and pulse.
cThese assessments should be performed within 30 minutes prior to the scheduled time for IP dose administration on Day 1.
dECGs will be performed in triplicate measurement at each time point.
eRandomization will occur p rior to administration of IP of Treatment Period 1, Day 1 only (and only after all eligibility criteria have been confirmed/re -confirmed).
fPD blood sampling assessments will include: total serum calcium, magnesium, phosphate, albumin, creatinine, 1,25 -dihyroxyvitamin D, and FGF23.
g The anti-PT H antibody sample should only be collected at Treatment Period 1, predose (regardless of BID or QD regimen), and the sample collected within 30 minutes prior to 
dosing.
h 24-hour urine collection for PD analysis will be collected according to the following collection intervals: 0 -3 hours, 3 -6 hours, 6 -9 hours, 9 -12 hours, 12 -15 hours, 15-18 hours, 
18-24 hours. ‘X’ denotes the start and stop of the entire urine collection period and ‘ →’ denotes continuous collecti on.
i PD urine collection assessments will include: calcium, sodium, citrate, phosphate, magnesium, cAMP, and creatinine.
j The last scheduled serial time point (ie, 24 hours) will also serve as the discharge procedure for these assessments on Day 2.
kTheurine sampling under predose inthistable is to signify thestop ofDay -1,18-24hour PDurine collection period, andthestart oftheDay 1,0
-3hour PDurine collection 
period. It is not a separate predose collection.
Shire CONFIDENTIAL Page 32
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 4:Detailed Schedule ofAssessments: Treatment Periods 1and2,Day 1/Day 2(BID Regimen)
Study Day 1 2
Timepoint
(relative tofirst
dosing time on 
Day 1)
(h=hour/m=minute)Predose 0 10m 20m 30m 1 1.5 2 4 6 8 10 Pre-
dose
(12hr)12 12h
10m12h
20m12.5 13 13.5 14 16 18 20 22 24 28 32 36
Vital signs (blood 
pressure, pulse) a,bXcX X X X X X XcX X X X X X X X X Xk
ECG (12-lead)
a,d XcX X X X X X XcX X X X X X X X X Xk
Randomization Xe
IP
administrationX X
PK blood 
samplingXcX X X X X X X X XfX X X X X X X X X X X
PD blood 
sampling, g XcX X X X X XfX X X X X X X X
Anti-PTH 
antibody
sampling hXc
PD urine 
sampling i,j Xl→ → → → → → → → → → → → → → → → → → → → → → → → → → X
Shire CONFIDENTIAL Page 33
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 4:Detailed Schedule ofAssessments: Treatment Periods 1and2,Day 1/Day 2(BID Regimen)
Study Day 1 2
Timepoint
(relative tofirst
dosing time on 
Day 1)
(h=hour/m=minute)Predose 0 10m 20m 30m 1 1.5 2 4 6 8 10 Pre-
dose
(12hr)[ADDRESS_717523] 5 minutes prior to vita ls collection. Vital signs include blood pressure 
and pulse.
c These assessments should be performed within 30 minutes prior to the scheduled time for IP dose administration on Day 1.
d ECGs will be performed in triplicate measurement at each timepoint.
e Randomization will occur prior to administration of IP of Treatment Period 1, Day 1 only (and only after all eligibility crit eria have been confirmed/re -confirmed).
f Predose PK/PD collection for the second dose of the BID regimen should be completed within 15 minutes prior to the dose.
g PD blood sampling assessments will include: total serum calcium, magnesium, phosphate, albumin, creatinine, 1,25-dihyroxyvitamin D, and FGF23.
h The anti- PTH antibody sample should only be collected at Treatment Period 1, predose (regardless of BID or QD regimen), and the sample collected within 30 minutes prior to 
dosing.
i 36-hour urine collection for PD analysis will be collected according to the following collection intervals: 0 -3 hours, 3 -6 hours, 6 -9 hours, 9 -12 hours, 12 -15 hours, 15-18hours, 
18-24 hours, 24 -30 hours, 30 -36 hours. ‘X’ denotes the start and stop of the entire urine collection period and ‘
→’ denotes continuous collection.
j PD urine collection assessments will include: calcium, sodium, citrate, phosphate, magnesium, cAMP, and creatinine.
k The last scheduled serial time point (ie, 36 hour time point) will also serve as the disch arge procedure for these assessments on Day 2.
l The urine sampling under predose in this table is to signify the stop of Day -1, 18 -24 hour PD urine collection period, and the start of the Day 1, 0 -3 hour PD urine collection 
period. It is not a separate p redose collection.
Shire CONFIDENTIAL Page 34
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
1.BACKGROUND INFORMATION
Hypoparathy roidism is a rare disorder characterized by  [CONTACT_548163] (PTH) (Avioli, 
1974; Haussler and Cordy, 1982 ; Shoback, 2008 ). The most frequent cause of 
hypoparathy roidi sm is resection of, or damage to, parathy roid glands during neck surgery (eg, 
thyroidectomy ), although multiple other genetic, metabolic and congenital etiologies exist. 
Hypoparathy roidism occurs in about 0.9% to 6.6% of thyroidectomies, with higher rates 
associated with more complicated interventions ( Shoback, 2008 ; Thomusch et al., 2003 ; 
Zarnegar et al., 2003 ; Page and Strunski, 2007). In 1 y ear spanning 2007 -2008 ( Powers et al ., 
2013) the incidence of chronic hy poparathy roidism ( ≥6 months) was said to be approximately  
60,000 subjects in the [LOCATION_002], which ris es to approximately  117,000 if the transient
hypoparathy roid population is included ( ≤6 months). The same authors suggest that, of those 
117,000 transient hy poparathy roid subjects, about 5% will become chronic.
Parathy roidhormone isan84-amino acid protein thatissecreted by[CONTACT_548164]. PTH
has a variety  of important phy siological functions that are outlined below to explain the effects of 
absent or deficient PTH levels. Parathyroid hormone functions to help regulate bone metabolism 
and serum levels of calcium and phosphate. In general, if serum calcium concentrations decrease, 
the parath yroid glands consequently increase PTH secretion, and, if serum calcium 
concentrations increase, the parath yroid glands consequently  reduce PTH secretion. The 
parath yroid glands sense the level of extracellular calcium at the surface of the parath yroid cell 
and adjust the sy nthesis and secretion of PTH accordingl y. The relationship between ionized 
extracellular calcium and PTH secretion is a steep sigmoida l curve where small variations in 
calcium level lead to significant changes in PTH secretion. Calcium sensing is initiated by  [CONTACT_548165] a calcium sensing receptor (CaSR) that is present at high levels onthe
plasma membrane oftheparath yroidcells. TheCaSR, amember oftheG-protein- coupled 
receptor superfamily , is activated by  [CONTACT_10172], in turn, induces intracellular
signals and, through largely unknown mechanisms, regulates thesynthesis andsecretion of PTH. 
The net phy siological effects are an increase in circulating PTH levels when the extracellular 
calcium decreases and a decrease in PTH levels when the extracellular calcium increases 
(Bilezikian et al., 2 011).
Acute s ymptoms of hy popar athyroidism, linked mainly to the h ypocalcemia, are generally  
reversible. The key  symptoms associated with hy pocalcemia involve mainly  theneuromuscular 
system: numbness, paresthesias, twitching, and tetany . More serious and potentially life
threatening effects ofhypocalcemia such asseizures, cardiac arrhy thmias, cardiomy opath yand 
laryngeal spasm are also recognized in hy poparathy roidism ( Behaghel and Donal, 2011 ).Other
symptomatology  includes difficulty  in concent rating described b y man y subjects as “brain fog”
(Bilezikian et al., 2011 ). Hy poparathy roidism has also been linked to effects on mood and 
ideation ( Arlt et al., 2002 ; Velasco et al., 1999 ).
The kidney s are especially  vulne rable in subjects with hy poparathy roidism. Circulating PTH
promotes renal calcium reabsorption, especially  at the level of the distal convoluted tubule 
(Blaine et al., 2015 ). This additional fraction of calcium is inste ad excreted through the kidney s 
(Shoback, 2008 ), leading to hy percalciuria which, together with a high-calcium -phosphate
product, can potentiall y can lead to nephrocalcinosis and kidney  stones and, ultimately , torenal
impairment ( Blaine et al., 2015 ).
Shire CONFIDENTIAL Page 35
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
For further details see the rhPTH(1 -84) investigator brochure.
Indication and Current Treatment Options 1.[ADDRESS_717524], pharmacological supplementation with active forms of vitamin D (eg,
1,25-dihydroxyvitamin D 3 [1,25(OH) 2D3], calcitriol, 1,25 -dihydroxycholecalciferol or α-calcidol
[1(OH)D 3]) is also required. Since PTH also functions in the kidney to stimulate the conversion 
of 25(OH)D 3, the major circulating form of vitamin D, to the active vitamin D hormone
(1,25[OH] 2D3), the relative lack of circulating PTH results in a reduction of the production of 
active vitamin D. Thus, exogenous active vitamin D overcomes the s ynthetic block in
endogenous production of the active vitamin D hormone in hypoparath yroidism. Together,
supplemental oral calcium and active vitamin D have formed the mainsta y of current treatment
of subjects with hy poparathy roidism. As noted above, the additional calcium load that results 
from supplementation with exogenous calcium and active vitamin D contributes to the 
hypercalciuria and renal risks often noted in patients with hypoparathy roidism.
In an effort to limit the extent and effect of h ypercalciuria, thiazide diuretics can be helpful since 
they promote renal calcium reabsorption. However, thiazides are associated with their own 
adverse events including hypokalemia a nd, more importantly , have no proven long -term effect to 
reduce h ypercalciuria or kidney  damage or improve the safety  profile in this patient population 
(Shoback, 2008 ). Although an accepted adjunct to the use of calcium and active vitamin D in 
hypoparathy roidism, thiazides are prescribed to only  a minorit y of h ypoparathy roidpatients.
The investigational product (rhPTH[1 -84]) is a recombinant human PTH that is identical in 
structure to endogenous human PTH, a single -chain poly peptide consisting of 84 amino acid 
residues andismanufacture dusing astrain ofEscherichia colimodified by[CONTACT_10173] . rhPTH(1 -84) was approved for marketing in the [LOCATION_002] on 23 January 2015 
under the brand name [CONTACT_465634]® as a once -daily injectable dose as an adjunct to calcium and 
vitamin D to control hy pocalcemia in patients with hypoparathy roidism.
Product Background 1.[ADDRESS_717525] 
evaluated the pharmacokinetics, pharmacod ynamics and t oxicology  of rhPTH(1 -84)at doses
ranging from 0.1to10,000 μg/kg given assingle doses orasdaily doses forupto2years. In the 
vast majority  of studies, rhPTH(1 -84) was administered by [CONTACT_6567] (SC) injection, the 
intended route of administration of rhPTH(1- 84) in humans. A total of [ADDRESS_717526] been performed.
Shire CONFIDENTIAL Page 36
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Inmale andfemale rats, theadministration ofPTH wasassociated with anincrease inthe
incidence of osteosarcoma. These data were interpreted as an increased risk for osteosarcoma in 
the clinic. Therefore, administration of rhPTH(1-84) should be avoided in subjects who are 
considered to be at increased risk for osteosarcoma (including those with Paget’s disease of bone 
or unexplained elevations of al kaline phosphatase, subjects with hereditary disorders 
predisposing to osteosarcoma or subjects with a history of prior external beam or implant 
radiation therap y involving the skeleton).
Currently  available results from animal reproductive toxicology  studies suggest that
rhPTH(1 -84) is not associated with significant fetal or neonatal toxicity ; however the safet y of
rhPTH(1 -84) in pregnant or nursing women is not established.
For full details see the rhPTH(1- 84) investigator brochure.
1.2.[ADDRESS_717527] been performed in the setting of h ypoparath yroidism. Study
CL1- 11- 040 (REPL ACE) was a double- blind, placebo controlled stud y of once dail y(QD) 
administration of 50 μg to 100 μg of rhPTH(1 -84) which resulted in 54.8% of the rhPTH(1 -84) 
subjects meeting a 3 -tiered primary  endpoint vs 2.5% of the placebo subjects (p<0.001).
Long -term, open-label studies have supported these findings with subjects maintaining the
physiologic benefit derived from rhPTH(1- 84) treatment. One study , PAR-C10-
008 (RACE), is 
ongoing with some subjects receiving treatment formore than 3years.
In clinical trials, rhPTH(1- 84) significantl y reduced the calcium -phosphate product. In these
studies hy percalciuria was defined as an excretion of calcium in the u rine greater than 300mg per 
[ADDRESS_717528] ACE Study  and the long -term open label study , RACE, show that 
rhPTH(1 -84) has a calcium -sparing effect, consistent with the reduction of calcium excretion 
seen in a previous pharmacokinetic/pharmacod ynamic study  (C09- 002) of single dose 
administration of rhPTH(1- 84) in patients with hypoparath yroidism in comparison with calcitriol 
administration.
The Phase [ADDRESS_717529] ed in hy poparathy roidism population and was the pi[INVESTIGATOR_10143](1 -84) iseffective inmaintaining serum calcium levels andenabling significant decreases
in active vitamin D and oral calcium doses. REPLACE also established the rhPTH(1 -84) dose
and dose titration and evaluated the ph ysiologic effects of PTH replacement on serum calcium, 
serum phosphate, urinary calcium excretion and bone turnover markers. Eight y-four subjects 
were evaluated in the active treatment group and 40 su bjects received placebo. Subjects received 
at a flexible dose range of 50 to 100 μg SC in the thigh once dail y for 6 months. The study met 
the primary  efficacy  triple endpoint, with a statistically  higher responder rate (54.8%) versus 
placebo (2.5%). To me et the primary  endpoint a subject had to fulfill all 3 conditions as follows: 
a 50% or greater reduction in oral calcium requirement, a 50% or greater reduction in active 
vitamin Dtherapy andanalbumin corrected total serum calcium (ACSC) concentration thatwas
maintained within a range of 7.5 to 10.6 mg/dL.
Shire CONFIDENTIAL Page 37
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
A review of safety  data across the h ypoparathryoidism program indicated that rhPTH(1 -84)
administered inthedose range of 25 to100μg SC QDissafeforuseforthetreatment of
hypoparathy roidism. Very  common adverse reactions (ie, reported in at least 1 in every
10subjects) included h ypocalcemia, h ypercalcemia, headaches, diarrhea, vomiting, and 
hypercalciuria. Common adverse reactions (ie, reported in at least 1 in every  100 subjects, but 
less th an 1 in every  10 subjects) included h ypomagnesemia, anxiety sym ptoms, palpi[INVESTIGATOR_814], 
flushing, coughing and associated s ymptoms, neck pain, pollakiuria, chest pain, thirst, blood 
25-hydroxy cholecalciferol decreased, and blood alkaline phosphatase increased.
There was no suggestion that rhPTH(1 -84) causes drug -induced liver injury in humans. There
were no renal -related AEs or abnormalities in renal function tests or urinalysis tests in clinical 
studies apart from changes expected from the mechanism of action of rhPTH(1 -84).Despi[INVESTIGATOR_304497], treatment 
with rhPTH(1 -84) did not result in worsening of hypercalciuria.
Potential risks include those effects which are extensions of the pharmacologic actions of PTH 
including h ypercalcemia. Post -treatment hy pocalcemia following the abrupt withdrawal of 
rhPTH(1 -84)canbeparticularl yproblematic. Following sustained withdrawal ofrhPTH(1 -84),
serum calcium levels must be carefully monitored with reinstatement of appropriate dosages of 
oral calcium and active vitamin D. No on -treatment events of h ypocalcemia occurred following
incidental missed doses of rhPTH(1 -84) during any  of the clinical studies; however, patients 
should be advised to take their rhPTH(1 -84) dose as soon possible following a missed dose and 
to take oral calcium.
The investigational product (rhPTH[1 -84]) has been developed for the treatment of 
hypoparathy roidism. In the [LOCATION_002] the drug is currentl y marketed under the brand name
[CONTACT_465634]® as a once a day  injectable treatment, indicated as an adjunct to calcium and vitamin D 
to control hy pocalcemia in patients with hy poparathy roidism. However, because of the potential 
risk of osteosarcoma, NATPARA® is recommended only  for patients who cannot be
well-controlled on calcium supplements and active forms of vitamin D alone.
Alway s refer to the latest version of the rhPTH(1 -84) investigator’s brochure for the overall 
risk/benefit assessment and the most accurate and current information regarding the drug 
metabolism, pharmacokinetics, efficacy  and safety  ofrhPTH(1 -84).
Risk/Benefit andEthical Assessment 1.[ADDRESS_717530] exposure to rhPTH(1 -84) are listed in the current investigator brochure and 
include, but are not limited to, the following:
Osteosarcoma: In male and female rats, parathyroid hormone caused an increase in the 
incidence of osteosarcoma (a malignant bone tumor). The occurrence of osteosarcoma 
was d ependent on parathyroid hormone dose and treatment duration. This effect was 
observed at parath yroid hormone exposure levels ranging from 3 to 71 times the exposure
levels inhumans receiving a100µg dose ofrhPTH(1 -84).
Shire CONFIDENTIAL Page 38
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
These data could notexclude a risk to humans. Because of a potential risk of 
osteosarcoma, use rhPTH(1-84) only insubjects who cannot bewell-controlled on
calcium andactive forms of vitamin D alone and for whom the potential benefits are 
considered to outweigh this potential risk. Avoid use of rhPTH(1 -84) in subjects who are 
atincreased baseline risk for osteosarcoma such as subjects with Paget’s disease of bone
or unexplained elevations of alkaline phosphatase, pediatric and young adult subjects with
open epi[INVESTIGATOR_548140], subjects with hered itary disorders predisposing to osteosarcoma or 
subjects with a prior history  of external beam or implant radiation therapy  involving the
skeleton.
Hypercalcemia during initiation of rhPTH(1 -84) administration: In previous efficacy  and 
safet y studies in hy poparathy roidism, 29 of 121 (24.0%) rhPTH(1-84)-treated subjects 
experienced an on -treatment event of h ypercalcemia. Monitoring of serum calcium during
thetreatment process canmitigate therisk, along with appropriate medical treatment.
Hypocalcemia with abrupt withdrawal of rhPTH(1 -84) therap y: In previous efficacy  and 
safet y studies in hypoparathyroidism, 24 of 121 (19.8%) subjects experienced a 
post-treatment event of hy pocalcemia. Monitoring of serum calcium during the treatment
process and after withdrawal can mitigate the risk, along with appropriate medical
treatment.
The safet y of rhPTH(1 -84) in pregnant or nursing women has not been established.
Pregnancy tests willbeperformed onallfemales on [ADDRESS_717531] agree toadequate
contraception methods (see Section 4.4) before taking part in the study .
Shire CONFIDENTIAL Page 39
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
2.STUDY OBJECTIVES AND PURPOSE
Rationale for the Study 2.1
Recombinant human PTH (rhPTH[1 -84]) is approved for use in the US as an adjunct to calcium 
and vitamin D to control hy pocalcemia in patients with hy poparathy roidism. As a once -dailySC
injection for hypoparathyroidism it has been shown to provide a 24 -hour sustained increase in 
serum calcium. Administration of rhPTH(1 -84) resulted in dose -related increases in total serum 
calcium levels with maximum mean increases (approximately  0.125 to 0.175 mmol/L) observed 
[ADDRESS_717532] reported experience with twice -daily use of a fragment of PTH
(PTH[1 -34]) injected SCinthesetting ofadult andpediatric subjects with hypoparathy roidism 
(Winer et al., 1998 ; Winer et al., 2003 ; Winer et al., 2008 ). In this setting, PTH(1 -34)maintained 
eucalcemia and reduced urinary  calcium excretion. In these studies, a comparison with calcitriol 
showed that either twice -daily  PTH(1 -34) or twice -daily  calcitriol each maintained similar serum 
calcium levels, although urinary  calcium excretion was lower in the PTH(1 -34)-treated subjects.
Thepresent study isbeing conducted tocharacterize theeffects oftwice -daily administration of 
rhPTH(1 -84) on pharmacokinetics, pharmacod ynamics, safet yandtolerability over thecourse of
24 hours as compared with the current once -daily  dosing regimen.
Study Objectives 2.2
2.2.1 Primary Objectives
To assess the pharmacokinetic profile and pharmacodynamic effects (control of serum calcium 
and urinary  calcium excretion) of rhPTH(1 -84) administered as SC doses of 25μg administered 
twice -daily,50μg administered twice -daily,and100μg administered once -daily ,aswell asthe 
effect of supplemental oral calcium intake, in subjects with hypoparathy roidism.
Secondary Objectives 2.3
To assess the safet y and tolerability of rhPTH(1- 84) administration in subjects with 
hypoparathy roidism.
Shire CONFIDENTIAL Page 40
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
3.STUDY DESIGN
Study Design and Flow Chart 3.1
Thepresent study isanopen -label, randomized, multi -center, 4 cohort, 2- period crossover study  
comparing QD and BID dosing regimens of rhPTH(1 -84) and the effect of adjunctive calcium 
(with no active vitamin D) in male and female adult subjects with a history of 
hypoparathy roidism.
A suffi cient number of subjects will be screened and enrolled to ensure that at least 8 subjects 
complete each treatment and provide sufficient data to meet the study objectives in their assigned 
cohort. Enrollment in the study  will be staggered as 4 sequential c ohorts (of at least 8 subjects 
per cohort, including 1 treatment crossover within each cohort), such that at least [ADDRESS_717533] dosing on Day 1 of
Treatment Period 1. The treatment sequence assignments within e ach cohort are as follows:
Table 5:Treatment Scheme
Cohort Treatment Period 1
(Day 1)Treatment Period 2
(Day 1)
1 
(n=8*)n=4A
(25 µg BID, no calcium)→B
(100 µg QD, no calcium)
n=4B
(100 µg QD, no calcium)→A
(25 µg BID, no calcium)
2 
(n=8*)n=4C
(50 µg BID, no calcium)→B
(100 µg QD, no calcium)
n=4B
(100 µg QD, no calcium)→C
(50 µg BID, no calcium)
3 
(n=8*)n=4D
(25 µg BID, with calcium)→E
(100 µg QD, with calcium)
n=4E
(100 µg QD, with calcium)→D
(25 µg BID, with calcium)
4 
(n=8*)n=4F
(50 µg BID with calcium)→E
(100 µg QD with calcium)
n=4E
(100 µg QD with calcium)→F
(50 µg BID with calcium)
BID=twice-daily; QD=once -daily
Where:
Treatment A= 25 µg BID, no supplemental oral calcium Treatment B= 100 µg QD, no supplemental oral calcium Treatment 
C=50 µg BID, no supplemental oral calcium Treatment D= 25 µg BID, with supplemental oral calcium Treatment E= 100 µg 
QD, with supplemental oral calcium Treatment F= 50 µg BID, with supplementa l oral calcium
With/without calcium refers toadjunctive therapy with dose; noactive vitamin D
*at least 8 subjects per cohort
Shire CONFIDENTIAL Page 41
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Replacement subjects may be enrolled in the event that any  subjects do not complete each 
treatment (which would include the crossover dose). Replacement subjects may  be enrolled on a 
case-by-case basis (as a subject is discontinued), and, if a subject is replaced, that subject will 
follow the same [ADDRESS_717534] who discontinued (regardless of 
when t he subject discontinued).
This study  will consist of the Administrative Screening Period (within 120 day s of Day  1of 
Period 1)thatincludes thetime required toauthorize release andobtain medical records for
subjects participating at sites outside their immediate care network (if applicable); the Clinical 
Screening Period; 2 treatment periods which are to be separated b y a washout ( ≥5 day s but 
≤30days) between the dose or first dose of investigational product in each period (for QD or
BID dosing, respe ctivel y); and a follow -up visit (30±[ADDRESS_717535] is administered). The maximal total duration of study  participation for a subject is
90days (~3 months), if the maximum clinical screening, washout and follow-up visit durations
areused. If the Administrative Screening Period is required, the maximum duration of study  
participation is [ADDRESS_717536] dose. Subjects who meet the 
inclusion/exclusion criteria as spe cified in the protocol will report to the Clinical Research 
Center (CRC) for admission on Day  -[ADDRESS_717537] been 
confirmed.
On Day  1 of Treatment Period 1:
Subjects inCohort 1 willreceive rhPTH(1-84) aseither atwice -dailyregimen (12hours 
apart) of two 25µg doses (without calcium) or a once -daily regimen of one100µg dose 
(without calcium) in the morning
Subjects in Cohort 2 will receive rhPTH(1 -84) as either as a twice- daily  regimen
(12hours apart) of two 50µg doses (without calcium) or a once- daily regimen of one 
100µg dose (without calcium)
Subjects in Cohort 3 will receive rhPTH(1 -84) either as a twice -daily  regimen (12 hours 
apart) of two 25µg doses (with calcium) or a once -daily  regimen of one 100µg dose (with
calcium).
Subjects in Cohort 4 will receive rhPTH(1 -84) either as a twice -daily  regimen (12 hours 
apart) of two 50µg doses (with calcium) or a once -daily  regimen of one 100µg dose (with
calcium).
On Day  1 of Treatment Period 2, subjects will receive the alternative treatment (according to the 
randomization schedule), following a washout period ( ≥5 day s [ie, 120 hours] and ≤30 days)
between administration of the dose or first dose ([for once -daily  or twice -daily dosing,
respect ively] of each treatment period). All investigational product will be administered via SC 
injection into alternating thighs at each administration.
Shire CONFIDENTIAL Page 42
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717538] scheduled assessment on Day  2 (investigators may
elect, attheir discretion, tokeep thesubject in-clinic after Treatment Period 1fortheduration of
the washout period, eg, if the washout period is short [eg, 120 -172 hours] or there are any safet y 
concerns).
For once -daily treatments (Treatments B and E), subjects will receive a single subcutaneous dose 
of rhPTH(1- 84) in the morning on Day  1. For twice- daily treatments (Treatments A, C, D, and
F), subjects will receive a sub cutaneous dose of rhPTH(1- 84) in the morning followed by [CONTACT_548166] 12 hours later on Day  1 (in the opposite thigh). If randomized to rhPTH(1 -84)with 
calcium, subjects willtake their usual supplemental oralcalcium onDay 1pertheir usual
schedule. Prior to discharge from the CRC at each treatment period, subjects will be given
specific instructions for when to take their supplemental oral calcium and active vitamin D 
supplements during the day (s) when subjects are not in the CRC.
Subjects enrolled in the study  must require daily  doses of calcium supplements of ≥ 1000 mg 
prior to baseline (Day  1). Subjects enrolled in the study  must also require minimum daily doses
of active vitamin D of ≥0.25 g (ie, 0.25μg calcitriol or equivalent). Subjects will be expected to 
adhere to standard meals provided during their confinement in the CRC during each period (from 
check -in on Day  -2 until discharge on Day  2). All subjects (in all treatments) will take their usual 
doses at the usual regimen of supplemental oral calcium and active vitamin D on Day  -[ADDRESS_717539] be withheld on Day 1 
through completion of all study  procedures on Day 2. Subjects may  resume active vitamin D 
following final procedures onDay2atthediscretion ordirection oftheinvestigator.
During Treatments A, B, and C (Cohorts 1 and 2), supplemental oral calcium and active vitamin 
D will be withheld starting on Day  1 (predose), through the completion of all study procedures 
on Day  2 for both the once- daily and twice -daily  dosing regimens. Upon completion of all study  
procedures on Day  2, subjects will then resume their usual supplemental oral calcium and active 
vitamin D at their next usual daily schedule.
During Treatments D, E , and F (Cohorts 3 and 4), subjects will withhold active vitamin D on 
Day 1 but take their usual dose(s) of supplemental oral calcium according to their usual regimen, 
regardless of the schedule/timing of investigational product administration(s).
Critical ly, oral calcium supplementation should be identical on Day  -1, Day  1 and Day  2in 
Treatment Period 1 and Treatment Period 2. On Day  2, subjects will continue with their usual 
supplemental calcium regimen (ie, identical on Day 
-1 and Day  1), and, following the 
completion of all study  procedures, subjects will then re- start their active vitamin D at their next 
usual daily schedule.
During the washout period, subjects will be instructed to take their usual doses of supplemental 
oral calcium and active vitamin D.
Any subject who experiences s ymptoms of hy pocalcemia or hy percalcemia may  be treated at the
investigator’s discretion, as per local standards. This may  include, but is not limited to, 
intravenous (IV) calcium and/or fluids.
Shire CONFIDENTIAL Page 43
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
For all dosing regimens, rhP TH(1 -84) will be administered in the morning of Day  [ADDRESS_717540] 
until approximately  2 hours after rhPTH(1-84) administration, at which time a standardized meal 
will be served (see Section 4.3 item 5). For subjects assigned to the twice -daily  dose regimen, the 
evening dose of investigational product will be administered 12 hours after the morning dose,
and 2 hours prior to the e vening meal. A snack or light meal may  be provided to the subjects 
prior totheevening dose, provided it isconsumed ≥2hours prior toinvestigational product dose
administration. It is suggested that lunch be divided into [ADDRESS_717541] portion co nsumed at 
lunch, and the second portion consumed as the snack or light meal.
Serial blood samples for pharmacokinetic anal ysis will be collected on Day 1 of each treatment 
period for the determination of PTH concentrations at predose and up to 24 hours pos tmorning 
dose (up to [ADDRESS_717542] second dose for the twice- daily regimen). These blood samples will be
collected according to the Schedule of Assessments ( Table 3 and Table 4). Serial blood andurine 
samples for pharmacod ynamic anal ysis will be collected on Day  -1, predose and on Day 1 
following the administration of rhPTH(1 -84) for the determination of concentrations of serum
total calcium (uncorrected and corrected for serum albumin levels) , phosphate, magnesium, 
creatinine, albumin, 1,25(OH) 2D3, and fibroblast growth factor 23 (FGF23), and urinary  
excretion of calcium, sodium, citrate, phosphate, cAMP, magnesium, and creatinine and the
calcium -phosphate product will be determined. In additi on, serum samples will be collected and 
analyzed for anti -PTH antibodies (for safety  purposes) at the time points specified in Table 1, 
Table 3, and Table 4. Samples will be analy zed using a val idated methodology .
Safety  and tolerability  will be monitored closely  during the time the subject is in- clinic during the 
study . AEs will be recorded from the time the informed consent is signed, through completion of 
the study  atfollow -up.
Asafety review willbe conducted atthecompletion of8 subjects in each of Cohorts 1, 2and3
(with orwithout theinclusion of the follow -up visit data), before an y subject can be enrolled in 
the next cohort. The review will include all available safet y data and will include, at a minimum, 
the Coordinating Investigator [INVESTIGATOR_548136]. Minutes of the review 
will be disseminated to all participating investigators. Expansion of previous cohorts can occur 
concurrently  if further information is required. Cohorts may  be expanded to include additional 
subjects to ensure that 
sufficient data for analy sis are collected to complete the study  objectives.
One or more interim analy ses may  be performed in this study . If the anal ysis is deemed to be 
necessary , then a prospective statistical analy sis plan will be developed prior to the anal ysis.The
plan willinclude, ataminimum: (1)rationale toperform theinterim analysis;(2)parameters to
be anal yzed; and (3) the distribution list for the interi m anal ysis results. Interim data may  beused 
for (but not limited to) PK/PD modeling and/or regulatory submissions. The trial will not stop 
due to the results of an y interim analysis.
Subjects who complete this study  may  have the opportunity  to enroll into anopen -label extension
trialifanopen -label extension study isavailable andapproved by[CONTACT_356058]’s I RB/EC.
Shire CONFIDENTIAL Page 46
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717543]’s maximum duration of participation is expected to be approximately  90 day s or
3months (if the maximum Clinical Screening Period, washout and follow -up periods are
utilized). I f the Administrative Screening Period is required, the maximum duration of study
participation is [ADDRESS_717544], whichever is later. The Study Completion Date is used to ascertain timing for study  
results posting and reporting.
Sites and Regions 3.3
It is anticipated that this study  will be a multi -site, multi -country  study . The regions to be 
targeted include North America and countries within Europe. It is expected that approximately  
20-30 sites in those regions will enroll approximately 1 -2 subjects per site.
Shire CONFIDENTIAL Page 47
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717545] participate in the informed consent process and provide written informed 
consent/assent before any procedures specified in the protocol are performed.
Inclusion Criteria 4.[ADDRESS_717546] will not be considered eligible for the study  without meeting all of the criteria below.
Subjects cannot be e nrolled or randomized before all inclusion criteria (including test results) are 
confirmed.
1.An understanding, ability, and willingness to full y comply  with study  procedures and 
restrictions.
2.Ability  to voluntaril y provide written, signed, and dated informe d consent as applicable 
to participate in the study.
3.Adult men or women aged ≥[ADDRESS_717547] signature 
[CONTACT_548215]. The 
Screening Period for this study  may encompass both the Administrative Screening Period 
(if needed) and the Clinical Screening Period. For purposes of this inclusion criterion, age 
will only  be assessed at the time the informed consent is first signed b y the study subject.
4.History  of hypopa rathyroidism for ≥[ADDRESS_717548] PTH 
concentrations below the lower limit of the laboratory  normal range.
5.Requirement for supplemental oral calcium treat ment ≥1000 mg elemental calcium per 
day.
6.Requirement for therap y with active forms of vitamin D at a minimum dose of ≥0.25µg 
per day  (ie, ≥0.25µg calcitriol or equivalent per day).
7.Serum calcium level within the laboratory normal reference range based on c linical
chemistry  lab results at the Clinical Screening Visit (based on central and/or local lab 
results) and Treatment Period 1, Day -2 (based on central and/or local lab results), or if 
outside of normal range, considered not clinically  significant b y the investigator.
8.Urinary  calcium excretion ≥200mg (5mmol)/24h, based on a 24 -hour collection, 
collected an ytime during the Clinical Screening Period, but prior to check -in to the CRC 
at Treatment Period 1, Day -2 (based on central and/or local lab results).
9.Serum magnesium level within the laboratory  normal range at the Clinical Screening 
Visit or, if outside of normal range, considered not clinically significant b y the 
investigator.
10.Serum thy roid function tests within normal laboratory  limits at the Clinical Screening 
Visit, or, if outside of normal range, considered as not clinically significant by [CONTACT_1275].
Shire CONFIDENTIAL Page 48
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
11.Serum 25(OH)D level between the lower limit of normal and 1.5 -fold the laboratory  
upper limit of normal, or, if outside of this range, c onsidered not clinicall y significant b y 
the investigator, at the Clinical Screening Visit.
12.Serum creatinine <1.5 mg/dL (<133µmol/L ) AND estimated creatinine clearance 
>60mL/minute (>1.002mL /s) at the Clinical Screening Visit, and serum creatinine 
<1.5 mg/dL (<133µmol/L) at Treatment Period 1, Day  -2.
13.Male or non- pregnant, non -lactating female who agrees to compl y with an y applicable 
contraceptive requirements of the protocol or females of non -childbearing potential.
Exclusion Criteria 4.2
Subjects areexcluded from thestudy ifanyofthefollowing exclusion criteria aremet:
1.Participation in any  other investigational drug study  in which the last dose of
investigational drug occurred within 3 months prior to Day  1 of Treatment Period 1 (or 
within 5 half -lives, if elimination half -life is greater than 18 days).
2.Presence or history  of a clinically  significant disorder involving the cardiovascular, 
respi[INVESTIGATOR_696] , renal, gastrointestinal, immunologic, hematologic, endocrine (with exception
of the condition under study ), or neurologic s ystem(s) or ps ychiatric disease as 
determined by [CONTACT_36705].
3.Known history  of hy poparathy roidism resulting from an activation mutation in the CaSR 
gene or impaired responsiveness to PTH (pseudohy poparathy roidism).
4.Any disease t hat might affect calcium metabolism or calcium -phosphate homeostasis
other than h ypoparath yroidism, including but not limited to, active hyperthyroidism;
poorly  controlled insulin -dependent diabetes mellitus or ty pe 2 diabetes mellitus; severe 
andchronic cardiac, liver or renal disease; Cushing's s yndrome; neuromuscular disease 
such asrheumatoid arthritis; my eloma; pancreatitis; malnutrition; rickets; recent
prolonged immobility ; active malignancy , bone metastases or a history  of skeletal
malignancies; pr imary  or secondary  hyperparath yroidism; a history  of parathy roid
carcinoma; h ypopi[INVESTIGATOR_297], acromegal y; or multiple endocrine neoplasia types 1 and 2, 
asdetermined by [CONTACT_36705].
5.In male and female rats, parath yroid hormone caused an increase in the incidence of
osteosarcoma (a malignant bone tumor). The occurrence of osteosarcoma was dependent 
on parath yroid hormone dose andtreatment duration. This effect wasobserved at
parath yroid hormone exposure levels ranging from 3 to 71 times the exposure levels in 
humans receiving a 100 µg dose of rhPTH(1 -84). Therefore, subjects who are at increased 
baseline risk for osteosarcoma such as subjects with Paget ’s disease of bone or 
unexplained elevations of alkaline phosphatase, pediatric and young adult subj ects with 
open epi[INVESTIGATOR_548140], subjects with hereditary  disorders predisposing to osteosarcoma or 
subjects with a prior history of external beam or implant radiation therap y involving the 
skeleton are excluded.
6.Subjects who have a known history  of hypercalcemia during initiation of treatment with 
PTH, PTH analogues or fragments of PTH.
Shire CONFIDENTIAL Page 49
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717549] a known history  of hypocalcemia following abrupt withdrawal of
treatment with PTH, PTH analogues or fragments of PTH.
8.Subjects dependent on regular parenteral ca lcium infusions (eg, calcium gluconate) to 
maintain calcium homeostasis within [ADDRESS_717550]
within:
14days–thiazide diuretics
30 day s –loop diuretics, lithium, sy stemic corticosteroids (medical judgment is 
required by[CONTACT_36705]. Primarily high doses ofsystemic corticosteroids [eg,
prednisone] should be excluded. Stable doses of hy drocortisone [eg, as treatment
forAddison’ s disease] may  beacceptable).
3months –calcitonin, cinacalcet hydrochloride, treatment with rhPTH(1 -84)or N-
terminal PTH or PTH- related peptide fragments or analogs
For females: changes in hormone replacement therap y within 3 months are
excluded. Stable (≥ 3 months) hormone replacement therap y isacceptable.
6 months – fluoride tablets, oral bisphosphonates, methotrexate, growth hormone, 
digoxin, raloxifene or similar selective estrogen receptor modulators (SERMs)
12 months – intravenous b isphosphonates, drug or alcohol abuse, as determined by
[CONTACT_36705].
10.Presence of an y clinically significant results from laboratory  tests, vital signs 
assessments, or electrocardiograms (ECGs), as judged b y the investigator.
11.Twelve -lead ECG values (average of triplicate readings) demonstrating QTc >450msec
(males) or >470 msec (females) at the Clinical Screening Visit and/or an y time points up
to and including predose of Day  1 (Period 1).
12.Any medical condition or prior therapy  that, in the opi[INVESTIGATOR_1101] t he investigator, would
make the subject unsuitable for this study .
13.Positive test result for any of the following viral infections at the Clinical Screening Visit:
Hepatitis B surface antigen
Hepatitis C
HIV
14.Known significant bleeding diathesis thatcould preclude multiple venipunctures as 
determined b y the investigator.
15.Subjects who have donated a total of [ADDRESS_717551] donated a total of more than 499 mL of whole blood 
within 56 day s prior to dosing.
Shire CONFIDENTIAL Page 50
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
16.A positive screen for drugs of abuse at the Clinical Screening Visit, and/or a positive
screen for drugs of abuse and alcohol at check -in to the CRC at Treatment Period 1. 
Subjects taking prescription medications that might be detected duri ng the urine screen 
for drugs of abuse (listed in Section [IP_ADDRESS] ) may  be enrolled per the investigator ’s 
medical judgment.
17.History ofaclinicall ysignificant illness during the4weeks prior todosing (asdetermined
by [CONTACT_36705]).
18.History  of any  clinicall y significant surgery  or procedure within the past 8 weeks, as 
determined b y the investigator.
19.History  of an allergic response(s) to PTH or PTH analogs, or other clinically significant 
allergies, as determined by [CONTACT_093].
Restrictions 4.[ADDRESS_717552] is to be administered in the morning (for all 
dosing regimens), subjects will be required to fast for at least [ADDRESS_717553] will be administered 12 hours after the morning dose, and 2 hours 
prior to the evening meal. A snack or light meal may  be provided to the subjects prior to 
theevening dose, provided it is consumed ≥[ADDRESS_717554] dose
administration.
5.Subjects will be required to follow standardized meal schedules and eat the meals 
provided b y the site while housed in the CRC. No outside food or bevera ges (including 
gum, mints, etc) will be permitted. Menus will be identical for all subjects at the CRC 
(meaning that the food options/choices offered to each subject within the site are the 
same, not the specifics of each food choice at each meal). The mea l choices for each 
subject in Period [ADDRESS_717555] 
be identical per day  across both Period 1 and Period 2. Copi[INVESTIGATOR_548141]/sponsor ’s designee for approval prior to the start of the study for 
each subject (ie, prior to the first in-patient visit per subject at each site). While confined, 
the total daily  nutritional compositio n should be approximately  50% carbohy drate, 35% 
fat, and 15% protein. The daily caloric intake per subject should not exceed 
approximately  3200 kcal.
Shire CONFIDENTIAL Page 51
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717556].
Female subjects should be either:
Post-menopausal (12 consecutive months of spontaneous amenorrhea).Post -menopausal 
status will be confirmed at Screening with a follicle- stimulating hormone (FSH) in the 
laboratory  post -menopausal range.
Surgicall y sterile (having undergone one of the following surgical procedures: 
hysterectom y, bilateral tubal ligation, bilateral oophorectom y orbilateral salpi[INVESTIGATOR_1656] ) 
and at least [ADDRESS_717557] -steriliza tion, or
Females of child -bearing potential with a negative urine and/or serum -HCG pregnancy  
test at the screening visit, upon check -in for each treatment period, at discharge from 
clinic after the second treatment period and at follow up. Females must a gree to abstain 
from sexual activity  that could result in pregnancy or agree to use acceptable methods of
contraception.
Acceptable methods of contraception are:
Intrauterine devices plus condoms
Double -barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least [ADDRESS_717558], plus condoms. Note: if 
subject becomes sexually active during the stud y,they should use one of the other
acceptable methods noted above in addition to the hormonal contraceptive until it has 
been stabilized for [ADDRESS_717559]. Acceptable methods of contraception fo r male subjects are:
Double -barrier methods (eg, condoms with spermicidal gel or foam)
Shire CONFIDENTIAL Page 52
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717560] at any  time (eg, in the interest of subject safet y). The investigator is
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
Ifinvestigational product is discontinued, regardless of the reason, the early withdrawal 
evaluations listed in Table 1are to be performed as completely  as possible. Whenever possible,
all discontinued subjects should also undergo the protocol -specified fo llow-up.Comments 
(spontaneous or elicited) or complaints made b y the subject must be recorded in the source
documents. The reason for termination and date of stoppi[INVESTIGATOR_548142].
Randomized subjects who discontinue from the study may be replaced at the sponsor’s discretion 
to ensure that at least [ADDRESS_717561]’s
medical record and on the CRF. If a subject is withdrawn for more than [ADDRESS_717562] clinically  relevant reason should be 
entered on the CRF.
Reasons for discontinuation include but are not limited to:
Adverse event
Protocol deviation
Withdrawal by [CONTACT_1130]
Lost to follow -up
Other (If “ Other” is selected, the investigator must specify  on the CRF)
4.5.2 Subjects “Lost to Follow -up” Prior to Last Scheduled Visit
A minimum of [ADDRESS_717563] (office visit or telephone contact). At least [ADDRESS_717564]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they 
return tothesiteforfinal safet yevaluations andreturn anyunused investigational product.
Shire CONFIDENTIAL Page 53
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
5.PRIOR AND CONCOMITANT TREATMENT
Prior Treatment 5.1
Prior treatment includes all treatment (including but not limited to herbal treatments, vitamins 
[except where required by [CONTACT_43038] y] and non -pharmacological treatment such as psychotherap y,
as appropriate) receive d within 30 day s (or as defined elsewhere in this protocol) or 
pharmacokinetic equivalent of 5 half -lives, (whichever is longer) of the date of first dose of 
investigational product. Prior treatment information must be recorded on the appropriate CRF 
page.
Concomitant Treatment 5.[ADDRESS_717565] beincluded asconcomitant medication.
For this study  it is imperative that the administration times and dose strengths of all calcium and 
active vitamin D be documented accuratel y and completely  in the source document and recorded 
in the CRF for Day s -1, 1, and 2 of both treatment periods.
5.2.1 Permitted Treatment
Subjects should refrain from taking anymedications andsupplements during thecourse ofthe
study  except for those prescribed by [CONTACT_548167] (including calcium and vitamin D as 
mandated b y protocol) and not excluded in the exclusion criteria. An y medication which is 
considered necessary forthesubject’s safet yandwellbeing may begiven atthediscretion ofthe
investigator. The administration of all medications and supplements (including investigational 
products) must be listed on the appropriate CRF page.
Shire CONFIDENTIAL Page 54
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717566] is rhPTH(1 -84), which will be provided as a multiple dose, dual chamber, glass 
cartridge containing a sterile ly ophilized powder and a sterile diluent for reconstitution at doses 
of 25µg, 50µg, and 100µg. The test product in the cartridge must be mixed using the provided 
mixing apparat us, and only  administered via the injector pen which is also provided. Additional 
information related to the investigational product, including preparation and administration, is 
provided in the current rhPTH(1 -84) investigator brochure, and in an investig ational product 
preparation andadministration manual thatwillbeprovided.
No additional investigational product will be supplied. It is expected that subjects will continue 
to take their own supplemental oral calcium and vitamin D (except when instructed to hold at the 
times indicated in the current protocol) and that any products required for emergency treatment, 
eg, fluid or calcium replacement, be provided b y the study physician.
Administration of Investigational Product(s) 6.[ADDRESS_717567] into the study  (for an y of the proposed treatment groups). Randomization 
willoccur through an interactive response s ystem. Randomization of a subject will trigger 
replacement supplies for that investigative stud ysite.
6.2.[ADDRESS_717568] numbers are assigned to all subjects as they 
consent to take part in the study . Within each site (numbered uniquel y within a protocol), the
subject number isassigned tosubjects according tothesequence ofpresentation forstudy
participation. This will be a [ADDRESS_717569] not be used 
again (if for example, a subject is withdrawn from the study ). If a randomization number is
allocated incorrectl y, the study monitor must be notified as soon as the error is discovered.
Individual subject treatment is automatically  assigned by  [CONTACT_548168]  
(IRT).
Shire CONFIDENTIAL Page 55
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717570] has completed the screening process and found to be eligible to proceed to 
dosing (inclusive of all clinical laboratory values), the subject will be randomly  assigned to 1 of 2 
treatment sequences (according to the randomization schedule) prior to dosing on Day [ADDRESS_717571] (seeTable 5):
On Day  1 of Treatment Period 1, subjects in Cohort 1 will receive rhPTH(1 -84)aseither 
a twice -daily  regimen (12 hours apart) of two 25µg doses (without calcium; Treatment A) 
or a once -daily regimen of one 100µg dose (without calcium) in the morning (Treatment 
B). On Day  1 of Treatment Period 2, subjects in Cohort 1 will receive the alternative
treatment.
On Day  1 of Treatment Period 1, subjects in Cohort 2 will receive rhPTH(1 -84)aseither 
as a twice -daily regimen (12 hours apart) of two 50µg doses (without calcium; Treatment 
C) or a once -dailyregimen of one 100µg dose (without calcium; Treatment B). On Day  1 
of Treatment Period 2, subjects in Cohort 2 will receive the alternative treatment.
On Day  1 of Treatment Period 1, subjects in Cohort 3 will receive rhPTH(1 -84)aseither 
a twice -daily  regimen (12 hours apart) of two 25µg doses (with calcium; Treatment D) or 
a once -daily  regimen of one 100µg dose (with calcium; Treatment E). On Day  1 of 
Treatment Period 2, subjects in Cohort 3 will receive the alternative treatment.
On Day  1 of Treatment Period 1, subjects in Cohort 4 will receive rhPTH(1 -84)aseither 
a twice -daily  regimen (12 hours apart) of two 50µg doses (with calcium, Treatment F) or 
a once -daily  regimen of one 100µg dose (with calcium, Treatment E). On Day  [ADDRESS_717572] to the clinical trial will be appended as 
regionally required. For example, in the US the following statement will be appended ‘For 
clinical trial use only’, and/or ‘CAUTION: New Drug -Limited by  [CONTACT_4496] (or US) Law to 
Investigational Use’ and the statement ‘Keep out of the reach of children’.
Shire CONFIDENTIAL Page 56
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Additional l abels (eg, those used when dispensing marketed product) may , on a case-by-case
basis, be applied to the investigational product in order to satisfy local or institutional 
requirements, and must not:
Contradict the clinical study label
Obscure the clinical study label
Identify  the study  subject by [CONTACT_10178]’s prior full agreement.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.[ADDRESS_717573]/nominated 
team member will enter the unique subject identifier (if allowed b y local law/regulations) on the
investigational product labels as they aredistributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible for 
ensuring that the temperature is monitored throughout the duration of the study and that records 
are maintained; the temperature should be monitored continuously b y using either anin-house 
system, a m echanical recording device such as a calibrated chart recorder, or by [CONTACT_3177],
such thatboth minimum andmaximum thermometric values over aspecific time period can be 
recorded and retrieved as required. Such a device (ie, certified min/max thermomet er) would 
require manual resetting upon each recording. The sponsor must be notified immediately upon 
discovery  of any  excursion from the established range. Temperature excursions will require site 
investigation as to cause and remediation. The sponsor wil l determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
Thesponsor should benotified immediately ifthere areanychanges tothestorage area ofthe
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.
Drug Accountability 6.4
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works un der the direct supervision of the investigator. 
This delegation must be documented in the applicable study delegation of authority form.
Shire CONFIDENTIAL Page 57
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
The investigator or his/her designee (as documented by [CONTACT_548169]) willadminister theinvestigational product only tosubjects included 
in this study  following the procedures set out in the study  protocol. Each subject will be given 
only the investigational product carry ing his/her treatment assignment. All administered 
medication will be documented on the CRFs and/or other investigational product record.
No investigational product stock or returned inventory from a Shire -sponsored study  may be
removed from thesitewhere originall yshipped without prior know ledge andconsent by[CONTACT_103]. If such transfer is authorized by [CONTACT_456], all applicable local, state, and national laws 
must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.
At the end of the stud y, or as instructed b y the sponsor, all unused stock and empty /used
investigational product are to be sent to a nominated contractor on behalf of the sponsor. 
Investigational products being ret urned to the sponsor’s designated contractors must be counted 
and verified b y clinical site personnel and the sponsor (or designated contract research 
organization [CRO]). For unused supplies where the original supplied tamper -evident feature is 
verified a s intact, the tamper -evident feature must not be broken, and the labeled amount is to be 
documented in lieu of counting. Shipment return forms, when used, must be signed prior to 
shipment from the site. Returned investigational products must be packed in a tamper -evident
manner to ensure product integrit y. Contact [CONTACT_548170]. Shipment of all returned 
investigational product must comply  with local, state, and national laws.
Only  in exceptional circumstances, and when agreed by [CONTACT_3186], a site may be 
required to destro y the used/unused supplies locally (based on their institution’s SOPs, 
guidelines, hospi[INVESTIGATOR_307]/pharmacy  regulations, etc.). In this c ase, and onl y with the written agreement
of the sponsor, all unused stock, and empty/used investigational product may be destro yed atthe 
site or a local facility. In this case, destruction records identify ing what was destroy ed, when and 
how, must be obta ined with copi[INVESTIGATOR_59695]. Destruction of investigational 
products must be in accordance with local, state, and national laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All investigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
Subject Compliance 6.[ADDRESS_717574] be assessed by  [CONTACT_548171]. The 
investigator/nominated person will record details on the drug accountability log(s) and/or source
documents. In addition, details of the dosing time (time, date, dose level) will be captured in the 
appropriate CRF.
Shire CONFIDENTIAL Page 58
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Retention of Bio availability and Bioequivalence Testing Samples 6.6
NotApplicable.
Shire CONFIDENTIAL Page 59
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
7.STUDY PROCEDURES
Dosing and Procedure Observations 7.1
Study Schedule 7.2
See Table 2, Table 3, and Table 4schedules of study procedures.
The following “priorit y order” will be in effect when more than 1 procedure or assessment is 
required at a particular time point.
Spontaneous or solicited AE reporting
ECG
Vital signs
Pharmacod ynamic blood sampling*
Pharmacokinetic blood sampling*
Clinica l laboratory tests*
Physical examination
* In order to avoid potential for cross -contamination of tube additives when collecting blood 
samples at one time point for different assays, all tubes requiring serum (eg. pharmacod ynamic 
samples, anti -PTH antibody , chemistry  panel, T3, T4, TSH, serum β -HCG, FSH, HBsAG, HIV, 
and 25[OH]D samples) should be drawn prior to any  tubes requiring plasma (eg, 
pharmacokinetic and hematology  samples). This sequence is important because serum samples 
require collection without anticoagulant (redtoptube) which should becollected prior tosamples 
requiring an anticoagulant (ie, purple top tube: being either a K3EDTA tube or a K2EDTA tube).
NOTE: Blood sampling for pharmacod ynamic and pharmacokinetic evaluations must be
performed at the precise protocol -scheduled time. Actual sampling time(s) must be accuratel y 
recorded in the source document and appropriate CRF.
7.2.[ADDRESS_717575] of the Administrative Screening Period (if needed) prior to the 
Clinical Screening Period.
Administrative Screening and Remote Consent Process [IP_ADDRESS]
The Administrative Screening Period is the time needed to assist those subjects and study sites 
who may  need to obtain historical medical records of a potential subject to confirm partial 
eligibility  and who may , or may  not, be remote from the study  site. An informed consent 
document must be signed by  [CONTACT_548172]. A copy  of the signed informe d consent must be given to the subject for 
their records.
Shire CONFIDENTIAL Page 60
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
The consent process may be performed remotely  only  if it is in compliance with the site’s local 
and/or regional regulations, and approved b y the site’s IRB/EC. Details of the remote consent 
process areprovided inAppendix 2.From thetime thesubject provides asigned consent form,
thesubject willberegistered asastudy participant. TheAdministrative Screening Period isonly 
for information gathering purposes (medical records), and NOT for an y active screening
procedures performed on the study  subject. As such, it is not part of the active screening process.
The Administrative Screening Period to collect appropriate medical records may be performed 
up to [ADDRESS_717576] then complete a clinical screen 
(described below).
Clinical Screening [IP_ADDRESS]
The Clinical Screening Period differs from the Administrative Screening Period in that the 
subject is phy sicall y present at the CRC during the Clinical Screening Visit and/or completes a 
required ass essment in the study  (outlined in Table 1). Following a subject’s informed consent, 
the study  specific screening procedures can be conducted.
For an y subject who does not require an administrative screen, the subject must sign an 
informed consent at the Cl inical Screening Visit, prior to an ystudy -specific procedures 
being performed.
For an y subject who completes an administrative screen, the subject must sign a (new) 
informed consent (and be given a new subject number) at the Clinical Screening Visit, 
prior to an y study -specific procedures being performed (the subject will be considered as 
an administrative screen failure under the prior assigned subject number).
Clinical screening visit procedures must be completed within [ADDRESS_717577] part (Day  -28 to Day  - 3) eligibility  for study  participation will be 
checked on an out -patient basis. In the second part of the Clinica l Screening Period, the 
remaining procedures for eligibility  will be confirmed as an in -patient. This is outlined in Table 
1.
Written, signed, and dated informed consent from the subject prior to the performance of any 
study  related procedures must be obta ined by  [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a designee. A cop yof
the signed informed consent form must be given to the subject for their records.
Shire CONFIDENTIAL Page 61
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Screening Failure [IP_ADDRESS]
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least [ADDRESS_717578](s).
For purposes of data collection, all subjects who give consent to the study, but are not enrolled 
and/or randomized, will be reported as screen failures, even if they  were otherwise full yeligible
forthestudy ,forexample alternates/reserve subjects.
Rescreening of Subjects [IP_ADDRESS]
Subjects who fail to meet all inclusion/exclusion criteria will be permitted to be rescreened based 
on investigator discretion and sponsor approval if the investigator assesses the reason for screen 
failure is transient and temporary .
Potentially  eligible subjects who continue to meet all inclusion/exclusion criteria, but are unable 
to participate in the study due eith er to scheduling conflicts/timing (including the time required 
to obtain medical records release, if applicable) or appropriate slot availability at an 
investigational site, may  be rescreened based on investigator discretion and sponsor approval 
should their availability  to participate fall outside the screening window.
In these cases, a new screening number must be assigned for each subject who is rescreened and 
a new informed consent form must be signed.
7.2.2 Treatment Period
[IP_ADDRESS] Day 1 to Day 2 (Treatment Periods 1 and 2)
Study  assessments for Day  [ADDRESS_717579] will occur on Day  1 of each treatment period.
The time points for pharmacokinetic/pharmacod ynamic assessments will be performed according
to the BID or QD dose regimen assigned to the subject in the treatment period. Subjects will be 
discharged from the CRC following completion of the last study  assessment on Day  2of
Treatment Period 1. Following a washout of (at least 120 hours [5 days] to [ADDRESS_717580] dose of each treatment period [QD or BID dosing, respectively ]) subjects will be 
admitted to the CRC for Treatment Period 2 procedures at Day -2.
7.2.3 Final Visit
For this study , the final visit will be the Follow up visit, which is intended to be an out-patient
clinic visit.
7.2.4 Follow -upPeriod
The fol low-up period for this protocol is 30±[ADDRESS_717581] will be followed to 
closure (see Section 8.1).
Shire CONFIDENTIAL Page 62
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717582] the opportunity  to enroll in an open -label extension 
trial if an open- label extension study  is available and approved b y the site’s IRB/EC.
Study Evaluations and Procedures 7.3
7.3.1 Demographic and Other Baseline Characteristics
Demographics [IP_ADDRESS]
Demographic information will be collected at the initial screening visit. I nformation to be 
collected will include:
Date of birth
Sex
Race and ethnicity
7.3.[ADDRESS_717583] part y vendor (eg, clinical laboratory ) used in this study will 
be maintained in the investigator’s and sponsor’s files.
Actual safety  assessment times will be monitored and recorded. The sponsor’s expectation is that 
the investigator will ensure that every  effort is made to perform all assessments at the precise 
protocol -scheduled time. Unless otherwise noted, any  safet y assessment that deviates from the
scheduled assessment time set forth in the protocol by  [CONTACT_726] 15 minutes will be considered
a protocol deviation.
AEs (defined as AEs occurring from the time of informed consent signature [CONTACT_548216]), TEAEs (all AEs occurring after the first treatment), prior medication 
andconcomitant medication usewillbeassessed andmonitored from thetime thesubject signs
the informed consent form to completion of study (including to time of screen failure or drop 
out/discontinuation). While confined in the CRC, subject safet y will also be closely monitored
through blood pressure measurements, ECG mea surement, clinical safet y labs and physician 
oversight.
In the event anti- PTH antibodies are detected following anal ysis for a subject, the investigator 
will be notified by  [CONTACT_1034]. It will be the investigator’s responsibility  to notify  thesubject.
Medical and Medication History [IP_ADDRESS]
A complete medical and medication history  will be performed at the Clinical Screening 
Visit/time points described in Table 1by a qualified licensed ph ysician, phy sician’s assistant, or 
a nurse practitioner. The medical history will be reviewed and recorded, including:
Recent use of medication ([ADDRESS_717584] dose of study treatment)
Shire CONFIDENTIAL Page 63
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
History  of respi[INVESTIGATOR_696] , cardiovascular, renal, gastrointestinal, hepatic, endocrine, 
hematological, neurological, psy chiatric, and othe rdiseases
Physical Examination (Including Height and Weight) [IP_ADDRESS]
A complete ph ysical examination will be performed at the time points described in Table 1bya 
qualified licensed ph ysician, phy sician’s assistant, or a nurse practitioner.
The phy sical examinat ion will include a review of the following bod ysystems:
General appearance
Skin
Head, ey es, ears, nose, and throat
Spi[INVESTIGATOR_050]/neck/thy roid
Musculoskeletal
Respi[INVESTIGATOR_696]
Cardiovascular
Neurological
Abdomen (including liver and kidney s).
Clinically  significant abnormalities identified at the Clinical Screening Visit will be documented 
in the subject’s source documents and on the medical history CRF. Changes after the Clinical 
Screening Visit will be captured as AEs on the AE CRF, as deemed b y the investigator.
Adverse Event Collection [IP_ADDRESS]
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have
occurred since theprevious visit (eg,“Have youhadany health problems since your lastvisit?”).
Adverse events are collected from the time informed consent is signed. (Please refer to Section 8, 
Adverse and Serious Adverse Events Assessment.)
Vital Signs, Blood Pressure and Pulse Rate [IP_ADDRESS]
Blood pressure and pulse rate will be measured at times specified in Table 1, Table 2, Table 3, 
and Table 4of this protocol. With exception of the predose assessment on Day  1 (which must be
within 30 minutes prior to administration of I P), any  subse quently  scheduled vital signs 
assessment collected during Periods 1 and 2 that deviates from the scheduled assessment time in 
Table 2, Table 3, and Table 4by [CONTACT_726] 15 minutes will be considered a protocol deviation.
Shire CONFIDENTIAL Page 64
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717585] safety and accurate recording of 
vital sign measurements. Any changes from baseline which are deemed clinically significant by 
[CONTACT_363589].
The same method for obtaining blood pressure measurement (auscultatory or oscillometric) 
should be used throughout t he study  for all subjects (and documented). In addition, the 
conditions of vital sign measurements should be controlled and as consistent as possible during 
the study , in order to minimize external variability of the readings. It is advised that 
measuremen tsbecollected atacomfortable room temperature with little to nobackground noise,
using the same (appropriately sized) cuff placed at the same location of the same arm during the
study . The bladder deflation rate should be deflated (calibrated for osci llometric method or 
manually  by [CONTACT_444101]) at a rate of 2 -3 mm Hg/s (and the first and last audible sounds 
recorded as s ystolic and diastolic pressure) after at least [ADDRESS_717586] a bladder lengt h that is 80% and a width that is at least 40% of arm 
circumference (a length -to-width ratio of 2:1).
The subject should be asked to remove all clothing that covers the location of cuff placement.
The subject should not have exercised or consumed caffeine, alcohol, or nicotine (as specified in 
the study  restrictions; Section 4.3) or within [ADDRESS_717587] should belyingcomfortabl y,with thelegsuncrossed. Thearmshould besupported 
with a pi[INVESTIGATOR_6356], such that the middle of the cuff on the upper arm is at the level of the right atrium 
(approximately  halfway  between the bed and the level of the sternum) .One reading (supi[INVESTIGATOR_548143]/diastolic blood pressure -pulse) should be taken.
The use of automated devices for measuring pulse rate is acceptable although, when done 
manually , pulse rate will be measured in the brachial/radial artery  for at least 30 seconds. When 
the timing of these measurements coincides with a blood collection, blood pressure and pulse
rate should be obtained prior to the nominal time of the blood collection.
Clinical Laboratory Evaluations [IP_ADDRESS]
All clinical laboratory  assay s will be performed according to the laboratory ’s normal procedures. 
Reference ranges are to b e supplied by  [CONTACT_64712] -of-range pathological changes. The investigator 
should assess out -of-range clinical laboratory  values for clinical significance, indicati ng if the 
value(s) is/are not clinically  significant or clinically significant. Abnormal clinical laboratory  
values, which are unexpected or not explained by [CONTACT_423]’s clinical condition, may , atthe
discretion of the investigator or sponsor, be repeat ed as soon as possible until confirmed, 
explained, or resolved. Samples for all clinical laboratory evaluations will be sent to a central 
laboratory . If an immediate (stat) result is required, a local laboratory  may  be used but a
duplicate sample must be s ent to the central laboratory. A manual full y describing the schedule
and method of sample handling will be provided.
Shire CONFIDENTIAL Page 65
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717588] for randomization at Treatment Period 1, the site can base 
eligibility  on the local lab results if the central lab results are not available, but, if results are 
available from both labs, eligibility  should be based on the central lab results.
However, local lab results will not be entered in the eCRF/clinical database, and copi[INVESTIGATOR_548144]. The central lab results (once 
received) will be entered in the eCRF/clinical database.
The following clinical laboratory  assessments will be performed:
Biochemistry
Blood samples (8.5mL)for serum biochemistry willbecollected intoagelseparator tube atthe
timepoints described in Table 1. The following parameters will be assessed:
Sodium
PotassiumPhosphorus
Total protein-HCGb
FSHb
Glucose Total CO 2(Bicarbonate) Magnesium
Blood urea nitrogen Albumin
Creatinine Aspartate transaminase
Calcium Alanine transaminase
Chloride Gamma glutamy ltransferase
Thyroid stimulating hormone (TSH)aAlkaline phosphatase
Thyroxine (T4 total)aTotal bilirubin
Triiodothy ronine (T3)aUric acid
25(OH)D Creatinine clearance
(estimated)a
-HCG=beta -human chorionic gonadotropin; FSH=follicle stimulating hormone; T3=triiodothyronine; TSH=thyroid stimulating 
hormone
a See Table 1.
b Females only.
Hematology
Blood samples (4 mL) for hematology  will be collected into eth ylenediaminetetraacetic acid 
tubes atthetime points described inTable 1. Thefollowing parameters willbeassessed:
Hemoglobin Total neutrophils (absolute)
Hematocrit Eosinophils (absolute)
Red blood cells Monocy tes (absolute)
Platelet count Basophils (absolute)
White blood cell count; total and differential Lym phocy tes (absolute)
Shire CONFIDENTIAL Page 66
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Urinalysis
A urine sample for urinalysis will be collected at the time points described in Table 1.The
following parameters will be assessed:
pH Blood Nitrites
Glucose Ketones Leukocy teesterase
Protein Bilirubin Specific gravity
Calcium
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinaly sis. At a minimum the microscopic examination will consist of red blood cells, white 
blood cells, casts, and bacteria.
Pregnancy Test [IP_ADDRESS]
A serum β -HCG pregnancy  test is to be performed on all females at the Clinical Screening Visit. 
A urine pregnancy  test is performed on all female subjects at all subsequent visits as outlined in 
Table 1.
Drug and Alcohol Screen [IP_ADDRESS]
A urine screen for drugs of abuse and alcohol breath test will be performed at the time points 
described in Table 1. Additional drug and alcohol screens may  be performed at the investigator’s 
discretion.
Urine samples are to be tested for amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, 
cocaine, methadone, opi[INVESTIGATOR_10149], andphencyclidine.
Results of urine drug and alcohol breath test screens will be reviewed and verified b y the study  
monitor, but will not be collected in the CRF database.
Any positive result for drugs of abuse at clinical screening or drugs of abuse or alcohol on Day -1 
(both treatment periods) will exclude the subject from further participation in the study (except as 
noted in Excl usion Criterion #16).
Serology Screen [IP_ADDRESS]
At the Clinical Screening Visit, a blood sample of approximately  8.5 mL will be drawn into a gel 
separator tube totestforthepresence ofHIV,hepatitis Bsurface antigen (HBsAg), andhepatitis 
C virus (HCV) antibody as outlined in Table 1.
The test results must be confirmed negative prior to enrollment in the study. If a test result is 
positive, the subject will be excluded from entering the stud y. Results of the virology screen will 
be reviewed and verified by  [CONTACT_10184], but will not be collected in the CRF database.
Shire CONFIDENTIAL Page 67
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Electrocardiogram [IP_ADDRESS]
Twelve- lead ECGs will be performed at the times specified in Table 1, Table 2, Table 3,and
Table 4. All ECGs will be performed in triplicate (with a minimum 2 minute gap between traces) 
using the equipment supplied by  [CONTACT_10186]. Two identical trace ECG recordings for each time 
point will be collected and one original provided to the study sponsor or ECG vendor. With 
exception of the predose assessment on Day  1 (which must be within 30 minutes prior to 
administration of I P) any subsequently  scheduled ECG assessment collected during Periods 1and 
2 that deviates from the scheduled assessment time in Table 2, Table 3,andTable 4by[CONTACT_726] 
15 minutes will be considered a protocol deviation.
Thefollowing parameters willbeprovided tothesponsor orthesponsor representative by[CONTACT_548173]: heart rate, PR, RR, QRS, and QT intervals along with information on T and 
U-wave morphology ; U-waves should be captured as absent/normal or abnormal. The QTcB and 
QTcF will be derived from the data pro vided b y the central ECG reader. The investigator’s 
assessment of the ECG tracing as normal or abnormal must be documented, and, if abnormal, 
his/her determination ofwhether theabnormalit yis clinically significant or not will be
documented on the tracing and recorded in the CRF.
The subject should be asked to remove all clothing that covers the location of lead placement. 
The subject should not have exercised or consumed caffeine, alcohol, or nicotine within 
60minutes prior to collection. The subj ect must be resting in the supi[INVESTIGATOR_21683]
5minutes prior to collecting the ECG.
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that lea ds are placed in 
approximately  the same positions each time in order to achieve precise ECG recordings. Only 
valid ECG tracings will be submitted to the ECG vendor for analy sis.
Triplicate recording, including a 10 second rh ythm strip, will be obtained approximately
2-4minutes apart for all assessments. The time and date of each valid ECG tracing obtained with 
the 3 assessments will be recorded in the CRF. The ECG parameters as described above will be 
evaluated b y a central reader and the interpretation pr ovided to the sponsor or the sponsor
representative. The average of the triplicate valid ECG measurements collected at each nominal 
time point will be used for anal ysis. The 3 recordings should be immediately  assessed as valid 
recordings and, if not valid, they should be repeated in order to obtain a total of 3 valid 
recordings. Invalid recordings will not be entered in the CRF.
When (triplicate) ECGs are obtained, the average of the triplicate ECG measurements collected 
predose on Day  [ADDRESS_717589]’s baseline ECG.
Toensure safet yofthe subjects, aqualified individual attheinvestigator sitewillmake
comparisons to baseline measurements.
If the QTcF interval (calculated on site) is increased by  >45msec from the baseline, or an
absolute QTc F value is >500 msec for an y scheduled ECG, then 2 additional ECGs will be
collected, approximately  2-4 minutes apart, to confirm the original measurement. 
Shire CONFIDENTIAL Page 68
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Ifeither oftheQTcF values from these repeated ECGs remains above the threshold value 
(>45msec increase from the baseline; or is >500 msec), then a single ECG must be repeated at 
least hourly until QTcF values from [ADDRESS_717590] follow -upECGs.
If QTcF values remain above 500 msec (or >45msec increase from the baseline) for >4 hours (or 
sooner at the discretion of the investigator); or QTcF intervals get progressively  longer, the 
subject should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
intervals do not return to <500 msec (or to <45 msec above the baseline) after 8 hours of
monitoring (orsooner atthediscretion oftheinvestigator).
If a machine -read QTcF/QTcB value is prolonged, as defined above, repeat measurements may 
not be necessary  if a qualified phy sician’s interpretation determines that the QTcF/QTcB values 
are in the acceptable range.
In cases where a central E CG reader is used, the eligibility  of the subject is based on the 
assessment of the ECG by [CONTACT_093]. If abnormal results are observed following 
assessment by  [CONTACT_9251], the investigator, in consultation with the appointed sponsor's 
medical monitor, reconfirms the subject's eligibility  to continue to participate in the study .
7.3.3 Pharmacokinetic Procedures
The name [CONTACT_10214] (ies) for this study  will be maintained in the 
investigator’s files at the/each site and in the Trial Master File at the sponsor. A manual fully 
describing the schedule and method of sample handling will be provided.
Actual pharmacokinetic blood sample collection times versus time of dosing will be monitored. 
The sponsor's expectation is that the investigator will ensure that every  effort is made to collect 
all pharmacokinetic blood samples at the precise protocol scheduled time. Pharmacokinetic 
blood collection must notdeviate from thenominal collection time setforth intheprotocol by
[CONTACT_726] [ADDRESS_717591] -dose, or b y more than
15minutes for samples drawn [ADDRESS_717592] -dose and bey ond. Samples drawn outside these 
parameters will be considered a protocol deviation.
Pharmacokinetic Blood Sample Colle ction and Handling Procedures [IP_ADDRESS]
Pharmacokinetic blood samples will be collected at the time specified in Table 1, Table 2, Table 
3,andTable 4to measure plasma concentrations of PTH.
A full description of the pharmacokinetic blood collection, handling, storage and shippi[INVESTIGATOR_548145].
Plasma sample tubes forbioanaly sismust befreezer -safeandidentified with freezer -safelabels
provided b y the CRC. The labels will contain the following information:
Study  number: SHP634 -101
Subject identifier
Shire CONFIDENTIAL Page 69
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Treatment Period
Nominal day
Nominal time
Matrix identifier (plasma)
Split (primary  orback -up).
Shipment of Plasma Pharmacokinetic Sampl es [IP_ADDRESS]
All pharmacokinetic plasma samples should be double -bagged to contain leaks and packed with 
asufficient quantity ofdryicetoensure thatthey remain frozen foratleast 72hours toallow for
delay s in shipment. All applicable shippi[INVESTIGATOR_548146]. Shipments should be 
scheduled so that no samples arrive on the weekend and should be shipped Monday -Wednesday  
only. Samples should be transported to ensure that they arrive at the bioanaly tical laboratory  
between the hours of 9:00 AM and 4:[ADDRESS_717593] be provided with 
the shipment tracking number.
All pharmacokinetic samples, along with the corresponding documentation will be shipped 
according to the instructions in the provided laboratory manual.
Pharmacokinetic samples will be stored nominally at -70◦C prior to and after anal ysis at the assay  
laboratory  until their disposal is authorized by [CONTACT_10188].
Pharmacokinetic Plasma Assay Methodology [IP_ADDRESS]
Plasma concentrations of PTH will be measured using the most current validated bioanal ytical
method according to the relevant Standard Operating Procedure in place at the designated 
bioanaly tical contract laboratory . In addition, selected plasma samples may be used to investigate 
incurred sample reproducibility  (full details will be described in the bioanaly tical study plan).
The presence of other metabolites or artifacts may be monitored or quantified as appropriate.
7.3.4 Pharmacodynamic Proce dures
The name [CONTACT_10214] (ies) for this study  will be maintained in the 
investigator’s files at the/each site and in the Trial Master File at the sponsor. A manual fully 
describing the schedule and method of sample handling will be provided.
Actual pharmacod ynamic blood sample andurine sample collection times versus time ofdosing
will be monitored. The sponsor's expectation is that the investigator will ensure that every effort 
is made to collect all pharmacod ynamic blood and urine samples at the precise protocol 
scheduled time. Pharmacody namic blood collection must not deviate from the nominal collection 
time set forth in the protocol by [CONTACT_726] [ADDRESS_717594]-dose, or b y more than [ADDRESS_717595] -dose and beyond. 
Samples drawn outside these parameters will be considered a protocol deviation.
Shire CONFIDENTIAL Page 70
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Pharmacodynamic Blood Sample Collection and Handling Procedures [IP_ADDRESS]
Pharmacod ynamic blood samples willbecollected atthetimespecified inTable 1, Table 2, Table 
3,andTable 4to measure serum calcium (total and albumin corrected), magnesium, phosphate, 
albumin, creatinine, fibroblast growth factor 23 (FGF23) and 1,25-dihydroxy cholecalciferol
(1,25(OH) 2D3).
Afulldescription ofthepharmacod ynamic blood collection, handling, storage andshippi[INVESTIGATOR_548147].
Serum sample tubes forbioanaly sismust befreezer -safeandidentified with freezer -safe labels
provided by[CONTACT_548174]. Thelabels willcontain thefollowing information:
Study  Number: SHP634 -101
Subject identifier
Treatment Period
Nominal day
Nominal time
Matrix identifier (serum)
Analy te(if there is more than 1)
Split (primary  orback -up).
Shipment of Serum Pharmacodynamic Samples [IP_ADDRESS]
All pharmacod ynamic serum samples should be double -bagged to contain leaks and packed with 
asufficient quantity ofdryicetoensure thatthey remain frozen f oratleast 72hours toallow for
delay s in shipment. All applicable shippi[INVESTIGATOR_548146]. Shipments should be 
scheduled so that no samples arrive on the weekend and should be shipped Monday -Wednesday  
only. Samples should be transported to ensure that they  arrive at the bioanaly tical laboratory  
between thehours of9:00 AMand4:[ADDRESS_717596] be provided with 
the shipment tra cking number.
Allpharmacod ynamic serum samples, along with thecorresponding documentation, willbe
shipped to the address provided in the laboratory manual.
Pharmacod ynamic serum samples will be stored nominally  at -70 C prior to and after analys isat 
the assay  laboratory  until their disposal is authorized by [CONTACT_10188].
Shire CONFIDENTIAL Page 71
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Pharmacodynamic Serum Assay Methodology [IP_ADDRESS]
Pharmacod ynamic serum parameter concentrations will be measured using the most current 
validated bioanal ytical methods according to the relevant Stand ard Operating Procedure(s) in 
place at the designated bioanal ytical contract laboratory . In addition, selected plasma samples
may be used to investigate incurred sample reproducibility  (full details will be described in the 
bioanaly tical study  plan). The p resence of other metabolites or artifacts may be monitored or 
quantified as appropriate. Raw data will be stored in the archive of the designated bioanal ytical
contract laboratory .
Pharmacodynamic Urine Sample Collection and Handling Procedures [IP_ADDRESS]
Pharmacod ynamic urine samples willbecollected atthetime specified inTable 1, Table 2, Table 
3,andTable 4to measure calcium, sodium, citrate, phosphate, magnesium, cAMP and creatinine.
Urine samples for pharmacod ynamic anal ysis will collected over 24 hours (or [ADDRESS_717597] dose of the BID regimen) in discrete time periods according the schedules in Table 1, Table 
2, Table 3,andTable 4. A full description of the pharmacod ynamic urine collection, handling
(including additives), storage and shippi[INVESTIGATOR_548148].
Urine sample tubes forbioanal ysismust befreezer -safeandidentified with freezer -safelabels
provided b y the CRC. The labels will contain the following information:
Study  number: SHP634 -101
Subject identifier
Treatment Period
Nominal day
Nominal time
Matrix identifier (urine)
Analy te (if there is more than 1)
Split (primary  orback -up).
Shipment of Urine Pharmacodynamic Samples [IP_ADDRESS]
All pharmacod ynamic urine samples should be double -bagged to contain leaks and packed with a
sufficient quantit yofdryicetoensure thatthey remain frozen foratleast 72hours toallow for
delay s in shipment. All applicable shippi[INVESTIGATOR_548146]. Shipments should be 
scheduled so that no samples arrive on the weekend and should be shipped Monday -Wednesday  
only. Samples should be transported to ensure that they  arrive at the bioanaly tical laboratory  
between the hours of 9:00 AM and 4:[ADDRESS_717598] be provided with 
the shipment tracking number.
All pharmacod ynamic urine samples, along with the corresponding documentation, will be 
shipped to the assay  laboratory  outlined in the provided laboratory manual.
Shire CONFIDENTIAL Page 72
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Pharmacod ynamic urine samples will be stored nominally  at -70◦C prior to and after anal ysisat 
the assay  laboratory  until their disposal is authorized by [CONTACT_10188].
Pharmacodynamic Urine Assay Methodology [IP_ADDRESS]
Pharmacod ynamic urine parameter concentrations will be measured using the most current
validated bioanal ytical methods according to the standard operating procedures at the contract 
bioanaly tical laboratory . In addition, selected urine samples may  be used to investigate incurred
sample reproducibility  (full details will be described in the bioanal ytical study  plan). The 
presence of other metabolites or artifacts may be monitored or quantified as appropriate.
Shire CONFIDENTIAL Page 73
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
7.3.5 Volume of Blood to be Drawn from Each Subjec t
Table 6:Volume of Blood to be Drawn from Each Subject
Assessment Sample
Volume
(mL)# Sam ples at
Clinical
Screening/Day
-2#
Baseline
Samples
(Day -1
and/or Day-2)#
Samples
each QD
regim en
(Days 1-2)#
Samples
each
BID
regim enFollow Up Total #
SamplesTotal
Volume
(mL)
PK samples (plasma PTH)a,d4*
*(unless
otherwise
specified)0 0 12
*(7 samples
of3mL +
5 samples
of4mL)21
*(11 samples
of3mL +
10 samples
of4mL)0 33
*(18 samples
of 3mL +
15 samples of
4mL)114
*(54mL+ 
60mL)
HBsAg, HIV, HCV 6 1 0 0 0 0 1 6
Safety Biochemistry and
-HCGb6 1
(Clinical Screening)2
(TP1 D -2 + TP2 D- 2)1 1 1 6 36
Hem atology 2 1 2 1 1 1 6 12
Serum 25(OH)D 2 1 0 0 0 0 1 2
PD total serum 4 0 18 0 0 0 18 72
samples
Baselinecalcium,
magnesium,(3mL+1mL
discard)(9TP1+9TP2)
(D-1)phosphate,
creatinine,
1,25(OH) 2D3c
FGF23, Albumin 2 0 18
(9TP1+9TP2)0 0 0 18 36
Shire CONFIDENTIAL Page 74
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Table 6:Volume of Blood to be Drawn from Each Subject
Assessment Sample
Volume
(mL)# Sam ples at
Clinical
Screening/Day
-2#
Baseline
Samples
(Day -1
and/or Day-2)#
Samples
each QD
regim en
(Days 1-2)#
Samples
each
BID
regim enFollow Up Total #
SamplesTotal
Volume
(mL)
PD total serum 4 0 0 11 15 0 26 104
samples
(Day s 1-calcium,
magnesium,(3mL+1mL
discard)
2) phosphate,
creatinine,
1,25(OH) 2D3c,d
FGF23, Albumin 2 0 0 11 15 0 26 52
anti-PTH antibody 3 0 1
(TP1, 
predose 
l )0 0 1 2 6
Total mL 440e
BID=twice -daily; -HCG=beta -human chorionic gonadotropin; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; QD=once=daily.
a If a catheter is used, the first 1mL is to be discarded when the PK sample is collected alone at a time point (ie without collection of a PD sample); then t ake 3mL into appropriate 
tube for PK sample. A total of 4mL of blood drawn has been used in determination of this sample volume.
b-HCG testing for females only.
c If a catheter is used, the first 1mL is to be discarded; then take 3mL into appropriate tub e(s) for PD assessments for total serum calcium, magnesium, phosphate, creatinine, 
1,25(OH) 2D3. A total of 4mL of blood drawn has been used in determination of sample volume. An additional sample of 2mL will be collecte d for FGF23 and albumin in a 
separate tube.
dWhen aPDandPKsample arecollected atthesame time point, thePDsample is to bedrawn prior tothePKsample (toavoid anypotential forcross -contamination oftube
additives), and if a catheter is used for this collection, the first 1mL of blood should be discarded prior to the PD blood sample collection. When either a PK or a PD sample is 
drawn alone at a scheduled time point, 1mL of blood should be discarded prior to the scheduled blood sample collection.
e This is an approximate calculation of total blood volume required for the study for each subject
Shire CONFIDENTIAL Page 75
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
During thisstudy ,it isexpected thatapproximately 440mLofblood willbedrawn from all
subjects, regardless of sex.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]; however, the total volume drawn over the course of the study  
should be approximately  440 mL . When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same type of tube, the assessments may  becombined.
Shire CONFIDENTIAL Page 76
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717599] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
All AEs are collected from the time the informed consent is signed unti l the defined follow -up 
period stated in Section 7.2.[ADDRESS_717600] be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  further improvement or worsening of the event), or the event is otherwise
explained. Whe n appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.[ADDRESS_717601] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia pr ior to 
dosing of investigational product, but the dyspepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate CRF).
Themedical assessment ofseverit yisdetermined by[CONTACT_548175]:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual a ctivities of daily  
living.
Moderate: A type of AE that is usually alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses no significant
orpermanent risk ofharm totheresearch subject.
Severe: A type of AE that interrupts usual activities of dail y living, or significantly affects
clinical status, or may  require intensive therapeutic intervention.
Shire CONFIDENTIAL Page 77
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessm ent of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If
there is no valid r eason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product a nd the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  behelpful:
Term Relationship Definition
RelatedThe temporal relationship betw een the event and the administration ofthe
investigational product iscompelling and/or follows aknown orsuspected response
pattern tothat product, andtheevent cannot beexplained by[CONTACT_24362]’s medical
condition, other therapi[INVESTIGATOR_014], or accident.
NotRelatedThe event canbereadily explained by[CONTACT_548176]’s underlying
medical condition, concomitant therapy, oraccident and noplausible temporal or
biologic relationship exists between the investigational product and the event.
8.1.[ADDRESS_717602] be recorded during the course of the stud y on the CRF. Outcomes are
asfollows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved With Sequelae
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in th e study ; however, significant worsening of the s ymptoms should be
recorded as an AE.
Shire CONFIDENTIAL Page 78
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717603] to the start of study  
treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (eg, concomitant disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical conditi on of a subject, 
whether a change in a clinical laboratory, vital sign, or ECG parameter is clinically  significant 
and therefore represents an AE.
8.1.[ADDRESS_717604] be reported within 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department using the Shire Investigational and Marketed Products Pregnancy  
Report Form. A cop y of the Shire Investigational and Marketed Products Pregnancy Report
Form (and an y applicable follow -up reports) must also be sent to the CRO/Shire Medica l
Monitor using the details specified in the emergency  contact [CONTACT_1739]. 
The pregnant female study participant must be withdrawn from the study .
Every  effort should be made to gather information regarding the pregnancy  outcome and
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
[ADDRESS_717605]-partum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  are 
considered SAEs and must be reported using the Shire Clinical Study  Serious Adverse Event and 
Non-serious AEs Required by [CONTACT_10191]. Note: An elective abortion is not considered an
SAE.
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Serious Adverse Event and
Non-serious AEs Required by  [CONTACT_10192]. The test date of the first positive serum/urine 
-HCG test orultrasound result will determine the pregnancy onset date.
Shire CONFIDENTIAL Page 79
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication e rror (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not a pply to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –Persistent or sporadic intentional intake of investigational product when used for
anon-medical purpose (eg,toalter one’s state ofconsciousness orgethigh) ina manner 
that may  be detrimental to the individual and/or society
Misuse –Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directed at the dose prescribed by  [CONTACT_400720])
Overdose –Intentional or unintentional intake of a dose of investigational product higher 
than the protocol -prescribed dose
Medication Error –An error made in prescribing, dispensing, administration, and/or use 
of an investigational product. For studies, medication errors are reportable to the sponsor 
only as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors. Medication errors should be collected/reported for all products under 
investigation. The administration and/or use of the unassigned treatment is/are always reportable
as a medicat ion error. The administration and/or use of an expi[INVESTIGATOR_319379] a reportable medication error.
Serious Adverse Event Procedures 8.2
8.2.1 Reference Safety Information
Thereference forsafet yinformation forthisstudy istherhPTH(1 -84)investigator brochure
which the sponsor has provided under separate cover.
8.2.[ADDRESS_717606] be reported by [CONTACT_38910]/Shire Medical Monitor 
within [ADDRESS_717607] awareness of the event. Note: The 24 hours reporting requirement for 
SAEs does not apply  to reports of abuse, misuse, overdose, or medication errors (see
Section 8.1.7 ) unless they result in an SAE.
The investigator must complete, sign, and date the Shire Clinical Study  Serious Adverse Event 
and Non -serious AEs Required by  [CONTACT_548177] (Note: Source documents are not
to be sent unless requested) and fax or e -mail the form to the Shire Global Pharmacovigilance
and Risk Management Department. 
Shire CONFIDENTIAL Page 80
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Acopy oftheShire Clinical Study Serious Adverse Event and Non -serious AEs Required b y the 
Protocol Form (and an y applicable follow -upreports) must also be sent to the CRO/Shire 
Medical Monitor using the details specified in the emergency contact [CONTACT_548178].
8.2.[ADDRESS_717608] medical occurrence (whether considered to be related to investigational 
product or not) that at any dose:
Results in death.
Is life threatening. Note: The term ‘life threatening’ in the definition of “serious” refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires in- subject hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_602] , which are the result of elective or previousl y scheduled surgery for
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_64635](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incap acity .
Is a congenital abnormality /birth defect.
Is an important medical event. Note: I mportant medical events that may  not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_10154], 
based upon appropriate medical judgm ent, they  may  jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in in- subject hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.2.4, and must be reported
to the Shire Global Pharmacovigilance and Risk Management Department and the CRO/Shire 
Medical Monitor within [ADDRESS_717609] awareness of the event.
In addition, any SAE(s) considered “related” to the investigational product and discovered by [CONTACT_548179] [ADDRESS_717610] awareness of
theevent.
Shire CONFIDENTIAL Page 81
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717611]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death , the 
outcome should be considered not resolved, without a resolution date recorded.
ForanySAE thatresults inthesubject’s death oranyongoing events atthetime ofdeath, unless
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of withdrawn should not be selected solel y as a result of the
subject’s death.
8.2.[ADDRESS_717612], Ethics Committee, and Site 
Reporting
The sponsor is responsible for notify ing the relevant regulatory  authorities in the US and EU of 
related, unexpected SAEs.
In addition, the CRO ([COMPANY_003]) is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during allinterventional studies across therhPTH(1 -84)program.
The investigator is responsible for notify ing the local institutional review board (IRB), local 
ethics committee (EC), or the relevant local regulatory  authority  of all SAEs that occur at his or 
her site as required.
Shire CONFIDENTIAL Page 82
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
9.DATA MANAGEMENT AND STATISTICAL METHODS
Data Collection 9.1
The investigators’ authorized site pers onnel must enter the information required by  [CONTACT_548180]. A study  monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for completeness and accuracy. Discrepancies 
between source dataanddata entered ontheCRF willbeaddressed by[CONTACT_548181].
When a data discrepancy warrants correction, the correction will be made by [CONTACT_59752]. Data collection procedures will be discussed with the site at the site init iation visit 
and/or at the investigator’s meeting. Once a subject is randomized, it is expected that site 
personnel will complete the CRF entry  within approximately  [ADDRESS_717613]’s 
visit.
Clinical Data Management 9.2
Data are to be entered into a clinical database as specified in the CRO data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy of
the clinical database.
Data are to be reviewed and checked for omissions, errors, and v alues requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all correc tions are documented in an auditable manner.
Data Handling Considerations 9.3
This is an open -label study , and, as such, there are no special handling considerations for blinded 
data.
Statistical Analysis Process 9.4
The study  will be anal yzed by  [CONTACT_548182] .
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the pharmacokinetic, pharmacod ynamic, and safet y data, as well as describe the
approaches to be taken for summarizing other study informat ion such as subject disposition, 
demographics and baseline characteristics, investigational product exposure, and prior and 
concomitant medications. The SAP will also include a description of how missing, unused and
spurious data will be addressed.
Topreserve theintegrit yofthestatistical analy sisandstudy conclusions, theSAP willbe 
finalized prior to database lock.
All statistical analy ses will be performed using SAS(SAS I nstitute, Cary , NC [ZIP_CODE]).
Shire CONFIDENTIAL Page 83
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 9.5
There is no planned interim analy sis, adaptive design, or data monitoring committee (DMC) in 
thisstudy .
One or more interim analyses may  be performed in this study . If an anal ysis is deemed to be
necessary , then a prospective s tatistical analy sis plan will be developed prior to the anal ysis.The
plan willinclude, ataminimum: (1)rationale toperform theinterim analysis;(2)parameters to
be anal yzed; (3) the distribution list for the interim anal ysis results. Interim data may be used for
(but not limited to) PK/PD modeling and/or regulatory  submissions. The trial will not stop due to 
the results of an y interim analysis.
Sample Size Calculation and Power Considerations 9.[ADDRESS_717614] 8 subjects will be required to complete treatme nt in each cohort. The sample size was 
determined based on a similar, prior pharmacokinetic/pharmacod ynamic study . The number of 
subjects in this study  is not based on statistical power considerations because the statistical 
analyses are primaril y descript ive, and no h ypothesis testing is specified in the study .
Study Population 9.7
Four anal ysis populations are defined for this study : the all -enrolled, safet y,pharmacokinetic, and 
pharmacod ynamic populations:
The all -enrolled population consists of all subjects who sign the informed consent form
and are randomized in the study .
Thesafet ypopulation includes enrolled subjects who have received atleast 1dose of
rhPTH(1 -84). All anal yses of safety  data will be based on this population.
The pharmacokinetic population consists of all-enrolled subjects wh o receive at least 
1 dose of rhPTH(1- 84) and have at least [ADDRESS_717615] -dose pharmacokinetic
concentration value available for 1 dose regimen.
The pharmacod ynamic population consists of all-enrolled subjects who receive at least 
1dose of rhPTH(1 -84) and have at least [ADDRESS_717616] day  of rhPTH(1 -84) administration. 
Shire CONFIDENTIAL Page 84
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717617] administration is referred to as Day 1. Day  1 is the day  
that is preceding Day  1, and a Day  0will not be defined.
The pharmacokinetic parameters will include, but not be limited to:
maximum observed concentration maximum (Cmax)
time of maximum concentration (Tmax)
area under the concentration curve (from time zero to the last measurable concentration 
and from time zero to infinity  (AUC 0-t andAUC 0-inf)
area under the concentration curve from time zero to [ADDRESS_717618] dose 
(AUC 0-24h)
elimination rate constant (Kel)
apparent clearance (CL/F)
apparent volume of distribution (Vz/F)
elimination half -life(t½)
Statistical Analysis of Pharmacokinetic Parameters [IP_ADDRESS]
Individual concentrations and Pharmacokinetic parameters of PTH will be listed and summarized 
with descriptive statistics (number, arithmetic mean, SD, coefficient of variation [CV%], median, 
minimum, maximum, geometric mean, and geometric CV%) b y treatme nt. Figures of individual 
and mean (+/ -SD) concentration -time profiles of raw and baseline -adjustment plasma PTH will 
begenerated.
9.8.2 Pharmacodynamic Analysis
All pharmacod ynamic analyses will be performed using the pharmacod ynamic population.
Pharmacod ynamic parameters will be computed from the individual concentrations of serum 
calcium (uncorrected and corrected for serum albumin levels), phosphate, albumin, creatinine, 
magnesium, 1,25(OH) 2D3 and FGF23 using a non -compartmental approach. The
calcium- phosphate product will be computed. Pharmacod ynamic parameters will be estimated 
based with and without baseline adjustments.
Individual concentrations andpharmacod ynamic parameters ofserum total calcium and
albumin -corrected calcium, phosphate, creatinine, albumin, magnesium, 1,25(OH) 2D3 and 
FGF23 will besummarized with descriptive statistics (number, arithmetic mean, SD, CV%, 
median, minimum, maximum, geometric mean, and geometric CV%).
The urinary  excretion of calcium, sodium, citrate, magnesium, cAMP, and phosphate will also be 
expressed relative to that of creatinine and will be summarized with descriptive statistics.
Shire CONFIDENTIAL Page 85
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Statistical Analysis of Pharmacodynamic Parameters [IP_ADDRESS]
The following parameters will be calculated using the serum concentration data:
AUC 0-24h: the area under the concentration versus time curve, from time 0 to 24 hours
TEmax: time to maximum effect
Emax: maximum effect
The parameters representing urinary  excretion of each analy sis will be calculated, if data allow:
Total amount of sodium, calcium, magnesium, citrate, phosphate, cAMP, and creatinine 
in each sample
Total amount of sodium, calcium, magnesium, citrate, cAMP, and phosphate excreted in 
each sample relative to the total amount of creatinine excreted
Renal clearance of sod ium, calcium, magnesium, citrate, creatinine, and phosphate 
(mL/min)
Fractional excretion of sodium, calcium, citrate, magnesium, and phosphate
9.8.3 Pharmacokinetic and Pharmacodynamic Analysis
Pharmacokinetic -pharmacody namic correlations between PTH concentrat ions and the above 
indicators of PTH bioactivity  will be assessed using exploratory  figures. If required, 
pharmacokinetic/pharmacody namic models may  be developed to describe the effect of PTH 
concentrations and biochemical indicators of PTH activity .
9.8.[ADDRESS_717619] 
on serum calcium concentration and urine calcium excretion from alternativ e dosing regimens 
other than theonce dailyandtwice dailydoses used inthestudy . Apopulation PKmodel anda 
quantitative sy stem pharmacology  model (QSPM) will be developed b y fitting PK and PD data 
obtained from historical studies in hy poparathy roid p atients as well as data from this study .
Inter -subject variability  on model parameters will be fully  evaluated. Once the population PK 
model andtheQSPM aresatisfactoril yvalidated, simulations using thefinal validated models
will be performed to explore the effects of alternative dosing other than once -daily and
twice -dailydosing, eg,3times daily (TID), pump infusion dosing, andpossibly new
formulations ofPTH, on the control of serum calcium concentration and urinary  excretion of 
calcium in hypoparathy roid patients. A separate data anal ysis plan and report will be prepared for
this additional modeling and simulation work. These data will not be used in conjunction with 
any study  patient identifiers.
Shire CONFIDENTIAL Page 86
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717620], AEs leading to 
withdrawal, SAEs, and deaths will be similarly summarized/listed.
Safety  data including clinical labor atory  tests, anti -PTH antibodies, concomitant medications, 
adverse events, ECG monitoring and vital signs assessments will be summarized by [CONTACT_548183]. Descriptive statistics (arithmetic mean, standard deviation, median, 
minimum and maximum) will be calculated for quantitative safet y data as well as for the
difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_300192].
Safety  will be assessed by  [CONTACT_364516]:
AEs and TEAEs (including epi[INVESTIGATOR_4101] h ypocalcemia and/or hypercalcemia [including 
paresthesia, numbness, tetany ] and hy percalciuria)
Laboratory  test results (hematology , serum chemistries, creatinine clearance, urinary  
chemistries (24 -hr urinary  calcium, sodiu m, citrate, phosphate, cAMP, magnesium and 
creatinine excretion), immunology  (anti -PTH antibody ), and urinal ysis
ECG
Physical examinations (including vital signs)
Shire CONFIDENTIAL Page 87
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
10.SPONSOR’S AND INVEST IGATOR’S RESPONSIBILITIES
This study  will be conducted in accordance with current applicable regulations, I CH,EU
Directive 2001/20/EC and its updates, and local ethical and legal requirements.
The name [CONTACT_317368] y vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s fil es, as appropriate.
Sponsor’s Responsibilities 10.[ADDRESS_717621] privacy will be 
maintained during all procedures including intimate procedures such as ECG lead placemen t.
In addition to the Sponsor’s responsibilities as outlined in this section and in Section 8it may be
incumbent upon the individual investigator to report AEs (including SAEs) and an y failures of
devices (Injector Pen and/or Mixing Apparatus) to their local, regional, or country specific 
regulatory authorities.
10.1.[ADDRESS_717622] been delegated will undertake their assigned roles for this stud y in compliance with all 
applicable industry  regulations, I CH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or thecompan y 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
inter/national government regulations and guidelines. Records and d ata may additionally be
reviewed b y auditors or by  [CONTACT_12721].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, sub mission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the A ssociation of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document issupplied 
to the investigator before study  initiation, per local country guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study .An insurance certificate is supplied to the investigator as necessary .
Shire CONFIDENTIAL Page 88
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities of 
Member States Concerned and Ethics Committees
The sponsor wil l provide a summary  of the clinical study  report to the competent authority of the 
member state(s) concerned as required b y regulatory requirement(s) and to comply with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of t he end of
the study  completion date for pediatric studies and within 1 y ear for non- pediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend o r terminate the stud y, or part of the stud y, at any time for any reason. 
Ifthestudy issuspended orterminated, thesponsor willensure thatapplicable sites, regulatory
agencies and IRBs/ECs are notified as appropriate. Additionally, the discontinuation ofa 
registered clinical study which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an end -of-study  declaration to the relevant competent authority as
required b y Article 10 (c) of Directive 2001/20/EC.
Investigator’s Responsibilities 10.[ADDRESS_717623] undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The
investigator should also be able to estimate or demonstrate a potential for recru iting the required
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and sub -investigators are provided to the study  
sponsor (or designee) before starting the study .
Ifa potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
Shire CONFIDENTIAL Page 89
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun 2018
Acoordinating principal investigator (has been/will be)appointed toreview thefinal clinical 
study  report for multicenter studies. Agreement with the final clinical study report will be
documented by[CONTACT_548184], in
compliance with Directive 2001/83/EC as amended by [CONTACT_1772] 2003/63/EC and I CHGuidance 
E3(1995).
10.2.[ADDRESS_717624] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with the study protocol.
If the investigator suspends or terminates the study at their site, the investigator will promptly  
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study  completion, t he investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required b y (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided atall 
phases duri ng the stud y, may be done b y the sponsor, applicable CRO, investigator, or, for 
multicenter studies, the coordinating investigator [INVESTIGATOR_548149].
10.2.3 Documentation and Retention of Records
Case Report Forms [IP_ADDRESS]
Case report forms are supplied by  [CONTACT_548185].
The investigator is responsible for maintaining adequate and accurate medical records from
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by[CONTACT_548186].
All data will have separate source documentation; no data will be recorded directly onto the 
CRF.
Alldata senttothesponsor must beendorsed by[CONTACT_36705].
The clinical research associate (CRA)/study monitor will verify the contents against thesource
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
Recording, Access, and Retention of Source Data and Study Documents [IP_ADDRESS]
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, original clinical laboratory reports, and histology and pathology reports.
All key  data must be recorded in the subject’s medical records.
Shire CONFIDENTIAL Page 90
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717625] permit authorized represen tatives of the sponsor, the respective national, 
local, or foreign regulatory authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monito r (and auditors, IRB/EC or regulatory inspectors) may check the CRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_409512]/auditor from the sponsor or its representatives, national or local
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory  reports, X -rays,etc).
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, [LOCATION_006] Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be
destroy ed without written permission from the sponsor.
Audit/Inspection [IP_ADDRESS]
Toensure compliance with relevant regulations, data generated by[CONTACT_548187], for example, the US FDA (as well as oth erUS
national and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
Financial Disclosure [IP_ADDRESS]
Theinvestigator isrequired todisclose anyfinancial arrangement during thestudy andfor1year
after, whereb y the outcome of the study could be influenced b y the value of the compensation for 
conducting the study , or other pay ments the investigator received from the spons or.The 
following information is collected: any significant payments from the sponsor or subsidiaries
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary  interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
Ethical Considerations 10.[ADDRESS_717626]’s legall y-authorized representative, as applicable, is requested to sign and date the subject 
informed consent form or a certified translation if applicable, after the subject has received and 
read (or been read) the written subject information and received an explanation of what the study  
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject’s rights and responsibilities. A copy of the informed consent documentation (ie,a 
complete set of subject information sheets and fully executed signature [CONTACT_3264] s) must be given to
the subject or the subject’s legally authorized representative, as applicable. 
Shire CONFIDENTIAL Page 91
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717627]’s study  file and must be available for verifi cation at any time.
The principal investigator [INVESTIGATOR_1682] a cop y of the consent form which was
reviewed b y the IRB/EC and which received their favorable opi[INVESTIGATOR_1649]/approval. A cop y of the
IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these doc uments must be provided to the 
sponsor, prior to the start of the study  unless it is agreed to and documented (abiding by 
[CONTACT_319428]) prior to study  start that another part y (ie, sponsor
or coordinating principal investig ator) is responsible for this action. Additionally, if the IRB/EC
requires modification of the sample subject information and consent document provided b ythe 
sponsor, the documentation supporting this requirement must be provided to the sponsor.
10.3.[ADDRESS_717628] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved by[CONTACT_548188]), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation.
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating princ ipal investigator or sponsor, according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the clinical trial agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any 
revisions of a ll informed consent documents and amendments to the protocol unless there is a 
subject safet yissue.
Investigational product supplies will not be released until the sponsor has received written 
IRB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_100025] I RB/EC apprised of the
progress ofthestudy andofanychanges made totheprotocol, butinanycase atleast once a 
year; for sites within the EU, this can be done b y the sponsor, the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
Privacy and Confidentiality 10.[ADDRESS_717629] to the sponsor.
Theconfidentialit yofrecords thatmay beable toidentify subjects willbeprotected in
accordance with applicable laws, regulations, andguidelines.
Shire CONFIDENTIAL Page 92
SHP634 -101 Protocol Amendment 5
rhPTH(1 -84) 18Jun [ADDRESS_717630] consented to take part in the study, the sponsor and/or its representatives’ 
may review their medical records and data collected during the stud y. These records and data 
may, in addition, be reviewed by  [CONTACT_1774]: independent auditors who 
validate the data on behalf of the sponsor; third parties with whom the sponsor may develop, 
register, or mark et rhPTH(1 -84); national or local regulatory  authorities; and the IRBs/ECs 
which gave approval for the study  to proceed. The sponsor and/or its representatives accessing 
the records and data will take all reasonable precautions in accordance with applicabl elaws,
regulations, and guidelines to maintain the confidentiality of subjects’ identities.
Subjects will be assigned a unique identify ing number; however, their initials and date of birth 
may also be collected and used to assist the sponsor to verify  theaccuracy  of the data (eg, to 
confirm that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical records, 
and possibly  initials and dates of birth –will be recorded. They  may  be transferred to,and used 
in, other countries which may  not afford the same level of protection that applies within the 
countries where this study is conducted. The purpose of an y such transfer would include: to 
support regulatory  subm issions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
Study Results / Publication Policy 10.5
Shire will endeavor to publish the results of all qualifying, applicable, a nd covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee. The purpose of
the publication steering committee is to act as a non -commercial body  that advises or decides on 
dissemination of scientific study  data in accordance with the scope of this policy .
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the
commencement of the study  or generated during the study . To the extent permitted by [CONTACT_319441], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
Theterm “publication” refers toanypublic disclosure including original research articles, review
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websi tes, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Shire CONFIDENTIAL Page 93
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717631] the right to publish the 
study  results, and any  background information provided by  [CONTACT_548189], ornecessary forother scholars toverify such study
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitte d for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by  [CONTACT_10188], the institution and principal
investigator [INVESTIGATOR_548150] l withhold submission of such publication for up to an additional 60 day sto 
allow for filing of a patent application.
Ifthestudy ispartofamulticenter study ,thefirstpublication ofthestudy results shall bemade 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonmen t, 
or termination of the study  at all sites, or after the sponsor confirms there shall beno multicenter 
study  publication of the study  results, an investigator may individuall y publish the study  results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of
publications.
Shire CONFIDENTIAL Page 94
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
11.REFERENCES
Arlt, W., Fremerey , C., Callies, F., Reincke, M., Schneider, P., Timmermann, W. & Allolio, B. 
2002. Well -being, mood and calcium homeostasis in patients with hy poparathy roidism 
receiving standard treatment with calcium and vitamin D. Eur J Endocrinol, 146, 215-22.
Avioli, L . V. 1974. The therapeutic approach to hypoparathy roidism. Am J Med, 57, 34-42.
Behaghel, A. & Donal, E. 2011. Hy pocalcaemia -induced transient dilated cardiom yopath y in 
elderl y: a case report. Eur J Echocardiogr, 12, E38.
Bilezikian, J. P., Khan, A., Potts, J. T., Jr., Brandi, M. L ., Clarke, B. L., Shoback, D., Juppner, 
H., D'Amour, P., Fox, J., Rejnmark, L ., Mosekilde, L ., Rubin, M. R., Dempster, D., 
Gafni, R., Collins, M. T., Sliney , J. & Sanders, J. 2011. Hy poparathy roidism in the adult: 
epi[INVESTIGATOR_623] , diagnosis, pathophy siology , target -organ involvement, treatment, and 
challenges for future research. J Bone Miner Res, 26, 2317-37.
Blaine, J., Chonchol, M. & Levi, M. 2015. Renal control of calcium, phosphate, and magnesium 
homeostasis. Clin J Am Soc Nephrol, 10, 1257-72.
Haussler, M. R. & Cordy, P. E. 1982. Metabolites and analogues of vitamin D. Which for what? 
Jama, 247, 841-4.
Page, C. & Strunski, V. 2007. Parathy roid risk in total thy roidectomy  for bilateral, benign, 
multinodular goitre: report of 351 surgical cases. J Laryngol Otol, 121, 237-
41.
Powers, J., Joy , K., Ruscio, A. & Lagast, H. 2013. Prevalence and incidence of 
hypoparathy roidism in the [LOCATION_002] using a large claims database. J Bone Miner Res,
28, 2570-6.
Shoback, D. 2008. Clinical practice. Hy poparathy roidism. N Engl J Med, 359, 391-403.
Thomusch, O., Machens, A., Sekulla, C., Ukkat, J., Brauckhoff, M. & Dralle, H. 2003. The 
impact of surgical technique on postoperative h ypoparath yroidism in bilateral thyroid 
surgery : a multivariate analy sis of 5846 consecutive patient s. Surgery, 133, 180 -5.
Velasco, P. J., Manshadi, M., Breen, K. & Lippmann, S. 1999. Psy chiatric aspects of parath yroid 
disease. Psychosomatics, 40, 486-90.
Winer, K. K., Ko, C. W., Rey nolds, J. C., Dowdy , K., Keil, M., Peterson, D., Gerber, L. H., 
McGarvey , C. & Cutler, G. B., Jr. 2003. L ong-term treatment of h ypoparathy roidism: a 
randomized controlled study  comparing parathy roid hormone -(1-34) versus calcitr iol and 
calcium. J Clin Endocrinol Metab, 88, 4214-20.
Winer, K. K., Sinaii, N., Peterson, D., Sainz, B., Jr. & Cutler, G. B., Jr. 2008. Effects of once 
versus twice -daily  parathy roid hormone 1 -34 therapy  in children with 
hypoparathy roidism. J Clin Endocri nol Metab, 93, 3389-
95.
Winer, K. K., Yanovski, J. A., Sarani, B. & Cutler, G. B., Jr. 1998. A randomized, cross -over 
trial of once -daily  versus twice -daily parath yroid hormone 1- 34 in treatment of 
hypoparathy roidism. J Clin Endocrinol Metab, 83, 3480-6.
Zarnegar, R., Brunaud, L. & Clark, O. H. 2003. Prevention, evaluation, and management of 
complications following thy roidectomy  for thy roid carcinoma. Endocrinol Metab Clin 
North Am, 32, 483-502.
Shire CONFIDENTIAL Page 95
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
12.APPENDICES
Shire CONFIDENTIAL Page 96
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Appendix 1Protocol History
Document Date Global/Country/Site Specific
Original Protocol 23 Nov 2015 Global
Amendment 1 26 Feb 2016 Global
Amendment 2 03 Jun 2016 Global
Amendment 3 29 Jul 2016 Global
Amendment 4 12 Jun 2017 Global
Amendment 5 18 Jun 2018 Global
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
1. 100µg QD with oral calcium treatment arms have been
added; treatment arms have been rearranged so that 25µg 
BID and 50µg BID (in the absence or presence of oral 
calcium) are each cross -compared with 100µg QD (in the 
absence or presence of oral calcium). Corresponding
tables, figure(s), and text modified acc ordingl yto
incorporate this design change.
Reason for change: To provide direct comparisons within 
the same study  of the alternative dosing regimens (BID
with and without oral calcium) to the 100µg QD dose
with and without oral calcium, in order to more fully  
characterize and understand the effects of both the PTH 
dosing regimen and oral calcium on serum calcium 
concentrations and urinary calcium excretion in various 
conditions.Synopsis; Section 3.1
(including Figure 1);
Section 6.2.3
2. An additional cohort (of 8 subjects) has been added, 
increasing the total number of subjects required to 
complete the study  from 24 to 32.
Reason for change: To accommodate the additional 
comparisons of all BID doses with and without oral 
calcium with the 100µg QD dose with and without oral
calcium in the study design.Synopsis; Section 3.1 
(including Table 5 and
Figure 1); Section 4.5;
Section 6.2.3
3. Number of sites has been increased from “approximately  Synopsis; Section 3.3
Shire CONFIDENTIAL Page 97
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
20” to “approximately 20-30”.
Reason for change: The number of sites has been
increased to accommodate for the increase in the number 
of patients required to complete this study .
4. The planned study period has been extended to Nov 2017
(approx. 18 months duration).
Reason for change: To accommodate the increase in the 
number of subjects required to enroll and complete the
study .Synopsis; Section 3.2
5. Access to participate in, and reference to the RACE 
(PAR -C10-008) open- label extension study  hasbeen 
removed from the protocol.
Reason for Change: The RACE (PAR -C10-008) open
label extension study  is no longer available for subjects 
completing this study .Synopsis; Section 1.3;
Section 7.2.5
6. Canada has been removed as a participating country . Synopsis; Section 3.3
7. Treatment scheme in tabular format added to 
methodology  section of synopsis.
Reason for change: Reflects Table 4 of Section 3.1, and 
has been added to the s ynopsis for ease of reference.Synopsis
8. Inclusion criterion # 6 has been modified to clarify active 
forms of vitamin D and minimum daily  dose required for 
study entry .
Reason for change: Clarification.Synopsis; Section 4.1
9. Inclusion criterion # 8 has been modified to allow for an
expanded timeframe (from 6 mos. to 12 mos.) for 
historical 24 -hour urine calcium excretion. Additionally , 
“calcium concentration” was corrected to “calcium 
excretion”.Synopsis; Section 4.1
Shire CONFIDENTIAL Page 98
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_548190]: To accommodate common clinical 
practice, since qualify ing [ADDRESS_717632] been performed greater than 6 months prior to 
baseline. Correction to term for calcium excretion.
10. Inclusion criterion # 9: “calcium concentration” was
corrected to “calcium excretion”.
Reason for change: Correction to term for calcium 
excretion.Synopsis; Section 4.1
11. Inclusion criterion # 11 has been modified to clarify how 
criterion should be interpreted if outside of the normal 
range.
Reason for change: Clarification.Synopsis; Section 4.1
12. Exclusion criterion # 9 has been modified to incorporate 
wording re: ral oxifine or similar selective estrogen 
receptor modulators (SERMs), and to exclude subjects on 
these medications, due to their potential impact on 
calcium kinetics.
Reason for change: Raloxifine and SERMs as a drug 
class are known potentially  to impact bone cell function 
and skeletal metabolism. Since SERMs theoretically 
could impact study  pharmacody namic outcomes with 
respect to calcium (as could eg, bisphosphonates), an 
exclusion for SERMs has been added.Synopsis; Section 4.2
13. Exclusion criterion # 11 has been revised to specify
>450msec (males) or >470msec (females), based on the 
difference in normal QT/QTc observed in males versus 
females.
Reason for change: The gender -independent QTc 
exclusion of >450msec which is a ty pi[INVESTIGATOR_548151] >470msec for females. The sex difference in 
the normal QT/QTc between men and women is well 
accepted, and the QTc upper limit of normal is Synopsis; Section 4.2
Shire CONFIDENTIAL Page 99
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_548191] 450msec for men and 470msec
forwomen.
14. The minimum washout period between 1st dose in 
Treatment Period [ADDRESS_717633] dose in Treatment Period 2 
has been changed from “ ≥4 day s (ie, 96 hours)” to “≥5 
day (ie, 120 hours)”.
Reason for Change: A [ADDRESS_717634] 4 day s (96) hours duration has elapsed between
the last dose of BID treatment in Treatment Period 1, and 
first dose of QD treatment in Treatment Period 2.Synopsis; Section 3.1
(including Figure 1);
Section 7.2.2
15. cAMP (Cy clic AMP) has been added as a urinary analyte 
for pharmacod ynamic assay .
Reason for change: C yclic AMP (cAMP) has been added 
as a pharmacod ynamic analy te to help confirm true 
hypoparathy roidism.Abbreviations; Synopsis; 
Table 2; Table 3; Section
[IP_ADDRESS]; Section 9.8.2;
Section [IP_ADDRESS]; Section 9.9
16. Albumin -corrected calcium has been removed from 
descriptions of PD sample collections in the Table 
footnotes (Tables 2 and 3), and in the assessment column 
for the blood volume table (Table 6).
Reason for change: Correction.Table 2; Table 3; Table 6
17 Statistical Methodology  for Safet y Endpoints (Synopsis),
and Safet y Analysis (Section 9.9): physical exams were
removed from this section, anti-PTH antibodies w ere
added to this section.
Reason for change: Ph ysical examinations are deleted 
since they  are not summarized by  [CONTACT_548192]. Anti -PTH antibodies have been added as a 
safet yparameter.Synopsis; Section 9.9
18. Footnote “r” of Table 1 is revised to indicate that
supplemental oral calcium should be taken within 15 
minutes prior to IP administration (for subjects assigned
to treatment D, E and F on Day 1/dosing).Table 1
Shire CONFIDENTIAL Page 100
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_548190]: The time window between oral 
calcium administrations pr ior to IP dosing was reduced 
from 1 hour prior, to15minutes prior todosing, toalign
oral calcium intake as closely  as possible to dosing, in 
order to get a true characterizing of calcium kinetics.
19. For the BID regimen, the PK/PD sample collection 
period has been extended to [ADDRESS_717635] the second 
dose for BID treatment. In addition, PK and PD sample
collection time points were added at 16 and 24 hours 
after the second dose in the BID treatment regimen 
(corresponding to [ADDRESS_717636] dose, 
respectivel y). In addition, vital signs and ECG
assessments were added at the 28, 32 and 36 hour time 
points for this regimen.
Reason for change: Sample collection period extended to 
[ADDRESS_717637] -second (BID) dose (including a 16 and24 
hour time point) to better characterize the PK/PD profile 
at trough and to collect corresponding safet yassessments 
(vitals, ECGs) at these same time points.Table 4; Section [IP_ADDRESS]
20. For the QD regimen, a PK sample collection time point at 
16 hrs postdose was added.
Reason for change: Added to better characterize the PK 
ofrhPTH.Table 3
21. These changes (item 19 and 20 above) necessitated the 
reorganization of Table 3 (from the original protocol v 
1.0) to be split into 2 separate tables in the amended 
protocol: Table 3 now summarizes assessments for the 
QD treatment period, and Table 4 (now added)
summarizes assessments for BID treatment period.
Subsequent tables in this protocol were renumbered 
accordingl y (ie, Table 4 becomes Table 5, Table5
becomes Table 6).
Reason for change: Clarification to tables.Table 3; Table 4 (newly  
added)
Shire CONFIDENTIAL Page 101
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
22. Table 2: Day  -1 (Prior to Treatments 1 and 2): Table 
revised to remove reference relative to BID post evening 
dose collection time points in the header; streamlined to 
remove time point/columns where no PD sampling is 
required.
Reason for change: Clarification to table.Table 2
23. Table 2: Day  -1 (Prior to Treatments 1 and 2): PD blood 
collections were removed at 18, 20, and [ADDRESS_717638]-
dose time poi nts.
Reason for change: To correspond to the revised 
pharmacod ynamic sampling time points on Day  1 for QD 
and BID treatment schedules, and to serve as a baseline 
(Day  -1) comparison for each respective time point on 
Day 1 of each treatment period. This should enable the 
assessment and comparisons of the treatment effects on 
serum calcium and urinary calcium profiles for each of 
the6treatments totheir corresponding respective
baseline time points.Table 2
24. Blood volumes required for pharmacod ynamic andanti-
PTH antibody  assay s were revised/corrected. Total blood 
volume required for the study  is revised to 468.5mL.
Additionally , table rows and columns were modified, and
pharmacod ynamic collections separated according to 
those samples collected at Ba seline (D -1), and during 
treatment (Day s 1-2), and further specify ingwhich 
pharmacod ynamic sample (anal ytes) can be grouped 
together (eg, FGF23, albumin).
Reason for change: Corrections/revisions required to 
blood sample volumes, based on current information 
from the bioanal ytical lab(s) performing the assay work.
Rearrangement to columns based on revised treatment 
comparisons (ie, all subjects now receive 1 BID regimen 
and 1 QD regimen, which is reflected in re-ordered 
columns).Table 6 (previously  Table 5, 
per protocol version 1.0)
Shire CONFIDENTIAL Page 102
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_548193].
25. The following PK/PD sample collection time points were 
removed from the stud yschedule:
PK sample collection time points removed:
QD: 5 min, 3 hr, 6 hr postdose.
BID: [ADDRESS_717639] second dose.
PD sample collection time points removed:
QD: 18, 22 hrs postdose.
Reason for change: Due to the overall increase in total 
volume of blood samples required for pharmacod ynamic
assessments, it was necessary  to revise the blood
collection schedule in order to maintain total blood 
volume within safe and acceptable ranges for a clinical
study . The specific collection time points removed do not 
compromise the intent o r integrit y of the planned PK/PD
analysis for this study .Table 3; Table 4; Table 6
26. Table 1 (Schedule of Assessments): Anti- PTH antibody  
collection time point moved from Treatment Period 1 
Day -2, to Treatment Period 1, Day  1 (predose). This
collection time point hasbeen removed from Table 1,and
newly  added as a line item to Table 3 and Table 4, with a 
corresponding footnote that the anti- PTH antibody
sample should be collected at Treatment Period 1, 
predose (regardless of QD or BID regimen).
Reason for change: The assessment/collection time point 
was moved to predose on Day  1, Period 1, in order to 
avoid the potential (and unnecessary ) collection of a 
blood sample on subjects who may  screen fail between 
Day -2 and Day  1 at predose.Table 1; Table 3; Table 4
27. Schedule of Assessments: Urine pregnancy  test added to 
the Follow -upvisit.Table 1
Shire CONFIDENTIAL Page 103
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_548190]: To confirm pregnancy  status at the 
final in -house study visit.
28. Schedule of Assessments: Collection time point for
serum 25(OH)D sample was removed from Period 1, Day
-2.
Reason for change: Since serum 25(OH)D results
collected at Period 1, Day  -2 are not being used to 
determine eligibility , this sample collection was removed. 
The 25(OH)D sample collected at Screening will be used 
to determine eligibility .Table 1
29. An additional safet y review has been added after
completion of Cohort 3 (and prior to start of Cohort 4), as 
a result of the additional cohort (4) now added.
Reason for change: Added to be consistent wi thsafety  
reviews required after each completed cohort.Synopsis; Section 3.1
(including Figure 1)
30. Reproductive Potential (Female and male contraception):
Abstinence has been deleted as an acceptable form of
contraception for females and males participating in the 
study .
Reason for change: Abstinence is not an acceptable form 
ofcontraception.Section 4.4.1; Section 4.4.2
31. Clarification made that calcium andvitamin Dused prior
to and during the stud y be included as a concomitant
medicatio n.
Reason for change: Clarification.Section 5.[ADDRESS_717640] been removed.
Reason for change: To allow for flexibility  inlabeling. 
Labeling will include all required elements based on 
regional differences, local regulations, andrequirements.Section 6.3.1
Shire CONFIDENTIAL Page 104
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
33. Pharmacokinetic Plasma Assay  Methodology  section has 
been revised to reflect the SOPs being followed for 
pharmacokinetic sample assay s for this study .
Reason for change: Correction/update warranted.Section [IP_ADDRESS]
34. Reference to pharmacodynamic “plasma” samples have 
been changed to pharmacody namic “serum” samples.
Reason for change: Correction.Section7.3.4.1; Section 
[IP_ADDRESS]; Section [IP_ADDRESS]
35. Pharmacod ynamic (Serum) Assay  Methodology section 
has been revised to reflect the SOPs being followed for 
pharmacod ynamic sample assay s for this study .
Reason for change: Correction/update warranted.Section [IP_ADDRESS]
36. Pharmacod ynamic urine assay  methodology  hasbeen 
revised to reflect the SOPs being followed for 
pharmacod ynamic sample assay s for this study .
Reason for change: Correction/update warranted.Section [IP_ADDRESS]
37. Reference to Natpara® package insert has been removed 
from the protocol. The reference for safet yinformation
for this study  is the rhPTH (1 -84) investigator brochure.
Reason for change: This study  will be recruiting sites and 
patients internationally . Therefore, the investigator 
brochure is appropriate for referencing safety information 
regarding rhPTH (1-84).Section 1.1; Section 1.3;
Section 8.2.1
38. Pharmacod ynamic Anal ysis: creatinine has been added to
this section.
Reason for change: Creatinine was added to help clarify  
pharmacod ynamic data.Section 9.8.2
39. The following acron yms/abbreviations have been added: 
1(OH)D 3 (α-calcidol), cAMP (cy clicadenosine 
monophosphate), SERMs (selective estrogen receptor 
modulators).Abbreviations
Shire CONFIDENTIAL Page 105
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
1Amendment Date
26 Feb 2016Global
Item #Description of Change Section(s) Affected by
[CONTACT_548190]: Acrony ms added to coincide with the 
amended text that has been added to the protocol.
40 A sentence has been added under safet y to allow for
notification of a positive anti- PTH result to the 
Investigator.
Clarification of procedure for safet y that wasn’t
addressed in the original protocol.Section 7.3.[ADDRESS_717641] 
Information
42. Minor editorial changes and corrections to typographical 
errors (which do not modify  content and/or intent of the 
original document) were made throughout the document 
asappropriate.
Reason for change: Clarification and/or typograp hical
corrections.All sections (as warranted)
Shire CONFIDENTIAL Page 106
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
03 Jun 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_64737]
1. Emergency  contact [CONTACT_548194] ([COMPANY_003]) contact [CONTACT_3031].Emergency Contact 
[CONTACT_7171]
2. Additional Contact I nformation page has been updated 
with CRO ([COMPANY_003]) contact [CONTACT_3031].Additional Contact 
[CONTACT_7171]
3. Safety  reviews at the end of Cohorts 1, 2 and 3 will be 
performed with or without the follow-up visit data for the
corresponding cohort.
Reason for change: Clarification made for when these 
safet y review meetings will occur. There is no anticipated
impact to patient safet y, given the short half -life of PTH. 
The primary  purpose of the follow -up visit is to collect an 
anti-PTH antibody sample.Synopsis; Section 3.1
4. Exclusion criterion 4: Text in parentheticals “(HbA1C
>8%; >64 mmol)” has been deleted for t ype 2 diabetes
mellitus.
Reason for change: To allow for Investigator discretion in 
determining if subject meets this criterion.Synopsis; Section 4.2
5. Analy sis Populations: PK and PD population definitions 
are bulleted separatel y for the anal ysispopulation.
Reason for Change: Clarification made, since these [ADDRESS_717642] treatment.Synopsis; Section 9.7
6. Table 1: Footnote “e” moved to far left column (study  
procedure column) rather than the Period 2, Day  2 column 
(for procedures where indicated).
Footnote “k” clarification added to specify  that creatinine 
clearance will be calculated using the Cockroft -Gault 
formula.
Reason for change: Clarification warranted.Table 1
7. Table 3: columns ([ADDRESS_717643]- dose) which have no 
assessments to be collected are now deleted.
Reason for change: Clarification warranted.Table 3
8. Table 4: columns ([ADDRESS_717644]-dose)
which have no assessments to be collected are now deleted.
The PK and PD sampling predose footnote “f” should be Table 4
Shire CONFIDENTIAL Page 107
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
03 Jun 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_548195] “c”.
The last row “1,25 (OH)2D” should be deleted (as this is 
alread y included in the PD blood sample assessment in the 
same tableabove, andisalread y specified infootnote “g”).
Footnote “f” clarified to remove reference to “1,25(OH)2D. 
Footnote “i” 24 hour urine collection corrected to “36”
hour urine collection (ie, 24 hours after the 2nd BID dose).
Reason for change: Minor clarification and/or corrections 
warranted to the table.
9. Figure 1: Revised to illustrate that safety  data review will
occur after Treatment Period 2, but not necessarily after the
follow -up visit) for Cohorts 1, 2 and 3.
Reason for change: Clar ification warranted.Figure 1
10. Biochemistry : Magnesium and creatinine clearance have 
been added to the safety  lab biochemistry panel.
Reason for change: to confirm and evaluate Inclusion 
Criterion # 10, and Inclusion Criterion # 13, respectively .Section [IP_ADDRESS]
11. Urinaly sis: an asterisk was added to the calcium parameter 
being collected (with note provided to clarify that 
eligibility  of the subject’s urinary  calcium excretion result, 
based on a 24-hour collection prior to check- in to the CRC 
atTreatment Period 1, Day  -2, will be based on the 
assessment of these results by  [CONTACT_737] (using local 
labs, if necessary ).
Reason for change: Clarification warranted.Section [IP_ADDRESS]
12. Table 6: Safet y blood volumes reduced for serology ,
biochem istry and hematology  panel, and increased (by 
1 mL ) for serum 25(OH)D sample.
Reason for change: The sample volumes were updated, 
based on the central lab’s confirmation of required sample 
volumes. This resulted in an overall reduction of total 
blood volume required for each subject (ie, from 468.5 mL
to 440 mL).Section 7.3.5, Table 6
13. Two sentences were revised to clarify  respective roles of 
the sponsor and the CRO in reporting responsibilities to 
regulatory  authorities and active study sites.Section 8.2.7
Shire CONFIDENTIAL Page 108
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
2Amendment Date
03 Jun 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_548196]: Clarification warranted.
14. Minor editorial changes and corrections to typographical 
errors (which do not modify  content and/or intent of the 
original document) were made throughout the document as 
appropriate.
Reason for change: Clarification and/or typographical
corrections.All sections (as
warranted)
Shire CONFIDENTIAL Page 109
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_64737]
1. Schedule of Assessments:
a)Table 1: The assessments for clinical safet y blood and
urine tests (Treatment Period 1 and Treatment Period
2), pregnancy  test (for all females, Treatment Period 2),
physical exam (Treatment Period 2), and weight
(Treatment Period 2) should be collected after the
scheduled serial assessments (for pharmacokinetic [PK]
and pharmacod ynamic [PD]) have been completed for
this study  day, and prior to discharging the subject from
the Clinical Researc h Center. Footnote “s” has been
added to Table 1 to clarify/specify this.
An “X” has also been placed in Table 1 in the washout 
period column for AEs and Concomitant Medications.
b) Tables 3 and 4: The last scheduled serial time point for
vital signs and EC G will also serve as the discharge
procedure for that assessment on Day  2 for the QD
regimen (see Table 3) and for the BID regimen (see
Table 4). Footnote “j” has been added to Table 3, and
footnote “k” has been added to Table 4, to
clarify /specify this.
Reason for change :
Clarification made that AEs and concomitant medications 
should be reported during the washout period (Table 1), 
and clarification made to the order of procedures to be 
collected prior to discharge in Tables 1, 3 and 4.Table 1, Table 3, and
Table 4
2. Schedule of Assessments
a) Table 2: Detailed Schedule of Assessments: Day -1
(Prior to Treatment Periods 1 and 2), PD urine
sampling:
For PD urine sampling, the X under the “pre-dose” 
column in this table is used to signify the action that the 
subject needs to empt y his/her bladder immediately  
before the start of the 0 -3-hour urine collection based
on the predicted dosing time on Day  1 (eg, if a dose is Table 2, Table 3, and
Table 4
Shire CONFIDENTIAL Page 110
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_548197] 08.00 on Day  1, the start of the 
0-3 hour PD urine collection on Day  -1 should be
08.00). It is not a separate pre -dose collection .Footnote 
“i” in Table 2 has been added to clarify  this. Also, 
reference to “pre -dose” in footnote “g” of Table 2 has 
been deleted.
b)Table 3: Detailed Schedule of Assessments: Treatment
Periods 1 and 2, Day  1/Day  2 (QD Regimen), PD urine
sampling:
For PD urine sampling, the X under the “pre-dose” 
column on Day  1 in this table is to signify  the stop of 
the Day  -1, 18- 24 hour PD urine collection period, and 
the start of the Day  1, 0-3 hour PD urine collection 
period. It is not a separate pre -dose collection (this is 
also explained in Table 2, footnote d which indicates 
that the last assessment time point from Day  -1 (ie 18-
24 hour PD urine collection) is the same as the pre-dose
collection time point on Day  1, in Table 3). Footnote 
“k” in Table 3 has been added to clarify  this. Also, 
reference to “pre -dose” in footnote “h” of Table 3 has 
been deleted.
c)Table 4: Detailed Schedule of Assessments: Treatment
Periods 1 and 2, Day  1/2 (BID Regime n), PD urine
sampling:
For PD urine sampling, the X under the “pre-dose” 
column on Day  [ADDRESS_717645] assessment time point from Day  -1 (ie 18-
24 hour PD urine collection) is the same as the pre-dose
collection time point on Day  1, in 
Table 4. Footnote “l”
in Table 4 has been added to clarify  this. Also,
reference to “pre -dose” in footnote “i” of Table 4 has 
Shire CONFIDENTIAL Page 111
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_548198].
Reason for change :
Clarification made to the Schedule of Assessments tables 
to clarify  that a separate pre -dose pharmacody namic urine
sample is NOT required to be collected for Day  -[ADDRESS_717646] been reversed: where itcurrently  
reads:
“Pharmacokinetic blood sampling
Pharmacod ynamic blood sampling”
Has been revised to:
“Pharmacodynamic blood sampling
Pharmacokinetic blood sampling”
Reason for change :
The order of PK and PD sampling was reversed (when 
samples are collected at the same time point) in order to
avoid the potential for EDTA contamination (from PK 
samples requiring an EDTA tube) being collected before
PD serum samples are collected, which could impact assay  
integrit y and/or assay results.Section 7.2
4. Rescreening of Subjects:
The last sentence of this section which reads: “In these
cases, anew screening number must beassigned foreach
subject who is rescreened and a new informed consent 
form must be signed.” has been moved as a separate 
paragraph at the end of this section.
Reason for change:
Making this sentence as a separate (stand -alone) paragraph 
indicates that this sentence will appl y to all subjects who
are rescreened (per scenarios described in the 1st and2ndSection [IP_ADDRESS]
Shire CONFIDENTIAL Page 112
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_548199]).
5. Pharmacokinetic Procedures:
2nd paragraph, 3rd sentence which read:
“Pharmacokinetic blood collection must not deviate from 
the nominal collection time set forth in the protocol by  
[CONTACT_726] ±[ADDRESS_717647]-dose or b y more than ±[ADDRESS_717648]-dose.”
Has been changed to read:
“Pharmacokinetic blood collection must not deviate from 
the nominal collection time set forth in the protocol by  
[CONTACT_726] ±[ADDRESS_717649]-dose or b y more than ±[ADDRESS_717650] -dose and beyond.”
Reason for change :
Clarification made that the ±[ADDRESS_717651]- dose time point.Section 7.3.3
6. Pharmacokinetic Blood Sample Collection and Handling 
Procedures, 3rdbullet:
“Cohort” has been deleted from the list of bulleted 
information that will appear on the PK sample labels.
Reason for change :
Correction to tube label information required, following 
confirmation from the bioanal yticallab.Section [IP_ADDRESS]
7. Pharmacokinetic Procedures
Section header has been revised from “Pharmacokinetic 
Procedures” to “Pharmacodynamic Procedures”
Reason for change : Section header corrected to be 
consistent with the sub- section headers (and content) below 
it (ie, Sections [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS],Section 7.3.4
Shire CONFIDENTIAL Page 113
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_64737]
[IP_ADDRESS]).
8. Pharmacokinetics (now corrected to Pharmaco dynamics ) 
Procedures:
2nd paragraph, 3rd sentence which read: “Pharmacody namic
blood collection must not deviate from the nominal 
collection time set forth in the protocol by  [CONTACT_726] ±[ADDRESS_717652]- dose or
by [CONTACT_726] ±[ADDRESS_717653]-dose.”
Has been changed to read:
“Pharmacod ynamic blood collection must not deviate from 
the nominal collection time set forth in the protocol by  
[CONTACT_726] ±[ADDRESS_717654]-dose or b y more than ±[ADDRESS_717655] -dose and beyond.”
Reason for change :
Clarification made that the ±[ADDRESS_717656]- dose time point.Section 7.3.4
9. Pharmacod ynamic Blood Sample Collection and Handling
Procedures:
a)“Cohort” should be deleted from the list of bulleted
information that will appear on the PD sample
labels.
b)“Anal yte name (if there is more than 1)” should be
added to the bulleted list of information that will
appear on the PD sample labels.
Reason for change :
Correction to tube label information required, following 
confirmation from the bioanal yticallab.Section [IP_ADDRESS]
10. Pharmacod ynamic Urine Sample Collection and Handling
Procedures:
a)“Cohort” should be deleted from the list of bulletedSection [IP_ADDRESS]
Shire CONFIDENTIAL Page 114
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_548200].
b)“Anal yte name (if there is more than 1)” should be
added to the bulleted list of information that will 
appear on the PD sample labels.
Reason for change :
Correction to tube label information required, following 
confirmation from the bioanal yticallab.
11. Table 6: Volume of Blood to be Drawn from Each 
Subject
a)PK Samples (first line item of table): “PK samples
(serum PTH)a” has been revised to: PK samples
(plasma PTH)a”.
b)Footnote “a” revised and footnote “d” added to clarify
that when a PD and PK sample are collected at the
same time point, the PD sample is to be drawn prior to
the PK sample (to avoid any  potential for cross-
contamination of tube additives), and if an indwelling
catheter is used for this collection, the first 1mL of
blood should be discarded prior to the PD blood sample
collection. When either a PK or a PD sample is drawn
alone at a scheduled time point (using a catheter), 1mL
of blood should be discarded prior to the scheduled
blood sample collection.
c)An 18mL  adjustment in the blood volumes was made:
the PK volume decreased 18mL , and the PD volume
(Day  1-2) increased 18mL. However, the overall blood
volume required for the study remains unchange d.
d)Footnote “c” added to 8th row description (PD samples
[Day  1-2] for total serum calcium, magnesium,
phosphate, creatinine, 1,25[OH] 2D3).
Reason for change :Section 7.3.5
Shire CONFIDENTIAL Page 115
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_64737]
a)The sample matrix was corrected to plasma, to be
consistent with the protocol, Section 7.3.3.
b)Clarification made (footnote a and d), regarding the
order of the 1mL discharge, and the PD and PK
sample when collected at the same scheduled time
point.
c)The 18mL  volume “shift” (from the PK total
volume to the PD [Day  1-2] total volume) was due
to the 1mL  discard being required prior to the PD
sample (instead of the PK sample), when these
samples are collected together using an indwelling
catheter. This “shift” does not change the overall
blood volume required for the study .
d)Footnote “c” was missing for this line item
description in the prior version of the protocol, and
has been added to this version.
12. Pharmacokinetic Anal ysis
1st paragraph which states:
“All the pharmacokinetic anal yses will be performed using 
the pharmacokinetic/pharmacod ynamic population.”
Has been changed to read:
“All the pharmacokinetic anal yses will be performed using 
the pharmacokinetic population.”
Reason for change :
Reference to pharmacodynamic population in this section 
is incorrect, and has been deleted.Section 9.8.1
13. Pharmacod ynamic Anal ysis
New sentence added at the beginning of this section which 
reads:Section 9.8.2
Shire CONFIDENTIAL Page 116
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_64737]
“All the pharmacod ynam ic anal yses will be performed 
using the pharmacod ynamics population.”
Reason for change :
Sentence added to clarify the population being used for the 
analysis.
14. Population Pharmacokinetic and Quantitative System 
Pharmacology  Modeling and Simulation ( new section and 
textadded ):
“Additional modeling and simulation will be performed to 
evaluate the PK of PTH and the effect on serum calcium 
concentration and urine calcium excretion from alternative 
dosing regimens other than the once daily  and twice daily  
doses used in the study . A population PK model and a
quantitative system pharmacolog y model (QSPM) will be 
developed b y fitting PK and PD data obtained from
historical studies in hy poparathy roid patients as well as 
data from this study . Inter -subject variability  onmodel 
parameters will be fully evaluated. Once the population PK
model and the QSPM are satisfactoril yvalidated,
simulations using the final validated models will be 
performed to explore the effects of alternative dosing other
than once -daily  and twice -daily dosing, eg, 3 times daily  
(TID), pump infusion dosing, andpossibly new
formulations of PTH, on the control of serum calcium 
concentrations and urinary excretion of calcium in 
hypoparathy roid patients. A separate data anal ysis plan and 
report will be prepared for this additional modeling and
simulation work. These data will not be used in
conjunction with any  study  patient identifiers.”
“QSPM” was also added to the list of abbreviations as a 
result of the term added to protocol text.
Reason for change : The addition of text regarding PK/PD 
modeling was provided to recognize that future work (ie, 
modeling and simulation), outside of this protocol, could 
potentially  examine alternative dosing regimens. This Abbreviations;
Section 9.8.4 (new section 
added)
Shire CONFIDENTIAL Page 117
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
3Amendment Date
29 Jul 2016Global
Item #Description of Change Section(s) Affected by 
[CONTACT_548201] y in an y wa y. A separate data analysis plan and report
will be prepared for this work.
15. Minor editorial changes and corrections to typographical 
errors (which do not modify  content and/or intent of the 
original document) were made throughout the document as 
appropriate.
Reason for change: Clarification and/or typographical
corrections.All sections (as
warranted)
Shire CONFIDENTIAL Page 118
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
1. Site(s) and Region(s):
“[LOCATION_002]” has been changed to “North America” as 
one of the regions participating.
Reason for change:
[LOCATION_002] has been corrected to the region it is located 
in (North America). This will also permit additional 
countries within this region that may  decide to participate 
in the future (without warranting a subsequent amendment 
for this change).Synopsis, Section 3.3
2. An administrative screening (within [ADDRESS_717657] 
dose) has been added prior to the normal screening period 
for the study. The administrative screen is only for purpose 
of requesting, authorizing and releasing medical records for 
a potential subject (if needed). As such, it is not part of the
active screening process. Thesubject must sign an
informed consent and a medical records release
authorization as the first step of the administrative 
screening process. This wording and addition to Table 1 
clarify  the current process to obtain any  necessary medical 
records.
Reason for change:
To allow for the necessary  time required to obtain medical 
records for subjects interested in participating at a site that 
is outside of their immediate care network (if needed).Synopsis; Table 1;
Section 3.1; Figure 1;
Section 3.2; Section 7.2.[ADDRESS_717658] been
added to the protocol.
Reason for change:
To support remote informed consenting as it relates to 
subjects who arelocated atadistance from thesiteand/or
who would require consent and medical record release for 
conducting an administrative screen (see above, item # 2).
To incorporate the wording from the Shire Note to File, 
(dated 06 Dec 2016) entitled “Remote Informed Consent Section [IP_ADDRESS]; Appendix
2
Shire CONFIDENTIAL Page 119
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548202]” into the protocol.
4. “Screening” has been re -stated as “Clinical Screening”,
“Clinical Screening Period”, or “Clinical Screening Visit” 
(as applicable) throughout the document.
Reason for change:
To distinguish the study -specific screening procedures
(now called “Clinical Screening”) from the newl yadded
“Administrative Screening” process.Synopsis; Table 1;
Section 3.1; Figure 1;
Section 7.2.1, Table 6
5. Table 1: Schedule of Assessments
a)Screening Column has been separated into 2
columns: 1 column for Administrative Screening
and 1 column for Clinical Screening.
b)New line item for medical records release has been
added (for admin screen) and informed consent has
been added to the administrative screening. New
footnote (d) regarding medical r ecords release
added.
c)Subsequent footnotes thereafter on this table have
been re -ordered alphabetically .
d)Footnote r (regarding Adverse Events to be
collected at the Administrative Screening Period)
and Footnote q (regarding 24 -hr urine sample
collected during the Clinical Screening Period)
have been added.
e)“Evening check -in to CRC” (22nd row) is corrected
to read “Check -in to CRC”
Reason for changes (a-d):
To distinguish the study -specific screening procedures
(now called “Clinical Screening”) from the 
“Administrative Screening” process.
Footnotes have been added for clarit y. 
Reason for change (e):Table 1
Shire CONFIDENTIAL Page 120
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
“Evening” should be deleted from description of time to 
check -in to the CRC. This change will allow sites and 
subjects more flexibility  in arrival time to CRC on Day -2 
for each period, and based on the schedule and timingof
required stud y assessments that need to be completed
and/or results received on this study day.
Per Administrative Clarification Memo # 1 (dated [ADDRESS_717659] 
2016).
6. For Cohorts 3 and 4 (Treatment D, E, and F), subjects 
should take their supplemental calcium at their usual 
dose(s)/regimen, and the dose/regimen and timing of their 
calcium administration should be identical at Day - 1, Day 1 
and Day  2 in each treatment period.
Furthermore , subjects in Cohorts 3 and 4 (Treatment D, E 
and F) will take their usual supplemental calcium at their 
usual dose(s)/regimen in Day  1, regardless of the rhPTH 
(1-84) dosing regimen.
The 30 minute window in which calcium supplement was 
to be taken prior to IP administration was removed.
Reason for changes:
The intent of the protocol was to allow for subjects to 
continue their usual regimen of supplemental calcium. 
Since many  subjects may take multiple calcium 
supplements throughout the day , the present protocol’s 
instructions to take the calcium supplement [ADDRESS_717660]’s usual regimen.
The re vised wording clarifies that subjects are to continue 
their usual regimen of supplemental calcium as intended on 
study  Day  1, regardless of whether subjects are to receive 
one or two doses of rhPTH(1- 84) on that day.Synopsis; Section 3.1
7. One or more interim analy ses may  be performed in this 
study . If an analy sis is deemed to be necessary , then a 
prospective statistical analy sis plan will be developed prior Synopsis; Section 3.1;
Section 9.5
Shire CONFIDENTIAL Page 121
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548203]. The plan will include, at a minimum: (1) 
rationale to perform the interim anal ysis; (2) parameters to 
be anal yzed; (3) the distribution list for the interim analy sis 
results. I nterim data may  be used for (but not limited to) 
PK/PD modeling and/or regulatory  submissions. The trial 
will not stop due to the results of any  interim analysis.
Reason for change:
To indicate that one or more interim anal yses may be
performed, as described above.
8. Statement added that subjects who complete this study may
have the opportunit y to enroll in an open- label extension 
trial.
Reason for change:
Wording has been added to indicate that subjects may have 
an opportunity  to enroll in an open -label trial, if an open -
label extension study  is available and approved by [CONTACT_39722]’s IRB/EC.Synopsis; Section 3.1,
Section 7.2.5
9. Sentence has been added regarding subjects assigned to the 
BID regimen, suggesting that lunch be divided into 2 
portions; the first portion consumed at lunch, and the 
second portion consumed as the snack or light meal.
Reason for change: Statem ent added to protocol, per
Clarification Memo (21 Dec 2016) regarding Site Meal 
Menus.Section 3.1
10. Inclusion criterion #3: the upper age limit has been 
removed. The Screening Period has been defined to 
encompass both the Administrative and Clinical Screening 
Periods, and age assessed at the time the consent is first 
signed b y the subject.
Reason for changes:
An upper age limit is unnecessary ; deletion of this upper 
limit does not compromise subject safety . Per the US Synopsis; Section 4.1
Shire CONFIDENTIAL Page 122
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548204], “Clinical studie s of N ATPARA didnot 
include sufficient numbers of subjects aged 65 and over to 
determine whether response in these subjects is different 
from y ounger subjects.” NATPARA is therefore indicated
for adults; there is no age limitation. No dose adjustment is 
recommended for patients ≥65 y ears of age. The US 
Package Insert also notes that phy sicians should be 
cautious regarding dose and treatment of geriatric patients. 
Exclusions #2 and #12 ensure that medical conditions that 
often tend to occur in geriatric pa tients are alread y 
excluded based on investigator judgment.
Clarification regarding when age will be assessed for the 
study .
11. Inclusion criterion #5: elemental calcium specified.
Reason for change:
Clarification warranted that the strength of supplemental 
calcium required per day  is based on the calcium within the 
formulation, irrespective of the counter ion.Synopsis; Section 4.1
12. Inclusion criterion #7: serum calcium level range revised to 
state within lab normal reference range, and based on 
central and/or local lab results at the Clinical Screening 
Visit and Period 1, Day  -2, and if not within normal range,
considered as not clinically  significant b y the investigator.
Reason for change:
Prior range ( ≥7.0 to ≤9.5 mg/dL) was restrictive and not 
consistent with lab normal range for this assessment.
Changed to be consistent with lab normal range but also to 
allow some investigator flexibility  in this regard based on 
medical judgment. Subjects will be confined to the CRC 
during treatment periods and will be closel y monitored by 
[CONTACT_548205] h ypocalcemia or
hypercalcemia. Subject safet y is not compromised because
of this change.Synopsis; Section 4.1
13. Inclusion criterion #8 (historical 24h urinary calcium Synopsis; Section 4.1
Shire CONFIDENTIAL Page 123
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548206]) has been deleted.
All subsequent criteria in this section have been re-
numbered as a result.
Reason for change:
An historical 24 -hr urinary  calcium may  be variable and 
not predictive of findings during screening; thus it is not 
needed to help identify  the patient population for this 
study . The change does not impact subject safety .
14. Inclusion criterion #9 (re -numbered as #8):
The time window for the 24 -hour urine collection is 
expanded; the sample is to be collected an ytime during the 
Clinical Screening Period, but prior to check -in to the CRC 
at Treatment Period 1, Day  -2. Eligibility  to be based on 
central or local lab urine calcium excretion results.
Reason for changes:
To allow for more flexibility  in the time interval in which 
the urine collection is obtained during screening.
Clarification made regarding which lab results can be used 
to determine eligibility .Synopsis; Section 4.1
15. Inclusion criterion #12 (re -numbered as #11):
The inclusion criterion for serum 25(OH)D has been 
revised to within lower limit of normal and 1.5 fold the 
laboratory  upper limit of normal, or, if outside of this 
range, considered not clinically  significant by [CONTACT_1275], at the Clinical Screening Visit.
Reason for change:
Changed to allow for some investigator flexibility  inthis 
regard based on medical judgment.Synopsis; Section 4.1
16. Inclusion criterion #13 (re -numbered as #12):
Study  visits at which the serum creatinine value and 
creatinine clearance values must be met have been added to
the text. Creatinine clearance is now corrected to read as Synopsis; Section 4.1
Shire CONFIDENTIAL Page 124
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548207].
Reason for changes:
Clarification warranted.
17. Exclusion criterion #9 (first bullet)
Thiazide diuretics (within [ADDRESS_717661]) has been added 
as an exclusion criterion, as new (first) bullet.
Reason for change:
This exclusion criterion added to restrict the use of a 
concomitant medication which could have an effect on 
urinary  calcium in this study .Synopsis; Section 4.2
18. Exclusion criterion #9 (first bullet, now re-positioned as 2nd
bullet):
Antacids have been removed from the list of exclusionary  
medications.
Reason for change:
Subjects may  be taking antacid tablets (Tums®for 
example) as a source of supplemental calcium. This
restriction was removed to allow for inclusion of these 
subjects. This change does not compromise subject safet y.Synopsis; Section 4.2
19. Exclusion criterion #10:
“…(not related to hy poparathy roidism)”… has been 
deleted from the text of this criterion.
Reason for change:
Clarification warranted.Synopsis; Section 4.2
20. Exclusion criterion #11:
ECG “values (average of triplicate readings)” has been
added and last sentence has been deleted.
Reason for change:Synopsis; Section 4.2
Shire CONFIDENTIAL Page 125
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548208] y being performed
at each time point, clarification was warranted in this 
criterion, and last sentence was unnecessary (therefore 
deleted).
21. Exclusion criterion #16:
Criterion regarding herbal supplements has now been
deleted.
All subsequent criteria in this section have been re-
numbered as a result.
Reason for change:
The need for the exclusion of herbal supplements is not 
relevant to this study  in this patient population and is not 
needed; deletion of this exclusion does not compromise 
patient safet y.Synopsis; Section 4.2
22. Exclusion criterion #17 (now re -numbered as #16):
Criterion regarding screen for drugs of abuse has been 
modified to allow for investigator discretion to enroll 
subjects who take prescription medications.
Reason for change:
Exclusion criterion has been modified to allow subjects on 
prescription medications that might be detected during the 
urine scre en for drugs of abuse (listed in section [IP_ADDRESS]) to 
be enrolled per the investigator medical judgment.Synopsis; Section 4.2
23. Restrictions: the following item #s have been deleted:
#2 (grapefruit/Seville oranges products)
#5 (regular use of an y medications, including OTC,
multi- vitamin, herbal, homeopathics)
#6 (foods or beverages containing caffeine/xanthine)
All subsequently  numbered restrictions in this section have 
been re -numbered as a result.
Reason for change:Section 4.3
Shire CONFIDENTIAL Page 126
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548209]/or 
medications is unnecessary  for this patient -population 
study ; deletion of these restrictions does not compromise 
subject safety .
24. Restrictions #4 (re -numbered as #3):
Tobacco (or nicotine products) use has been revised to 
specify  that this restriction only  applies to its use within 60 
minutes prior to the collection of an y vital signs, ECG or
blood draws while confined to the CRC.
Reason for change: Prior restriction was too limiting and 
unnecessary  for this pat ient population. This change does 
not compromise subject safet y.Section 4.3
25. Restriction #8 (re -numbered as #5):
Clarifications added to the text surrounding meal menus, 
food options/choices and the need for meal choices to be 
identical for each subje ct within a site between Period 1 
and Period 2.
Reason for change:
To incorporate wording from the Sponsor’s Memo to File 
(dated 21 Dec 2016) entitled “Site Meal Menus” which was 
previously  forwarded to all participating study sites.Section 4.[ADDRESS_717662]’s source
documents.
Reason for change:
Statement added to emphasize this point.Section 5.2
27. Text added to allow for local destruction of used/unused 
investigational product/supplies, and only  inexceptional 
circumstances (with prior written agreement b ythe
sponsor).Section 6.4
Shire CONFIDENTIAL Page 127
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548190]:
To permit local destruction of used/unused supplies for
sites who are not permitted to return them to the vendor 
(due to institution’s SOPs, hospi[INVESTIGATOR_307]/pharmacy regulations, 
etc.)
28. Study  Schedule (priority order)
Statement added regarding the order/sequence of blood 
sampling, in order to avoid the potential for cross -
contamination of tube additives when collecting blood 
samples at the same time point for different assay s (based 
on tubes requiring serum versus tubes requiring plasma, 
which require an anticoagulant).
Reason for change:
Statement added to protocol, per Administrative 
Clarification Memo #1 (dated [ADDRESS_717663] 2016).Section 7.2
29. Rescreening of Subjects
Clarification and statement added that a total of 2 re-
screenings are permitted in this study : one re -screening due 
to failure to meet inclusion/exclusion criteria that is 
considered as transient/temporary , and one re-screening
due to scheduling/timing issues related to the study
schedule (including the time to release medical records, if 
applicable).
Reason for change:
Statement added to protocol, per Administrative 
Clarification Memo # 1 (dated [ADDRESS_717664] 2016).Section [IP_ADDRESS]
30. Vital Signs:
Sentence added regarding scheduled assessment time and 
allowable window in which vital signs must be obtained. A 
measurement made outside of this window would be
considered a protocol deviation.Section [IP_ADDRESS]
Shire CONFIDENTIAL Page 128
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548190]:
Clarification warranted.
31. Clinical LabEvaluations:
a) Two statements added:
In order to qualify  the subject for randomization at 
Treatment Period 1, the site can base eligibility on 
the local lab results if the central lab results are not 
available, but, if results are available from both
labs, eligibility  should be based on the central lab 
results.
However, local lab results will not be entered in the
eCRF/clinical database, and copi[INVESTIGATOR_548152]. The central lab results (once received) 
will be entered in the eCRF/clinical database.
b) Asterisked Note at end of this section (regarding
urinary  calcium eligibility ) was deleted as this is 
now redundant with (and encompassed b y)the
newly  added text.
c)Creatinine clearance is now corrected to read as
estimated creatinine clearance.
Reason for changes:
Clarification warranted regarding the use of local lab 
results for eligibility purposes.
Clarification made to how creatinine clearance was being
assessed.Section [IP_ADDRESS]
32. 4thparagraph:
Sentence modified to include qualifier statement “(except 
as noted in Exclusion Criterion # 16)” at end of the 
sentence, so it reads:
“Anypositive result fordrugs ofabuse atclinical screening
or drugs of abuse or alcohol on Day - 1 (both treatment Section [IP_ADDRESS]
Shire CONFIDENTIAL Page 129
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548210]) will exclude the subject from further participation 
in the study  (except as noted in Exclusion Criterion #16)”
Reason for change:
Clarification warranted.
33. ECGs:
a)Sentence added regarding scheduled assessment time
and allowable window in which ECGs must be
obtained. A measurement made outside of this window
would be considered a protocol deviation.
b) “sponsor representative” has been revised as “ECG
vendor”
c)Added “Onl y valid ECG tracings will be submitted to
the ECG vendor for analy sis”.
d)“Valid” added in 2 places within the 5th paragraph to
clarify  the ECG measurements.
e)Third paragraph: sentence which reads: “The subject
should not have exercised or consumed caffeine,
alcohol, or nicotine within 30 minutes prior to
collection” is changed to: “The subject should not have
exercised or consumed caffeine, alcohol, or nicotine
withi n 60 minutes prior to collection”.
Reason for changes (a-d): 
Clarifications warranted.
Reason for change (e):
The time (30 minutes) was revised (to 60 minutes) to be 
consistent with the time required for withhold nicotine use Section [IP_ADDRESS]
Shire CONFIDENTIAL Page 130
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_548211] # 4 (re-
numbered as # 3).
34. PD Blood Sample Collection and Handling Procedures
3rd paragraph, 6thbullet:
“Matrix identifier (plasma)”
is corrected to read
“Matrix identifier (serum)”
Reason for change:
Matrix corrected to be consistent with other sections of the 
protocol (sections [IP_ADDRESS], [IP_ADDRESS], 7.3.5). Per
Administrative Clarification Memo # 1 (dated [ADDRESS_717665] 
2016).Section [IP_ADDRESS]
35. Safety  Anal ysis, 3rd paragraph: 1st and 2nd bullets which
read:
AEs and TEAEs
Clinical epi[INVESTIGATOR_548153]/or
hypercalcemia (including, paresthesia, numbness,
tetany ) and hypercalcemia
These [ADDRESS_717666] been combined into 1 bullet which 
reads:
AEs and TEAEs (including epi[INVESTIGATOR_548154]/or hy percalcemia [including, paresthesia,
numbness, tetany ] and hypercalciuria )
Reason for changes:
The term “h ypercalcemia” was inadvertentl y stated twice
in the 2nd bullet. The 2nd appearance of this term in this 2nd
bullet was a ty pographical error and is now corrected to
“hypercalciuria”.
The 1st bullet was combined with the 2nd to be consistent 
with the safet y endpoints section of the synopsis.Section 9.9
Shire CONFIDENTIAL Page 131
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun 201 8
Protocol Amendments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number
4Amendment Date
12 Jun 2017Global
Item #Description of Change Section(s) Affected by
[CONTACT_64737]
36. Synopsis, Safet y Endpoints, 1stbullet
The update made inSection 9.9(see item #35 above), is
also reflected in the synopsis (Safety Endpoints, 1stbullet).
“AEs including epi[INVESTIGATOR_548155]-andhypercalcemia”
This sentence is now clarified to read:
“AEs including epi[INVESTIGATOR_548156], hypercalcemia, 
andhypercalciuria”
Reason for change:
Tobe consistent with the ty pographical correction made in 
Section 9.9.
Per Administrative Clarification Memo # 1 (dated [ADDRESS_717667] 
2016).Synopsis
37. Minor editorial changes and corrections to typographical 
errors (which do not modify  content and/or intent of the 
original document) were made throughout the document as 
appropriate.
Reason for change:
Clarification and/or t ypographical corrections.All sections (as
warranted)
Shire CONFIDENTIAL Page 132
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717668] medical records released toassess
preliminary  suitability  for participation. The remote consent process may  be performed onl y ifit
is in compliance with the site’s local and/or regional regulations and approved by [CONTACT_779]’s 
IRB/EC prior to institution.
The study  staff of the site selected will contact [CONTACT_548212] (patient) and arrange 
for two copi [INVESTIGATOR_548157] (patient) 
along with two copi[INVESTIGATOR_1309] a medical records release form by [CONTACT_30367]. The initial package will also 
contain a pre -paid self -addressed courier envelope and form for return of signed documents.
Within a reasonable time after the initial package has been mailed, the study site will contact [CONTACT_548213] (patient) and arrange to go over the informed consent form by [CONTACT_756]. 
This step should include the opportunity  for the potential study  subject (patient) to ask medical 
questions of a site phy sician listed on the clinical study  Statement of Investigator (FDA 1572) 
form.
Following the telephone call with the study  site, if the potential study  subject (patient) remain s 
interested inthestudy ,thesubject would sign anddate onecopyoftheinformed consent form
and one cop y of the medical record release form and return both documents to the study  sitein 
the courier envelope provided. One cop y of the informed consent form and one cop y ofthe
medical release form would be retained b y the potential study  subject (patient) for reference.
The study  site personnel must document this remote consenting process in their source 
documents and include the date and time of when th ey reviewed this process with the prospective 
subject (patient).
Upon receipt of the signed informed consent and medical release forms, the study  site staff will 
register (enroll) the potential study  subject (patient) in the study  (IRT) and then request historical 
medical records from the potential study  subject’s (patient’s) current care provider.
Upon receipt of the signed informed consent document, the study  site personnel who discussed 
the informed consent over the telephone should sign and date the las t page (with the date of 
signature) of the subject’s signed consent form and indicate that the consent process was carried 
out by  [CONTACT_756]. The study  site personnel must not sign the consent in the witness block, if one
exists.
Once the historical medical records are received, the study  site phy sician will review the record 
to determine if the subject (patient) remains potentially  eligible for the study (pending 
completion of full screening). The potential study  subject (patient) will then be contact[INVESTIGATOR_530]. If the 
potential study  subject (patient) does not meet eligibility  criteria, they  will be informed and 
regarded as a screen failure in the study .
Ifthepotential study subject (patient) appears tobeeligible, they willbeinformed, andthestudy  
site personnel will arrange travel (if applicable) to the study  site for further eligibility screening.
Shire CONFIDENTIAL Page 133
SHP634 -101 Protocol Am endment 5
rhPTH(1 -84) 18Jun [ADDRESS_717669]
(patient [once at the study  site]) to verify  the signature [CONTACT_447617] e informed consent document that 
was signed remotely .
Should the potential subject (patient) not be able to complete screening within the designated 
screening window per protocol (eg, due to a delay in the receipt of medical records or because of
travel), the potential subject (patient) would be considered a screen failure. In this case, if the 
potential subject (patient) remains interested in study  participation, they  would sign a new 
informed consent form, either onsiteorremotely ,andrestart thescree ning process (with anew
screen number).